documents incorporated reference portions proxy statement registrants annual meeting stockholders held may filed within days conclusion registrant 's fiscal year ended december incorporated reference part iii annual report part item business general bristolmyers squibb company may referred bristolmyers squibb bms company us incorporated laws state delaware august name bristolmyers company successor new york business started bristolmyers company changed name bristolmyers squibb company result merger engaged discovery development licensing manufacturing marketing distribution sale biopharmaceutical products global basis operate one segmentbiopharmaceuticals additional information business segments refer item financial statementsnote business segment information compete worldwide researchbased drug companies smaller research companies generic drug manufacturers products sold worldwide primarily wholesalers retail pharmacies hospitals government entities medical profession manufacture products united states us puerto rico six foreign countries percentage revenues significant regioncountry follows year ended december dollars millions united states europe japan china total revenues acquisitions divestitures transitioned bms leadingedge specialty biopharmaceutical company focused exclusively discovering developing delivering innovative medicines address serious unmet medical needs transition encompassed areas business operations part strategy divested diabetes nonpharmaceutical businesses restructured alliances divest certain mature brand products implemented acquisition licensing strategy executed productivity transformation initiative significant divestitures include anticipated divestiture investigational hiv medicines first half erbitux north america diabetes business mead johnson part acquisition licensing strategy acquired cardioxyl pharmaceuticals inc cardioxyl flexus biosciences inc flexus ipierian inc ipierian amylin pharmaceuticals inc amylin inhibitex inc inhibitex amira pharmaceuticals inc amira entered several license collaboration arrangements transactions allowed continue allow us focus resources behind growth opportunities drive greatest longterm value disease standpoint focused following core therapeutic areas oncology immunooncology immunoscience cardiovascular disease fibrosis genetically defined diseases products pharmaceutical products include chemicallysynthesized drugs small molecules increasing portion products produced biological processes typically involving recombinant dna technology called biologics small molecule drugs typically administered orally eg form pill tablet although drug delivery mechanisms used well biologics typically administered patients injections infusion revenues come products following therapeutic classes virology including hiv infection oncology immunoscience cardiovascular neuroscience pharmaceutical industry majority innovative products commercial value usually realized period product market exclusivity business focused innovative biopharmaceutical products rely patent rights various forms regulatory protection maintain market exclusivity products us european union eu countries patent rights forms exclusivity expire generic versions medicine approved marketed often substantial rapid declines sales original innovative product discussion patent rights regulatory forms exclusivity refer intellectual property product exclusivity discussion impact generic competition business refer generic competition following chart shows key products together year earliest basic exclusivity loss patent rights data exclusivity occurred currently estimated occur us eu japan china also sell pharmaceutical products countries however data provided countrybycountry basis individual country revenues significant outside us eu japan china many instances basic exclusivity loss date listed expiration date patent claims active ingredient drug method using drug approved indication one approved indication instances basic exclusivity loss date listed chart expiration date data exclusivity period situations data exclusivity without patent protection competitor could seek regulatory approval submitting clinical trial data obtain marketing approval prior expiration data exclusivity estimate market exclusivity period products purpose business planning length market exclusivity products impossible predict certainty complex interaction patent regulatory forms exclusivity inherent uncertainties regarding patent litigation assurance particular product enjoy market exclusivity full period time appears estimate exclusivity limited estimate following schedule presents revenues key products estimated basic exclusivity loss us eu japan china total revenues product past currently estimated year basic exclusivity loss dollars millions us eua japan china virology baraclude entecavir b c hepatitis c franchised e reyataz atazanavir sulfate franchise f sustiva efavirenz franchise g h oncology empliciti elotuzumabi erbitux cetuximab j k opdivo nivolumab l l l sprycel dasatinib yervoy ipilimumab n p neuroscience abilify aripiprazole q q immunoscience orencia abatacept r cardiovascular eliquis apixaban u v v note currently estimated earliest year basic exclusivity loss includes statutory extensions exclusivity granted instances may able obtain additional six months exclusivity product based pediatric extension certain instances may laterexpiring patents cover particular forms compositions drug well methods manufacturing methods using drug patents may sometimes result favorable market position products product exclusivity predicted assured us healthcare law enacted qualifying biologic products receive years data exclusivity biosimilar enter market described detail intellectual property product exclusivity indicates brand names products trademarks owned bms specific trademark ownership information included exhibit index currently market product country region indicated uncertainty china 's exclusivity laws resulted generic competition china market uncertainty china 's exclusivity laws may apotex inc actavis group ptc ehf generics uk limited mylan unnamed company filed oppositions european patent office epo seeking revocation european patent ' patent covering dasatinib active ingredient sprycel patent scheduled expire april excluding potential term extensions january opposition division epo revoked patent company appeal epos decision epo board appeal patent remain force pending outcome appeal epos decision intend pursue legal options defend intellectual property rights future infringement refer note legal proceedings contingencies information references eu throughout include member states european union year ended december basic patent applications filed current member states listed products instances date basic exclusivity loss different various eu member states eu countries basic patent obtained may data protection available b baraclude us september teva pharmaceuticals launched generic version baraclude experienced negative impact us net product sales baraclude beginning fourth quarter actions follow decision june us court appeals federal circuit uphold lower court decision invalidating baracludes patent february may us supreme court denied company 's petition writ certiorari accordingly case concluded information patent litigation matter refer item financial statementsnote legal proceedings contingencies c baraclude eu composition matter patent expires eu exclusivity period relates daklinza brand e composition matter covering daclatasvir japan expires including granted patent term extension f reyataz eu data exclusivity eu expired projected market exclusivity expires g sustiva us exclusivity period relates sustiva brand include exclusivity related combination therapy composition matter patent efavirenz us expired method use patent treatment hiv infection expired september pediatric exclusivity granted provides additional six month period exclusivity added term patents listed orange book october company announced successfully resolved outstanding us patent litigation relating efavirenz loss exclusivity us efavirenz expected occur december h sustiva eu exclusivity period relates sustiva brand include exclusivity related combination therapy market exclusivity sustiva expired november countries eu data exclusivity sustiva expired eu empliciti commercialization agreement abbvie inc abbvie empliciti information arrangement abbvie refer alliances item financial statementsnote alliances abbvie owns patent covering elotuzumab composition matter expires us excluding potential patent term extension eu japan china excluding potential patent term extensions eu japan j erbitux us biologic product approved biologics license application bla data exclusivity us expires patent specifically claims composition matter cetuximab active ingredient erbitux company transferred rights including full commercialization manufacturing responsibilities erbitux north america lilly return salesbased royalties information arrangement lilly refer alliances item financial statementsnote alliances k erbitux japan exclusivity period based regulatory data protection bms transferred cocommercialization rights japan merck kgaa exchange salesbased royalties l opdivo jointly patent ono pharmaceutical co ltd ono covering nivolumab composition matter expires us excluding potential patent term extension eu excluding potential patent term extensions composition matter patent covering nivolumab japan expires including granted patent term extension sprycel patent term extension granted us extending term basic composition matter patent covering dasatinib june company entered settlement agreement apotex regarding patent infringement suit covering monohydrate form dasatinib whereby apotex launch generic dasatinib monohydrate abbreviated new drug application product september earlier certain circumstances us orphan drug exclusivity expired n yervoy us exclusivity period based regulatory data protection data exclusivity expires us patent covering ipilimumab composition matter currently expires us excluding potential patent term extension yervoy eu exclusivity period based regulatory data protection data exclusivity expires eu patent covering ipilimumab composition matter currently expires eu excluding potential patent term extensions p yervoy japan exclusivity period based regulatory data protection patent covering ipilimumab composition matter currently expires japan excluding potential patent term extension q abilify commercialization rights abilify terminated april us june eu r orencia us series patents covering abatacept method use us patent term extension granted one composition matter patents extending term us patent data exclusivity expires us method use patent expires orencia eu eu composition matter patent covering abatacept expired majority eu countries applied supplementary protection certificates also pediatric extension supplementary protection certificates protection protection certificates granted data exclusivity expires eu method use patent expires orencia japan exclusivity period based regulatory data protection u eliquis us composition matter patent covering apixaban us expires february excluding potential patent term extension august received petition inter partes review composition matter patent covering apixaban filed united states patent trademark office coalition affordable drugs information patent litigation matter refer item financial statementsnote legal proceedings contingencies v eliquis eu japan composition matter patent covering apixaban eu expires applied supplementary protection certificates supplementary protection certificates granted expire data exclusivity eu expires composition matter covering apixaban japan expires including granted patent term extension summary indication product partner thirdparty manufacturing arrangements products us applicable eu japan baraclude baraclude potent selective inhibitor hepatitis b virus approved us food drug administration fda treatment chronic hepatitis b virus infection baraclude discovered developed internally bulk active entecavir manufactured company third party product finished facilities hepatitis c franchise daklinza daclatasvir dcv oral small molecule nsa replication complex inhibitor treatment hepatitis c virus infection hcv approved fda use gilead sciences inc 's gilead sofosbuvir genotype sunvepra asunaprevir asv oral small molecule ns protease inhibitor treatment hcv part dual regimen dcvasv japan manufacture bulk requirements daclatasvir finish product facilities obtain bulk requirements asunaprevir thirdparty manufacturer finish product thirdparty facility reyataz franchise reyataz protease inhibitor treatment hiv reyataz franchise includes reyataz combination therapy evotaz atazanavir mg cobicistat mg oncedaily single tablet two drug regimen combining reyataz gilead 's tybost cobicistat treatment hiv infection adults developed atazanavir worldwide license novartis pharmaceutical corporation novartis royalty paid based percentage net product sales entitled promote reyataz use combination norvir ritonavir nonexclusive license agreement abbvie amended royalty paid based percentage net product sales licensing agreement gilead evotaz approved us january eu july manufacture bulk requirements atazanavir finish product facilities sustiva franchise sustiva nonnucleoside reverse transcriptase inhibitor treatment hiv sustiva franchise includes sustiva antiretroviral drug used treatment hiv well bulk efavirenz included combination therapy atripla efavirenz mg emtricitabine mg tenofovir disoproxil fumarate mg oncedaily single tablet threedrug regimen combining sustiva gileads truvada emtricitabine tenofovir disoproxil fumarate information arrangement gilead refer alliances item financial statementsnote alliances rights market efavirenz us canada united kingdom uk france germany ireland italy spain licensed merck co inc merck royalty based percentage revenues efavirenz marketed another company japan obtain bulk requirements efavirenz third parties produce finished goods facilities supply third parties bulk efavirenz gilead responsible producing finished atripla product empliciti empliciti humanized monoclonal antibody approved fda treatment multiple myeloma part alliance abbvie terms alliance granted exclusive global rights codevelop commercialize empliciti november fda approved empliciti treatment multiple myeloma combination therapy revlimid dexamethasone patients received one three prior therapies revlimid product celgene corporation january committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending empliciti granted approval treatment multiple myeloma manufacture bulk requirement elotuzumab finish product facilities erbitux erbitux biological product igg monoclonal antibody designed exclusively target block epidermal growth factor receptor egfr expressed surface certain cancer cells multiple tumor types well normal cells erbitux approved combination irinotecan treatment patients egfrexpressing metastatic colorectal cancer mcrc failed irinotecanbased regimen monotherapy patients intolerant irinotecan fda approved erbitux use combination radiation therapy treatment locally regionally advanced squamous cell carcinoma head neck single agent treatment patients recurrent metastatic squamous cell carcinoma head neck prior platinumbased therapy failed fda also approved erbitux firstline recurrent locoregional metastatic head neck cancer combination platinumbased chemotherapy fluorouracil exclusive distribution rights north america cetuximab granted company imclone systems incorporated imclone predecessor company imclone llc whollyowned subsidiary eli lilly company lilly part alliance lilly october transferred erbitux rights north america lilly including full commercialization manufacturing responsibilities return salesbased royalties information arrangement lilly refer alliances item financial statementsnote alliances opdivo opdivo biological product fully human monoclonal antibody binds programmed death receptor pd natural killer nkt cells fda approved opdivo previously untreated patients metastatic melanoma previously treated patients advanced renal cell carcinoma previously treated nonsquamous nsq squamous sq nonsmall cell lung cancer nsclc opdivo received approval eu previously treated sq nsclc firstline previously treated unresectable metastatic melanoma opdivoyervoy ipilimumab regimen also approved fda treatment braf v wild type unresectable metastatic melanoma several ongoing potentially registrational trials opdivo head neck cancer hodgkin nonhodgkin lymphoma bladder cancer among tumor types refer alliances item financial statementsnote alliances discussion arrangement ono opdivo japan south korea taiwan obtain bulk requirements opdivo third party finish product facilities sprycel sprycel multitargeted tyrosine kinase inhibitor approved firstline treatment adults philadelphia chromosomepositive chronic myeloid leukemia chronic phase treatment adults chronic accelerated myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy including gleevec imatinib mesylate gleevec trademark novartis sprycel internally discovered part alliance otsuka pharmaceutical co ltd otsuka information alliance otsuka refer alliances item financial statementsnote alliances manufacture bulk requirements dasatinib finish product facilities yervoy yervoy biological product monoclonal antibody treatment patients unresectable metastatic melanoma yervoy approved us eu japan fda approved yervoy adjuvant treatment patients cutaneous melanoma information research development yervoy refer research development yervoy discovered medarex codeveloped company medarex subsidiary bulk ipilimumab manufactured company third party product finished facilities thirdparty facility abilify abilify atypical antipsychotic agent adult patients schizophrenia bipolar mania disorder major depressive disorder abilify also pediatric uses schizophrenia bipolar disorder among others bms 's rights abilify expired us april eu countries june information arrangement otsuka refer alliances item financial statementsnote alliances orencia orencia biological product fusion protein novel immunosuppressive activity targeted initially adult patients moderately severely active rheumatoid arthritis ra inadequate response certain currently available treatments orencia available intravenous subcutaneous formulation us europe japan refer alliances item financial statementsnote alliances discussion collaborations ono orencia japan bulk abatacept manufactured company third party finish formulations product facilities eliquis eliquis oral factor xa inhibitor targeted stroke prevention atrial fibrillation prevention treatment venous thromboembolic vte disorders apixaban discovered internally part alliance pfizer inc pfizer information alliance pfizer refer item financial statementsnote alliances apixaban manufactured company third party product finished facilities research development invest heavily research development rd believe critical longterm competitiveness major rd facilities new jersey expanding existing californiabased research facility announced future plans opening new rd site massachusetts research activities connecticut facility phased next years research development also carried various facilities throughout world including belgium uk india japan sites us supplement internal drug discovery development programs alliances collaborative agreements help us bring new products pipeline drug development engage services physicians hospitals medical schools research organizations worldwide conduct clinical trials establish safety effectiveness new products management continues emphasize leadership innovation productivity quality strategies success research development activities concentrate research development efforts following disease areas significant unmet medical needs immunooncology oncology immunoscience cardiovascular fibrotic diseases genetically defined diseases also continue analyze may selectively pursue promising leads areas addition discovering developing new molecular entities look ways expand value existing products new indications formulations provide additional benefits patients order new drug reach market industry practice government regulations us eu foreign countries provide determination drugs effectiveness safety preclinical tests controlled clinical evaluation clinical development potential new drug includes phase phase ii phase iii clinical trials designed specifically support new drug application particular indication assuming trials successful phase clinical trials involve small number healthy volunteers patients suffering indicated disease test safety proper dosing phase ii clinical trials involve larger patient population investigate side effects efficacy optimal dosage drug candidate phase iii clinical trials conducted confirm phase ii results significantly larger patient population longer term provide reliable conclusive data regarding safety efficacy drug candidate rd process typically takes fourteen years approximately three years often spent phase iii latestage development consider rd programs phase iii significant rd programs programs include investigational compounds phase iii development initial indications marketed products phase iii development additional indications formulations drug development time consuming expensive risky average one chemical compounds discovered pharmaceutical industry researchers proves medically effective safe enough become approved medicine drug candidates fail stage process even latestage product candidates sometimes fail receive regulatory approval according kmr group based industry success rates approximately compounds enter phase development fail achieve regulatory approval failure rate compounds enter phase ii development approximately compounds enter phase iii development approximately total research development expenses include costs discovery research preclinical development early latestage clinical development drug formulation well postcommercialization medical support marketed products proportionate allocations enterprisewide costs appropriate costs research development spending billion billion billion includes payments thirdparty collaborations contracts end employed approximately people rd activities including substantial number physicians scientists holding graduate postgraduate degrees higherskilled technical personnel manage rd programs portfolio basis investing resources stage research development early discovery latestage development continually evaluate portfolio rd assets ensure appropriate balance earlystage latestage programs support future growth company spending latestage development programs represented approximately annual rd expenses last three years individual investigational compound marketed product represented rd expenses last three years except opdivo listed investigational compounds phase ii iii clinical trials whether investigational compounds ultimately becomes one marketed products depends results clinical studies competitive landscape potential products market manufacturing processes necessary produce potential product commercial scale among factors assurance seek regulatory approval compounds approval sought obtained also assurance compound approved commercially successful stage development determine intellectual property issues patent protection may may available investigational compounds data january immuno genetically defined oncology oncology immunoscience cardiovascular fibrotic diseases diseases virology phase phase phase phase phase phase anticsf ra antifucosyl gm anticd factor xia inhibitors galectin inhibitorf antietauj antigitr antiherd anticdl par antagonist pegfgf antimyostatin antilag bet inhibitor btk inhibitor lirilumab antikirb mesothelinadc tyk inhibitor urelumab ulocuplumab anticd anticxcr antipdl phase ii phase ii phase ii phase ii bms lulizumab bms hiv maturation anticd ikur inhibitor lpa antagonistg inhibitork nitroxyl donore pegfgfh pentraxini phase iii phase iii prostvacc beclabuvir bms hiv attachment inhibitork exclusively licensed five prime therapeutics inc b exclusively licensed innate pharma sa c obtained exclusive option license bavarian nordic obtained exclusive license acquire fstar alpha ltd e obtained acquisition cardioxyl pharmaceuticals inc f obtained exclusive option acquire galecto biotech ab g obtained acquisition amira pharmaceuticals inc refer item financial statementsnote goodwill intangible assets additional information h exclusively licensed ambrx inc obtained exclusive warrant acquire promedior inc j obtained acquisition ipierian inc k pending sale viiv healthcare additional information latestage investigational compounds phase iii clinical trials regulatory review least one potential indication patent coverage highlighted includes patent terms patent term extensions granted beclabuvir beclabuvir oral small molecule nonnucleoside nsb inhibitor regulatory review japan use combination dcv asv treatment hcv patent covering beclabuvir composition matter expires us bms bms investigational compound studied hiv shown antiviral activity hiv infected individuals attachment inhibitors distinct mode action entry inhibitors prevent entry hiv host cell following attachment bms prodrug metabolized active basic compound hold patent covering bms composition matter expires november us bms expected sold viiv healthcare first half prostvac prostvac bavarian nordic 's investigational phase iii prostatespecific antigen psatargeting cancer immunotherapy development treatment asymptomatic minimally symptomatic metastatic castrationresistant prostate cancer bms exclusive option license commercialize prostvac following table lists potential additional indications andor formulations key marketed products potentially registrational trials currently regulatory review key marketed product potential indication andor formulation hepatitis c franchise combination antivirals treatment hcv empliciti additional indication firstline multiple myeloma opdivo additional indications melanoma renal cell carcinoma rcc lung cancer hodgkin nonhodgkin lymphoma head neck cancer bladder cancer glioblastoma hepatocellular carcinoma gastric cancer esophageal cancer monotherapy andor combination yervoy orencia additional indications lupus nephritis psoriatic arthritis early ra autoinjector device eliquis pediatric vte treatment following key developments currently expected occur respect significant pipeline programs outcome timing expected developments dependent upon number factors including among things availability data outcome certain clinical trials acceptance presentations certain medical meetings andor actions health authorities undertake obligation publicly update information whether result new information future events otherwise hepatitis c franchise data available clinical trials potential approvals additional indications empliciti potential approval multiple myeloma eu japan data available phase iii study firstline multiple myeloma opdivo potential approval eu nsq nsclc opdivoyervoy combination melanoma rcc data available potentially registrational clinical trials hodgkin nonhodgkin lymphoma head neck cancer bladder cancer glioblastoma lung cancer potential submissions various tumors based registrational trials alliances enter alliances third parties transfer rights develop manufacture market andor sell pharmaceutical products owned parties alliances include licensing arrangements codevelopment comarketing agreements copromotion arrangements joint ventures alliances involve sharing research development costs risk incurring research development expenses compounds lead revenuegenerating products reduced however profitability alliance products generally lower profits alliance products shared alliance partners actively pursue arrangements view alliances important complement discovery development commercialization activities alliances third parties rights manufacture market andor sell pharmaceutical products contain customary early termination provisions typically found agreements kind generally based material breach agreement party bankruptcy voluntary involuntary party product safety concerns amount notice required early termination generally ranges immediately upon notice days receipt notice termination immediately upon notice generally available party files voluntary bankruptcy petition material safety issue arises product medical riskbenefit incompatible welfare patients continue develop commercialize product termination notice period generally available involuntary bankruptcy petition filed dismissed material breach party occurred cured alliance agreements also permit us terminate without cause typically exercisable substantial advance written notice sometimes exercisable specified period time elapsed alliance agreement signed alliances typically otherwise contain provisions provide party right terminate alliance general retain rights product brought alliance another party partys intellectual property alliance terminates loss rights one products marketed sold us pursuant alliance could material results operations cash flows could material financial condition liquidity customary pharmaceutical industry terms alliances generally coextensive exclusivity period may vary countrybycountry basis significant current alliances currently marketed products investigational compounds described refer item financial statementsnote alliances additional information alliance agreements otsuka maintain worldwide commercialization agreement otsuka codevelop copromote abilify excluding certain asian countries us portion agreement expired april agreement expired eu countries june nonus country exclusive right sell abilify agreement expires later april loss exclusivity country bms received share us net sales abilify based tiered structure bms otsuka also alliance sprycel us japan eu oncology territory february copromotion agreement otsuka terminated japan ixempra ixabepilone included alliance prior bms 's divestiture business fee paid otsuka based combined annual net sales sprycel ixempra oncology territory including post divestiture ixempra sales gilead joint ventures gilead develop commercialize atripla us canada europe company gilead share responsibility certain activities related commercialization atripla us canada throughout eu certain european countries gilead recognizes atripla revenues us canada countries europe alliance revenues recognized atripla include bulk efavirenz component atripla calculated differently eu us following loss exclusivity sustiva eu alliance revenues deferred related alliance receivable recognized atripla sold thirdparty customers collaboration agreement governing commercialization atripla us canada continue terminated mutual agreement parties otherwise described event material breach one party collaboration agreement nonbreaching party may terminate agreement breaching party cure material breach parties agree desirable practicable withdraw combination product markets commercialized time one generic versions partys component products launched us party right terminate collaboration agreement control joint venture commercialization combination product us canada however three years terminated party continue receive percentage net product salesbased contribution bulk components atripla otherwise retains rights products europe following loss exclusivity sustiva effective january percentage atripla net sales europe recognized bms equal difference average net selling prices atripla truvada alliance continue europe either party terminates arrangement last patent expiration occurs atripla truvada sustiva entered licensing agreement gilead develop commercialize fixeddose combination containing reyataz gileads cobicistat pharmacoenhancing boosting agent increases blood levels certain hiv medicines potentially allow one pill daily dosing evotaz approved fda january european commission ec july lilly bms commercialization agreement lilly lillys subsidiary imclone codevelopment promotion erbitux us canada japan october bms transferred rights erbitux north america lilly exchange salesbased royalties transferred rights include limited full commercialization manufacturing responsibilities bms shared rights erbitux japan agreement lilly merck kgaa received pretax profit merck kgaas net sales erbitux japan shared equally lilly bms transferred cocommercialization rights japan merck kgaa exchange sales based royalties abbvie bms abbvie alliance empliciti terms alliance bms granted exclusive global rights codevelop commercialize empliciti pdl biopharma inc part abbvie parties codeveloping product abbvie funds global development costs bms solely responsible supply distribution sales marketing activities within alliance principal end customer product sales abbvie shares profits losses us paid tiered royalties net sales empliciti outside us addition abbvie entitled receive milestone payments bms certain regulatory events sales thresholds achieved astrazeneca february sold astrazeneca plc astrazeneca diabetes business comprised global alliance including rights ownership onglyza farxiga bydureon byetta symlin myalept astrazeneca terminated existing alliance agreements connection sale entered several new agreements including transitional services agreement supply agreement development agreement supply agreement continue manufacturing responsibilities onglyza kombiglyze farxiga pfizer company pfizer parties worldwide codevelopment cocommercialization agreement eliquis pfizer funds development costs depending study companies share commercialization expenses profits losses equally global basis except certain countries pfizer commercializes eliquis pays bms compensation based percentage net sales ono bms principal end customer product sales exclusive right develop manufacture commercialize opdivo territories worldwide except japan south korea taiwan ono responsible development commercialization prior arrangement described ono entitled receive royalties following regulatory approvals territories excluding three countries listed royalty rates net sales north america applicable territories subject customary adjustments alliance arrangement expanded july establish collaboration activities japan south korea taiwan pertaining opdivo several bms compounds including yervoy lirilumab urelumab bms antilag parties right obligation jointly develop commercialize compounds bms responsible supply products profits losses development costs shared equally combination therapies involving compounds parties otherwise sharing activities involving one partys compounds bms ono also alliance codevelop cocommercialize orencia japan bms responsible order fulfillment distribution intravenous formulation ono responsible subcutaneous formulation formulations jointly promoted parties assigned customer accounts bms responsible product supply copromotion fee paid party sale made partys assigned customer alliances may bms reckitt benckiser group plc reckitt started threeyear alliance regarding several overthecounterproducts sold primarily mexico brazil reckitt received right sell distribute market products may bms also granted reckitt option acquire trademarks inventory certain assets exclusively related products end alliance period including bms manufacturing facility located mexico price determined primarily based multiple net sales may may july reckitt notified bms exercising option substantially employees facility expected transferred reckitt closing expected occur may licensing arrangements addition alliances described inlicensing outlicensing arrangements respect inlicenses agreements novartis reyataz merck efavirenz among others also certain compounds outlicensed third parties development commercialization including obtained acquisitions entitled receive milestone payments compounds move regulatory process royalties based net product sales products commercialized intellectual property product exclusivity license number patents us foreign countries primarily covering products also developed many brand names trademarks products consider overall protection patents trademarks licenses intellectual property rights material value act protect rights infringement pharmaceutical industry majority innovative products commercial value usually realized period product market exclusivity products market exclusivity generally determined two forms intellectual property patent rights held innovator company regulatory forms exclusivity innovative drug entitled patents key determinant market exclusivity branded pharmaceuticals patents provide innovator right exclude others practicing invention related medicine patents may cover among things active ingredients various uses drug product pharmaceutical formulations drug delivery mechanisms processes intermediates useful manufacture products protection individual products extends varying periods accordance expiration dates patents various countries protection afforded may also vary country country depends upon type patent scope coverage availability meaningful legal remedies country market exclusivity also sometimes influenced regulatory intellectual property rights many developed countries provide certain nonpatent incentives development medicines example us eu japan certain countries regulatory intellectual property rights offered incentives research medicines rare diseases orphan drugs medicines useful treating pediatric patients incentives extend market exclusivity period product beyond patent term us eu japan china also provide minimum period time approval new drug regulatory agency may rely upon innovators data approve competitors generic copy data protection regions china however questionable whether data protection laws enforceable certain markets patent protection forms market exclusivity may expired data protection particular importance however regulatory forms exclusivity prevent competitor gaining regulatory approval prior expiration regulatory data exclusivity basis competitors safety efficacy data drug even drug identical marketed innovator specific aspects law governing market exclusivity data protection pharmaceuticals vary country country following summarizes key exclusivity rules markets representing significant sales united states us key products protected patents varying terms depending type patent filing date significant portion products patent life however lost time takes innovative company develop obtain regulatory approval new drug compensation least part lost patent term innovator may depending number factors extend expiration date one patent maximum term five years provided extension cause patent effect years date drug approval company seeking market innovative pharmaceutical us must submit complete set safety efficacy data fda innovative pharmaceutical chemical company files new drug application nda medicine biological product bla filed type application filed affects regulatory exclusivity rights chemical products competitor seeking launch generic substitute chemical innovative drug us must file abbreviated new drug application anda fda anda generic manufacturer needs demonstrate bioequivalence generic substitute approved nda drug anda relies upon safety efficacy data previously filed innovator nda innovator company required list certain patents covering medicine fda commonly known orange book absent successful patent challenge fda approve anda innovators listed patents expire however innovator marketed product four years generic manufacturer may file anda allege one patents listed orange book innovators nda either invalid infringed allegation commonly known paragraph iv certification innovator must decide whether file patent infringement suit generic manufacturer time time andas including paragraph iv certifications filed respect certain products evaluate andas casebycase basis warranted file suit generic manufacturer protect patent rights addition benefiting patent protection certain innovative pharmaceutical products receive periods regulatory exclusivity nda designated orphan drug receive seven years exclusivity orphan indication time period neither ndas andas drug product approved orphan use company may also earn six months additional exclusivity drug specific clinical trials conducted written request fda study use medicine treat pediatric patients submission fda made prior loss basic exclusivity medicines approved nda also receive several types regulatory data protection innovative chemical pharmaceutical entitled five years regulatory data protection us competitors file fda approval generic substitutes innovators patent challenged described generic manufacturer may file anda fourth year fiveyear data protection period pharmaceutical drug product contains active ingredient previously approved nda approved new formulation drug new indication basis new clinical trials receives three years data protection formulation indication biologic products us healthcare legislation enacted created approval pathway biosimilar versions innovative biological products previously exist prior time innovative biologics essentially unlimited regulatory exclusivity new regulatory mechanism fda approve products similar generic copies innovative biologics basis less extensive data required full bla innovator marketed product four years manufacturer may file application approval biosimilar version innovator product however although application approval biosimilar may filed four years approval innovator product qualified innovative biological products receive years regulatory exclusivity meaning fda may approve biosimilar version years innovative biological product first approved fda law also provides mechanism innovators enforce patents protect innovative biological products biosimilar applicants challenge patents patent litigation may begin early four years innovative biological product first approved fda us increased likelihood generic biosimilar challenges innovators intellectual property increased risk loss innovators market exclusivity first generic companies increasingly sought challenge innovators basic patents covering major pharmaceutical products second statutory regulatory provisions us limit ability innovator company prevent generic biosimilar drugs approved launched patent litigation ongoing result developments possible predict length market exclusivity particular product certainty based solely expiration relevant patents current forms regulatory exclusivity european union patents pharmaceutical products generally enforceable eu us may extended compensate patent term lost regulatory review process extensions granted countrybycountry basis primary route use obtain marketing authorization pharmaceutical products eu centralized procedure procedure compulsory certain pharmaceutical products particular using biotechnological processes also available certain new chemical compounds products company seeking market innovative pharmaceutical product centralized procedure must file complete set safety data efficacy data part maa ema ema evaluates maa provides recommendation ec ec approves denies maa also possible new chemical products obtain marketing authorization eu mutual recognition procedure application made single member state member state approves pharmaceutical product national procedure applicant may submit approval mutual recognition procedure member states obtaining marketing authorization approval company must obtain pricing reimbursement pharmaceutical product typically subject member state law certain eu countries process take place simultaneously product marketed eu countries process must completed company market new product pricing reimbursement procedure take months sometimes years complete throughout eu products marketing authorizations filed octobernovember subject regime eight years innovator received first community authorization medicinal product generic company may file marketing authorization application product health authorities marketing authorization application approved generic company may commercialize product either years elapsed initial marketing authorization granted innovator possible extension years available innovator first eight years marketing authorization obtains additional indication significant clinical benefit comparison existing treatments products filed prior octobernovember year period data protection centralized procedures period either six years mutual recognition procedure depending member state contrast us patents eu listed regulatory authorities generic versions pharmaceutical products approved data protection expires regardless whether innovator holds patents covering drug thus possible innovator may seeking enforce patents generic competitor already marketing product also european patent system opposition procedure generic manufacturers may challenge validity patents covering innovator products within nine months grant general eu law treats chemicallysynthesized drugs biologicallyderived drugs respect intellectual property data protection addition relevant legislation annexes related biologic medicinal products ema issued guidelines outline additional information provided biosimilar products also known generic biologics order review application marketing approval japan japan medicines new chemical entities generally afforded eight years data exclusivity approved indications dosage patents pharmaceutical products enforceable generic copies receive regulatory approval data exclusivity patent expirations us patents japan may extended compensate patent term lost regulatory review process general japanese law treats chemicallysynthesized biologicallyderived drugs respect intellectual property market exclusivity china china medicines new chemical entities generally afforded six years data exclusivity approved indications dosage uncertainty chinas exclusivity laws resulted generic competition china market generic copies receive regulatory approval data exclusivity patent expirations currently unlike us china patent term restoration compensate patent term lost regulatory process general chinese law treats chemicallysynthesized biologicallyderived drugs respect intellectual property market exclusivity rest world countries outside us eu japan china wide variety legal systems respect intellectual property market exclusivity pharmaceuticals developed countries utilize systems similar either us eu among developing countries adopted patent laws andor regulatory exclusivity laws others developing countries formally adopted laws order comply world trade organization wto commitments taken steps implement laws meaningful way enforcement wto actions long process governments assurance outcome thus assessing likely future market exclusivity innovative drugs developing countries take account formal legal rights political factors well marketing distribution customers promote appropriate use products directly healthcare professionals providers doctors nurse practitioners physician assistants pharmacists technologists hospitals pharmacy benefit managers pbms managed care organizations mcos also provide information appropriate use products consumers us directtoconsumer print radio television digital advertising promotion addition sponsor general advertising educate public innovative medical research corporate mission discussion regulation promotion marketing pharmaceuticals refer government regulation price constraints field sales medical organizations explain risks benefits approved uses products medical professionals work gain access products formularies reimbursement plans lists recommended approved medicines products including medicare part plans providing information clinical profiles products marketing sales prescription pharmaceuticals limited approved uses particular product continue develop scientific data information products provide information response unsolicited inquiries doctors medical professionals managed care organizations operations include several marketing sales organizations product marketing organization supported sales force may responsible selling one products also marketing organizations focus certain classes customers managed care entities certain types marketing tools digital consumer communications sales forces focus communicating information new products new uses well established products promotion physicians increasingly targeted physician specialists treat patients need medicines products sold principally wholesalers lesser extent directly distributors retailers hospitals clinics government agencies pharmacies gross revenues three largest pharmaceutical wholesalers us percentage global gross revenues follows mckesson corporation amerisourcebergen corporation cardinal health inc us business inventory management agreements imas substantially direct wholesaler distributor customers allow us monitor us wholesaler inventory levels requires wholesalers distributors maintain inventory levels one month demand imas including three largest wholesalers expire december subject certain termination provisions number defined countries outside us established full scale distributor model make medically necessary drugs available patients continue marketing authorization trademarks products contracted services fullservice distributor provide distribution logistics regulatory pharmacovigilance sales advertising promotion certain products sales distributorbased countries represented approximately companys total revenues competition markets compete generally broad based highly competitive compete worldwide researchbased drug companies many smaller research companies limited therapeutic focus generic drug manufacturers important competitive factors include product efficacy safety ease use price demonstrated costeffectiveness marketing effectiveness product labeling customer service research development new products processes sales products impacted new studies indicate competitors product safer effective treating disease particular form disease one products revenues also impacted additional labeling requirements relating safety convenience may imposed products fda similar regulatory agencies different countries competitors introduce new products processes therapeutic cost advantages products subject progressive price reductions decreased volume sales generic competition one biggest competitive challenges face generic pharmaceutical manufacturers us eu regulatory approval process exempts generics costly timeconsuming clinical trials demonstrate safety efficacy allowing generic manufacturers rely safety efficacy innovator product result generic pharmaceutical manufacturers typically invest far less research development researchbased pharmaceutical companies therefore price products significantly lower branded products accordingly branded product loses market exclusivity normally faces intense price competition generic forms product upon expiration loss market exclusivity product lose major portion revenues product short period time rate revenues decline product expiration exclusivity varies country general decline us market rapid developed countries though observed rapid declines number eu countries well also declines developed countries tend rapid developing countries rate revenues decline expiration exclusivity also historically influenced product characteristics example drugs used large patient population eg prescribed key primary care physicians tend experience rapid declines drugs specialized areas medicine eg oncology drugs complex manufacture eg sterile injectable products usually experience slower decline simpler manufacture certain countries outside us patent protection weak nonexistent must compete generic versions shortly launch innovative products addition generic pharmaceutical companies may introduce generic product exclusivity expired resolution related patent litigation information market exclusivity refer intellectual property product exclusivity believe longterm competitive position depends upon success discovering developing innovative costeffective products serve unmet medical needs together ability manufacture products efficiently market effectively highly competitive environment managed care organizations growth mcos us also major factor healthcare marketplace half us population participates version managed care mcos include medical insurance companies medical plan administrators healthmaintenance organizations medicare part prescription drug plans alliances hospitals physicians physician organizations organizations consolidating fewer larger entities thus enhancing purchasing strength importance us successfully compete business mcos must often demonstrate products offer medical benefits also cost advantages compared forms care new products introduce compete products already market products later developed competitors noted generic drugs exempt costly timeconsuming clinical trials demonstrate safety efficacy often lower costs brandname drugs mcos focus primarily immediate cost drugs often favor generics reason many governments also encourage use generics alternatives brandname drugs healthcare programs laws us generally allow many cases require pharmacists substitute generic drugs rated government procedures essentially equivalent brandname drug substitution must made unless prescribing physician expressly forbids exclusion product formulary lead sharply reduced usage mco patient population consequently pharmaceutical companies compete aggressively products included possible companies compete inclusion based upon unique features products greater efficacy better patient ease use fewer side effects lower overall cost therapy also important factor products demonstrate fewer therapeutic advantages must compete inclusion based primarily price generally although universally successful major products included mco formularies government regulation price constraints pharmaceutical industry subject extensive global regulation regional country state local agencies federal food drug cosmetic act fdc act federal statutes regulations various state statutes regulations laws regulations foreign governments govern varying degrees testing approval production labeling distribution postmarket surveillance advertising dissemination information promotion products lengthy process laboratory clinical testing data analysis manufacturing development regulatory review necessary required governmental approvals extremely costly significantly delay product introductions given market promotion marketing manufacturing distribution pharmaceutical products extensively regulated major world markets addition operations subject complex federal state local foreign environmental occupational safety laws regulations anticipate laws regulations affecting manufacture sale current products introduction new products continue require substantial scientific technical effort time expense well significant capital investments particular importance fda us jurisdiction virtually activities imposes requirements covering testing safety effectiveness manufacturing labeling marketing advertising postmarketing surveillance products many cases fda requirements increased amount time money necessary develop new products bring market us fda mandates drugs manufactured packaged labeled conformity current good manufacturing practices cgmp established fda complying cgmp regulations manufacturers must continue expend time money effort production recordkeeping quality control ensure products meet applicable specifications requirements ensure product safety efficacy fda periodically inspects drug manufacturing facilities ensure compliance applicable cgmp requirements failure comply statutory regulatory requirements subjects us possible legal regulatory action suspension manufacturing seizure product voluntary recall product adverse experiences use products must reported fda could result imposition market restrictions labeling changes product removal product approvals may withdrawn compliance regulatory requirements maintained problems concerning safety efficacy occur following approval federal government extensive enforcement powers activities pharmaceutical manufacturers including authority withdraw delay product approvals commence actions seize prohibit sale unapproved noncomplying products halt manufacturing operations compliance cgmps impose seek injunctions voluntary recalls civil monetary criminal penalties restriction prohibition sales withdrawal approval products marketed us could materially adversely affect business financial condition results operations cash flows marketing authorization products subject revocation applicable governmental agencies addition modifications enhancements approved products changes manufacturing locations many circumstances subject additional fda approvals may may received may subject lengthy application process distribution pharmaceutical products subject prescription drug marketing act pdma part fdc act regulates activities federal state level pdma implementing regulations states permitted require registration manufacturers distributors provide pharmaceuticals even manufacturers distributors place business within state states also permitted adopt regulations limiting distribution product samples licensed practitioners pdma also imposes extensive licensing personnel recordkeeping packaging quantity labeling product handling facility storage security requirements intended prevent sale pharmaceutical product samples product diversions medicines priced based number factors including value scientific innovation patients society context overall health care spend economic factors impacting health care systems ability provide appropriate sustainable access necessity sustain investment innovation platforms address serious unmet medical needs central price clinical value innovation brings market current landscape alternative treatment options goal ensuring appropriate patient access innovation sustaining investment innovative platforms continue explore innovative pricing approaches ensure patients access medicines enhancing patient access medicines priority us focused offering creative tiered pricing voluntary licensing reimbursement support patient assistance programs optimize access protecting innovation advocating sustainable healthcare policies infrastructure leveraging advocacypayers input utilizing partnerships appropriate improving access care supportive services vulnerable patients partnerships demonstration projects fda amendments act imposed additional obligations pharmaceutical companies delegated enforcement authority fda area drug safety key elements legislation give fda authority require companies conduct postmarketing safety studies drugs impose certain drug labeling changes relating safety mandate risk mitigation measures education healthcare providers restricted distribution medicines require companies publicly disclose data clinical trials prereview television advertisements marketing practices us pharmaceutical manufacturers subject federal state healthcare laws used protect integrity government healthcare programs office inspector general us department health human services oig oversees compliance applicable federal laws connection payment products government funded programs primarily medicaid medicare laws include federal antikickback statute criminalizes offering something value induce recommendation order purchase products services reimbursed government healthcare program oig issued series guidances segments healthcare industry including compliance program guidance pharmaceutical manufacturers oig guidance includes recommendation pharmaceutical manufacturers minimum adhere phrma code voluntary industry code marketing practices subscribe phrma code implemented compliance program address requirements set forth oig guidance compliance healthcare laws failure comply healthcare laws could subject us administrative legal proceedings including actions federal state government agencies actions could result imposition civil criminal sanctions may include fines penalties injunctive remedies impact could materially adversely affect business financial condition results operations cash flows also subject jurisdiction various federal state regulatory enforcement departments agencies federal trade commission department justice department health human services us also licensed us drug enforcement agency procure produce controlled substances therefore subject possible administrative legal proceedings actions organizations actions may result imposition civil criminal sanctions may include fines penalties injunctive administrative remedies activities outside us also subject regulatory requirements governing testing approval safety effectiveness manufacturing labeling marketing products regulatory requirements vary country country whether fda approval approval ec obtained product approval product comparable regulatory authorities countries outside us eu case may must obtained prior marketing product countries approval process may less rigorous country country time required approval may longer shorter required us approval one country assure product approved another country many markets outside us operate environment governmentmandated costcontainment programs several governments placed restrictions physician prescription levels patient reimbursements emphasized greater use generic drugs andor enacted acrosstheboard price cuts methods cost control eu countries example government regulates pricing new product launch often direct price controls international price comparisons controlling profits andor reference pricing markets uk germany government set pricing restrictions launch pricing freedom subsequently limited operation profit price control plan uk operation reference price system germany companies also face significant delays market access new products mainly france spain italy belgium two years elapse new medicines become available national markets additionally member states eu regularly imposed new additional cost containment measures pharmaceuticals volume discounts cost caps cost sharing increases excess prior year costs individual products aggregated market level spending outcomebased pricing schemes free products portion expected therapy period recent years italy example imposed mandatory price decreases existence price differentials within eu due different national pricing reimbursement laws leads significant parallel trade flows us healthcare industry subject various governmentimposed regulations authorizing prices price controls continue impact total revenues participate state government medicaid programs well certain qualifying federal state government programs whereby discounts rebates provided participating state local government entities also participate government programs specify discounts certain government entities significant us department defense us department veterans affairs entities receive minimum discounts based defined nonfederal average manufacturer price purchases result patient protection affordable care act hr reconciliation bill containing package changes healthcare bill experienced continue experience additional financial costs certain changes business example minimum rebates medicaid drug sales increased percent percent medicaid rebates also extended drugs used riskbased medicaid managed care plans addition extend discounts certain critical access hospitals cancer hospitals covered entities required expansion b drug pricing program public health service act required provide percent discount brandname drugs patients fall within medicare part coverage gap also referred donut hole pay annual nontaxdeductible fee federal government based allocation market share branded drug sales certain government programs including medicare medicaid department veterans affairs department defense tricare discussion rebates programs refer item managements discussion analysis financial condition results operations total revenues critical accounting policies sources availability raw materials general purchase raw materials supplies required production products open market products purchase raw materials supplies one source source available us single source approved source among many available us thereby requiring us obtain raw materials supplies particular source attempt possible mitigate raw material supply risks inventory management alternative sourcing strategies discussion sourcing refer manufacturing quality assurance discussions particular products manufacturing quality assurance operate manage manufacturing network manner permits us improve efficiency maintaining flexibility reallocate manufacturing capacity pharmaceutical production processes complex highly regulated vary widely product product given shifting adding manufacturing capacity lengthy process requiring significant capital expenditures well regulatory approvals maintain operate flexible manufacturing network consisting internal external resources minimize unnecessary product transfers inefficient uses manufacturing capacity discussion regulatory impact manufacturing refer government regulation price constraints pharmaceutical manufacturing facilities located us puerto rico france italy ireland japan mexico china require significant ongoing capital investment maintenance compliance increasing regulatory requirements addition product line changes next several years expect continue modification existing manufacturing network meet complex processing standards may required newly introduced products including biologics biologics manufacturing involves complex processes traditional pharmaceutical operations fda approved large scale multiproduct bulk biologics manufacturing facility devens massachusetts may continue make capital investments facility building new largescale biologics manufacturing facility cruiserath ireland rely third parties manufacture supply us portion active ingredients necessary us manufacture various products including baraclude sustiva franchise yervoy opdivo reyataz orencia eliquis beginning october following transfer rights erbitux north america lilly lilly assumed manufacturing responsibilities erbitux maintain stable supply products take variety actions including inventory management maintenance additional quantities materials possible designed provide reasonable level ingredients held thirdparty supplier us manufacturing operations interrupted additional protection cases take steps maintain approved backup source available example rely capacity devens massachusetts facility capacity available third party contract manufacturers manufacture orencia thirdparty manufacturer rely existing future products unable maintain stable supply products operate sufficient capacity meet order requirements comply government regulations manufacturing pharmaceuticals meet complex processing requirements biologics business performance prospects could negatively impacted additionally thirdparty suppliers experience extended plant shutdowns substantial unplanned increases demand suspension manufacturing regulatory reasons could experience interruption supply certain products product shortages production could resumed expanded connection divestitures licensing arrangements distribution agreements certain products certain circumstances entered agreements agreed supply products third parties addition liabilities could arise failure supply products agreements arrangements could require us invest facilities production nonstrategic products result additional regulatory filings obligations cause interruption manufacturing products success depends great measure upon customer confidence quality products integrity data support safety effectiveness product quality arises total commitment quality parts operations including research development purchasing facilities planning manufacturing distribution maintain qualityassurance procedures relating quality integrity technical information production processes control production processes involves detailed specifications ingredients equipment facilities manufacturing methods processes packaging materials labeling perform tests various stages production processes final product ensure product meets regulatory requirements standards tests may involve chemical physical chemical analyses microbiological testing combination along analyses quality control provided business unitsite quality assurance groups monitor existing manufacturing procedures systems used us subsidiaries thirdparty suppliers environmental regulation facilities operations subject extensive us foreign laws regulations relating environmental protection human health safety including governing discharges pollutants air water use management disposal hazardous radioactive biological materials wastes cleanup contamination pollution controls permits required many operations permits subject modification renewal revocation issuing authorities environment health safety group monitors operations around world providing us overview regulatory requirements overseeing implementation standards compliance also incur operating capital costs matters ongoing basis expended approximately million million million capital projects undertaken specifically meet environmental requirements addition invested projects reduce resource use energy water although believe substantial compliance applicable environmental health safety requirements permits required operations nevertheless could incur additional costs including civil criminal fines penalties cleanup costs thirdparty claims property damage personal injury violations liabilities laws many current former facilities operation many years time operators facilities generated used stored disposed substances wastes considered hazardous federal state andor foreign environmental laws including us comprehensive environmental response compensation liability act cercla result soil groundwater certain facilities may contaminated may required make significant expenditures investigate control remediate contamination cases provide compensation andor restoration damages natural resources currently involved investigation remediation current former facilities also identified potentially responsible party prp applicable laws environmental conditions approximately former waste disposal reprocessing facilities operated third parties investigation andor remediation activities ongoing may face liability cercla federal state foreign laws entire cost investigation remediation contaminated sites natural resource damages regardless fault ownership time disposal release addition certain sites bear remediation responsibility pursuant contractual obligations generally thirdparty operator sites involving multiple prps liability expected apportioned based nature amount hazardous substances disposed party site number financially viable prps additional information matters refer item financial statementsnote legal proceedings contingencies employees december employed approximately people foreign operations significant operations outside us conducted subsidiaries distributors discussion total revenues geographic area refer item managements discussion analysis financial condition results operationstotal revenues international operations subject certain risks inherent conducting business abroad including limited currency fluctuations possible nationalization expropriation price exchange controls counterfeit products limitations foreign participation local enterprises restrictive governmental actions international businesses also subject governmentimposed constraints including laws pricing reimbursement use products depending direction change relative us dollar foreign currency values increase decrease reported dollar value net assets results operations change foreign exchange rates net unfavorable impact growth rate revenues predict certainty future changes foreign exchange rates effect growth rate revenues attempt mitigate impact operational means using various financial instruments refer discussions item quantitative qualitative disclosures market risk item financial statementsnote financial instruments fair value measurements bristolmyers squibb website internet website address wwwbmscom website make available free charge annual quarterly current reports including amendments reports soon reasonably practicable electronically file material furnish material us securities exchange commission sec information relating corporate governance bristolmyers squibb including principles integrity code ethics senior financial officers code business conduct ethics directors collectively codes corporate governance guidelines information concerning executive committee board directors including board committees committee charters transactions bristolmyers squibb securities directors executive officers available website investorscorporate governance caption print stockholder upon request waivers codes directors executive officers material amendment code business conduct ethics directors code ethics senior financial officers posted promptly website information relating stockholder services including dividend reinvestment plan direct deposit dividends available website investorsstockholder services caption addition information sustainability programs available website responsibility caption incorporate reference certain information parts proxy statement annual meeting stockholders sec allows us disclose important information referring manner please refer information proxy statement annual meeting stockholders annual report available website investorssec filings caption march item risk factors factors described could significantly negatively affect business prospects financial condition operating results credit ratings could cause trading price common stock decline additional risks uncertainties presently known us risks currently consider immaterial could also impair operations financial condition face intense competition manufacturers including innovative medicines lowerpriced generic products bms dependent market access uptake expansion marketed brands new product introductions new indications product extensions co promotional activities alliance partners deliver future growth competition keen includes lowerpriced generics increasingly aggressive generic commercialization tactics ii lower prices companies ' products real perceived superior efficacy benefit safety risk profiles differentiating factors iii technological advances patents attained competitors iv clinical study results products competitors products affect value proposition products v business combinations among competitors major thirdparty payers vi competing interests external partnerships develop bring new products markets could lose market exclusivity product earlier expected pharmaceutical biotechnology industries majority innovative products commercial value realized market exclusivity period us countries market exclusivity expires generic versions approved marketed biosimilars introduced even competing product usually substantial rapid declines products revenues market exclusivity products based upon patent rights certain regulatory forms exclusivity scope patent rights varies country country may also dependent availability meaningful legal remedies country failure obtain patent intellectual property rights limitations use loss rights could material us countries including certain eu member states basic patent protections products may exist certain countries historically offer right obtain specific types patents andor licensors file countries addition patent environment unpredictable validity enforceability patents predicted certainty absent relevant patent protection product data exclusivity period expires generic versions approved marketed generic biosimilar product manufacturers well groups seeking financial gain also increasingly seeking challenge patents expire could face earlierthanexpected competition products time patents covering key products likely continue subject patent litigation cases manufacturers may seek regulatory approval submitting clinical trial data obtain marketing approval choose launch generic product risk expiration applicable patents andor final resolution related patent litigation assurance particular product enjoy market exclusivity full time period appears estimates disclosed form k addition countries india allowing competitors manufacture sell competing generic products negatively impacts protections afforded company lowerpriced biosimilars bms biologic products competing biologics could negatively impact volumes prices increased pricing pressure restrictions us abroad managed care organizations institutional purchasers government agencies programs among others could negatively affect revenues profit margins products continue subject increasing pressures across portfolio market access pricing discounting restrictions us eu regions around world including rules practices managed care organizations institutional governmental purchasers ii judicial decisions changes laws regulations federal healthcare programs medicare medicaid well us healthcare reform government actions inquiries iii potential impact changes pharmaceutical reimbursement increased pricing pressure medicare part formularies medicare part b reimbursement rates well commercial formularies general iv reimbursement delays v government price erosion mechanisms across europe countries resulting deflation pharmaceutical product pricing vi collection delays governmentfunded public hospitals outside us vii impact pricing parallel trade across borders viii developments technology andor industry practices could impact reimbursement policies practices thirdparty payers ix inhibited market access due real perceived differences value propositions products compared competing products thirdparty royalties represent significant percentage pretax income operating cash flow entered several arrangements entitle us potential royalties third parties outlicensed intellectual property commercialization rights salesbased contingent proceeds related divestiture businesses many arrangements minimal continuing involvement contribute financial success activities royalties continued represent significant percentage pretax income including royalties related sanofi alliance outlicensed intellectual property contingent proceeds resulting divestiture diabetes erbitux businesses pretax income generated royalties approximately million pretax income could adversely affected royalty streams decline future periods failure execute business strategy could adversely impact growth profitability may able consistently maintain rich pipeline internal rd programs transactions third parties support future revenue growth competition among pharmaceutical companies acquisition product licensing opportunities intense may able locate suitable acquisition targets licensing partners reasonable prices successfully execute transactions also may able successfully realize expected efficiencies effectiveness changes structure operations diversified specialty biopharmaceuticals strategy unable support grow marketed products successfully execute launches newly approved products advance latestage pipeline manage change transformational issues manage costs effectively operating results financial condition could negatively impacted failure attract retain highly qualified personnel could affect ability successfully develop commercialize products success largely dependent continued ability attract retain highly qualified scientific technical management personnel well personnel expertise clinical research development governmental regulation commercialization competition qualified personnel biopharmaceutical field intense sure able attract retain quality personnel costs materially increase public announcement data clinical studies competitors news developments related competitors ' immunooncology products latestage compounds may cause significant volatility stock price development key immunooncology compounds whether alone part combination therapy delayed discontinued stock price could decline significantly focusing efforts resources certain disease areas focused portfolio investors placing heightened scrutiny products latestage compounds particular opdivo important asset immunooncology portfolio announced multiple regulatory milestones opdivo fully human monoclonal antibody approved anticancer treatment nonsmall cell lung cancer renal cell cancer melanoma investigated tumor types alone combination approved cancer products yervoy expect receive news ongoing clinical trials health authorities announcement data clinical studies competitors news developments related competitors ' immuno oncology products latestage compounds opdivo may cause significant volatility stock price furthermore announcement negative unexpected data discontinuation development key immunooncology compounds whether alone part combination therapy delay anticipated timelines filing regulatory approval significant advancement competitor likely cause stock price decline significantly assurance data clinical studies support filing regulatory approval even approved key immunooncology compounds become commercially successful approved indications may experience difficulties delays development commercialization new products compounds products may appear promising development fail reach market within expected optimal timeframe addition product extensions additional indications may approved developing commercializing new compounds products include inherent risks uncertainties including due efficacy safety concerns delayed denied regulatory approvals delays challenges producing products commercial scale excessive costs manufacture ii failure enter implement optimal alliances development andor commercialization new products iii failure maintain consistent scope variety promising latestage products iv failure one products achieve maintain commercial viability v changes regulatory approval processes may cause delays denials new product approvals regulatory approval delays especially common product expected risk evaluation mitigation strategy required fda address significant riskbenefit issues inability bring product market significant delay expected approval related launch date new product could negatively impact revenues earnings addition certain acquired pipeline programs including inprocess research development iprd canceled believe commercial prospects reduced may recognize material noncash impairment charges programs example recognized million iprd impairment charge lpa antagonist recognized million iprd impairment charge peginterferon lambda finally losing key molecules intermediaries compound library natural manmade disaster act sabotage could negatively impact product development cycle businesses assets acquire future may underperform may able successfully integrate existing business may continue support pipeline compounds products obtained licensing acquisitions future revenues profits cash flows acquired companys products technologies pipeline candidates may materialize due lower product uptake delayed missed pipeline opportunities inability capture expected synergies increased competition safety concerns regulatory issues supply chain problems factors beyond control substantial difficulties costs delays could result integrating acquisitions including rd manufacturing distribution sales marketing promotion information technology activities ii policies procedures processes controls compliance iii company cultures iv compensation structures human resource activities v tax considerations depend several key products revenues cash flows earnings historically derived majority revenue earnings several key products heavily dependent one two products past years dependence profitability certain products likely continue instance orencia eliquis sprycel hepatitis c franchise represented approximately greater consolidated revenues expect growth products opdivo eliquis become increasingly important part revenue base reduction revenues one products could significantly negatively impact revenues cash flows earnings could experience difficulties delays manufacturing distribution sale products product supply related patient access could negatively impacted among things product seizures recalls forced closings manufacturing plants ii failure failure suppliers comply current good manufacturing practices applicable regulations quality assurance guidelines could lead manufacturing shutdowns product shortages delays product manufacturing iii manufacturing quality assurancequality control supply problems governmental approval delays iv failure sole source single source supplier provide us necessary raw materials supplies finished goods within reasonable timeframe v failure thirdparty manufacturer supply us bulk active finished product time vi construction regulatory approval delays new facilities expansion existing facilities including intended support future demand biologics products opdivo vii failure meet new emerging regulations requiring products tracked throughout distribution channels using unique identifiers verify authenticity supply chain viii manufacturing distribution issues including limits manufacturing capacity changes types products produced biologics physical limitations business interruptions ix disruption supply chain continuity including natural manmade disasters one facilities critical supplier changes us foreign laws regulations may negatively affect revenues profit margins could become subject new government laws regulations could negatively affect business operating results financial condition company additional healthcare reform initiatives us countries including additional mandatory discounts fees ii increasing tax revenues us countries means reduce debt changing tax rates limiting phasingout eliminating deductions tax credits modifying tax collection processes taxing certain tax havens taxing certain excess income intellectual property changing rules earnings repatriations changing tax laws iii new laws regulations judicial governmental decisions affecting pricing drug reimbursement receivable payments access marketing within across jurisdictions iv changes intellectual property law v changes accounting standards vi increasing data privacy regulations enforcement vii emerging new global regulatory requirements reporting payments value transfers healthcare professionals viii potential impact importation restrictions legislative andor regulatory changes product labeling changes marketed products could result negative impact revenues profit margins regulatory authorities may need change labeling pharmaceutical product including product marketed several years changes often result additional data postmarketing studies headtohead trials adverse events reports studies identify biomarkers objective characteristics indicate particular response product therapy studies postmarketing experience produce important additional information product new information added products label affect riskbenefit profile leading potential recalls withdrawals declining revenue well product liability claims sometimes additional information studies identifies portion patient population may nonresponsive medicine would higher risk adverse reactions labeling changes based studies may limit patient population studies providing additional information may sponsored us could also sponsored competitors insurance companies government institutions managed care organizations scientists investigators interested parties additional safety efficacy information studies assist us healthcare providers identifying best patient population product also negatively impact revenues due inventory returns limited patient population going forward additionally certain study results especially headtohead trials could affect products formulary listing could also adversely affect revenues adverse outcomes legal matters could negatively affect business current future lawsuits claims proceedings government investigations could preclude delay commercialization products could adversely affect operations profitability liquidity financial condition possible insurance recoveries available legal matters include intellectual property disputes ii adverse decisions litigation including product liability commercial cases iii antibribery regulations us foreign corrupt practice act uk bribery act including compliance ongoing reporting obligations government resulting settlements civil settlement reached company sec october iv recalls withdrawals pharmaceutical products forced closings manufacturing plants v failure fulfill obligations supply contracts government customers vi product pricing promotional matters vii lawsuits claims asserting investigations violations securities antitrust federal state pricing consumer protection data privacy laws viii environmental health safety sustainability matters iv tax liabilities depend third parties meet contractual regulatory obligations rely suppliers vendors outsourcing partners alliance partners third parties research develop manufacture commercialize copromote sell products manage certain marketing selling human resource finance information technology business unit functional services meet contractual regulatory obligations third parties located markets subject political social risk corruption infrastructure problems natural disasters addition country specific privacy data security risk given current legal regulatory environments failure critical third party meet obligations including future royalty milestone payments adequately deploy business continuity plans event crisis andor satisfactorily resolve significant disagreements us address factors could material adverse impact companys operations results addition third parties violate alleged violated laws regulations including local pharmaceutical code us foreign corrupt practice act uk bribery act similar laws regulations performance obligations us possible could suffer financial reputational harm negative outcomes including possible legal consequences illegal distribution sale third parties counterfeit versions products stolen products could negative impact reputation business third parties may illegally distribute sell counterfeit versions products meet rigorous manufacturing testing standards patient receives counterfeit drug may risk number dangerous health consequences reputation business could suffer harm result counterfeit drugs sold brand name addition thefts inventory warehouses plants intransit properly stored later sold unauthorized channels could adversely impact patient safety reputation business increasingly dependent information technology systems infrastructure face certain risks including cyber security data leakage significant breakdown invasion corruption destruction interruption critical information technology systems infrastructure workforce others authorized access systems unauthorized persons could negatively impact operations everincreasing use evolution technology including cloudbased computing creates opportunities unintentional dissemination intentional destruction confidential information stored systems nonencrypted portable media storage devices could also experience business interruption theft confidential information reputational damage industrial espionage attacks malware cyberattacks may compromise system infrastructure lead data leakage either internally thirdparty providers although aggregate impact operations financial condition material date target events nature expect continue possibly increase frequency invested industry appropriate protections monitoring practices data information technology reduce risks continue monitor systems ongoing basis current potential threats assurance however efforts prevent breakdowns breaches thirdparty providers databases systems could adversely affect business social media platforms present risks challenges inappropriate andor unauthorized use certain media vehicles could cause brand damage information leakage could lead legal implications including improper collection andor dissemination personally identifiable information employees patients healthcare professionals stakeholders addition negative inaccurate posts comments us social networking website could damage reputation brand image goodwill disclosure nonpublic companysensitive information workforce others external media channels could lead information loss identifying new points entry social media continues expand presents new challenges adverse changes us global regional local economic conditions could adversely affect profitability global economic risks pose significant challenges companys growth profitability difficult mitigate worlds major economies hold historicallyhigh debt levels many experiencing slow growth high unemployment rates several risks lie ahead including management us debt european sovereign debt significant operations europe including manufacturing exposure customer credit risks europe south america markets including governmentguaranteed hospital receivables markets payments received time addition future pension plan funding requirements continue sensitive global economic conditions related impact equity markets also exposed commercial risks economic factors control could pose significant challenges underlying profitability changes foreign currency exchange interest tax rates could material adverse effect operating results liquidity significant operations outside us generating approximately revenues revenues earnings cash flow exposed risk strengthening us dollar euro japanese yen chinese renminbi canadian dollar south korean among others difficult mitigate derivative financial instruments used hedge certain underlying economic exposures financial instruments used including derivatives subject counterparty credit risk addition results operations could negatively impacted member country exiting eurozone monetary union eu also exposed changes interest rates ability access money markets andor capital markets could impeded adverse liquidity market conditions occur debt ratings would pressured financial clinical expectations met item b unresolved staff comments none item properties principal executive offices located park avenue new york ny lease approximately square feet floor space lease approximately properties countries manufacture products worldwide locations owned us manufacturing locations aggregate square feet floor space geographic area follows december number locations square feet united states europe rest world total portions manufacturing locations properties owned leased us us elsewhere used research development administration storage distribution information properties refer item businessmanufacturing quality assurance item legal proceedings information pertaining legal proceedings found item financial statementsnote legal proceedings contingencies incorporated reference herein item mine safety disclosures applicable part ia executive officers registrant listed information executive officers february executive officers elected board directors initial term continues first board meeting following next annual meeting stockholders thereafter elected oneyear term successors elected executive officers serve pleasure board directors name current position age employment history past years giovanni caforio md senior vice president oncology immunology global commercialization chief executive officer director president us pharmaceuticals member leadership team executive vice president chief commercial officer chief operating officer director company present chief executive officer director company charles bancroft chief financial officer company executive vice president chief financial officer present executive vice president chief financial officer company member leadership team emmanuel blin president general manager japan senior vice president head president global commercialization commercialization policy operations present senior vice president head commercialization policy operations member leadership team joseph c caldarella present senior vice president corporate controller senior vice president corporate controller francis cuss mb bchir frcp senior vice president research executive vice president chief scientific officer present executive vice president chief scientific officer member leadership team john e elicker senior vice president investor relations senior vice president public affairs investor present senior vice president public affairs investor relations relations member leadership team murdo gordon senior vice president access senior vice president head worldwide senior vice president oncology immunology markets president us pharmaceuticals member leadership team present senior vice president head worldwide markets ann powell judge chief human resources officer shire pharmaceuticals senior vice president global human resources present senior vice president global human resources member leadership team sandra leung general counsel corporate secretary executive vice president general counsel executive vice president general counsel corporate secretary member leadership team present executive vice president general counsel anne nielsen vice president associate general counsel senior vice president chief compliance senior vice president deputy general counsel ethics officer present senior vice president chief compliance ethics officer member leadership team louis schmukler senior vice president specialtybiotechnology operating unit pfizer president global manufacturing supply present president global manufacturing supply member leadership team paul von autenried vice president chief information officer senior vice president enterprise services chief senior vice president chief information officer information officer present senior vice president enterprise services chief information officer member leadership team part ii item market registrants common stock stockholder matters market prices bristolmyers squibb common stock traded new york stock exchange nyse symbol bmy quarterly summary high low market prices presented high low high low common first quarter second quarter third quarter fourth quarter holders common stock number record holders common stock december number record holders based upon actual number holders registered books date include holders shares street names persons partnerships associations corporations entities identified security position listings maintained depository trust companies dividends board directors declared following quarterly dividends per share paid periods indicated common preferred first quarter second quarter third quarter fourth quarter december board directors declared quarterly dividend per share common stock paid february shareholders record january board directors also declared quarterly dividend per share preferred stock payable march shareholders record february unregistered sales equity securities use proceeds following table summarizes surrenders equity securities month period ended december total number shares approximate dollar value average price purchased part shares may yet total number paid publicly announced purchased period shares purchaseda per sharea plans programsb plans programsb dollars millions except per share data january february march three months ended march april may june three months ended june july august september three months ended september october november december three months ended december twelve months ended december reflects shares common stock surrendered company satisfy tax withholding obligations connection vesting awards longterm incentive program b may board directors authorized repurchase billion common stock june board directors increased authorization repurchase common stock additional billion repurchase program expiration date may consider future repurchases item selected financial data five year financial summary amounts millions except per share data income statement dataa total revenues continuing operations net earnings net earnings attributable noncontrolling interest bms net earnings per common share attributable bms basic diluted average common shares outstanding basic diluted cash dividends paid bms common preferred stock cash dividends declared per common share financial position data december cash cash equivalents marketable securitiesb total assets longterm debtb equity discussion items affected comparability results years refer item managements discussion analysis financial condition results operationsnongaap financial measures b includes current noncurrent portion item managements discussion analysis financial condition results operations executive summary bristolmyers squibb company may referred bristolmyers squibb bms company us global specialty biopharmaceutical company whose mission discover develop deliver innovative medicines help patients prevail serious diseases revenues increased result recently launched products hepatitis c franchise including previously deferred revenue france opdivo nivolumab continued sales growth eliquis apixaban impacts partially offset changes foreign currency rates expiration us european union eu commercialization rights abilify aripiprazole competitive pressures resulting exclusivity losses factors baraclude entecavir reyataz atazanavir sulfate sustiva efavirenz certain markets expirationtransfer certain licensing royalty rights decrease gaap earnings per share eps due higher research development expenses result upfront payments licensing asset acquisitions investigational compounds tax impact specified items contributed changes effective tax rate including nontaxdeductible research development charges acquisitions flexus biosciences inc flexus cardioxyl pharmaceuticals inc cardioxyl adjusting specified items increase nongaap eps primarily due higher revenues highlights following table summarizes financial information year ended december dollars millions except per share data total revenues total expenses earnings income taxes provision income taxes effective tax rate net earnings attributable bms gaap nongaap diluted earnings per share gaap nongaap cash cash equivalents marketable securities nongaap financial measures including nongaap earnings related eps information adjusted exclude specified items represent certain costs expenses gains losses items impacting comparability financial results detailed listing specified items information reconciliations nongaap financial measures refer nongaap financial measures significant product pipeline approvals received approvals new medicines additional indications formulations currently marketed medicines including major markets us eu japan following summary significant approvals received product date approvals japanese ministry health labour welfare manufacturing marketing approval patients december unresectable advanced recurrent nonsmall cell lung cancer nsclc received ono pharmaceutical co ltd ono us food drug administration fda approval single agent treatment previously untreated november patients braf v wildtype unresectable metastatic melanoma fda approval treatment previously treated patients advanced metastatic renal cell carcinoma november rcc opdivo october fda approval treatment previously treated patients nonsquamous nsq nsclc eu approval treatment locally advanced metastatic squamous sq nsclc prior july chemotherapy eu approval treatment firstline previously treated unresectable metastatic melanoma june patients regardless braf status fda approval treatment patients advanced sq nsclc progression platinum march based chemotherapy opdivo september yervoy ipilimumab fda approval treatment patients braf v wildtype unresectable metastatic melanoma october fda approval adjuvant treatment patients cutaneous melanoma yervoy japanese ministry health labour welfare approval first second line treatment unresectable july malignant melanoma fda approval treatment multiple myeloma combination therapy revlimid empliciti elotuzumab november dexamethasone patients received one three prior therapies hepatitis c portfolio fda approval use sofosbuvir treatment patients chronic hepatitis c virus hcv july daklinza daclatasvir genotype refer product pipeline developments developments marketed products latestage pipeline strategy transitioned specialty biopharmaceutical company strategy designed leverage reach resources major pharmaceutical company well entrepreneurial spirit agility biotech firm focused discovering developing delivering innovative medicines address serious unmet medical needs four strategic priorities drive business performance maintain leadership immunooncology maintain diversified portfolio within outside immunooncology continue disciplined approach capital allocation business development top priority developing new medicines following core therapeutic areas oncology immunooncology immunoscience cardiovascular diseases fibrosis genetically defined diseases pioneering innovative medicines area immunooncology unlock bodys immune system battle cancer yervoy first immunooncology agent introduced treatment metastatic melanoma announced several significant clinical regulatory milestones us eu opdivo programmed death receptor pd immune checkpoint inhibitor within months opdivo 's first approval us metastatic melanoma late december worked unprecedented speed fda received five additional us approvals indications across three different tumor types transforming cancer care advanced nsclc melanoma rcc end opdivo approved countries continue invest significantly deep pipeline innovative medicines covering broad array cancers entered several collaboration agreements research develop opdivo approved investigational oncology agents combination regimens additionally enhanced portfolio acquiring rights novel assets across several therapeutic areas including cardiovascular diseases fibrosis evolving commercial model growing marketed product portfolio manner consistent overall strategy oncology building rapid commercial acceptance opdivo revenues approximately million continued success yervoy sprycel dasatinib beyond oncology remain strongly committed orencia abatacept eliquis revenues approximately billion received us approval daklinza use sofosbuvir treatment patients chronic hcv genotype also continue support key brands virology franchise reyataz baraclude sustiva franchise december announced divestiture pipeline investigational human immunodeficiency virus hiv medicines viiv healthcare global specialist company exclusively dedicated finding new medicines people living hiv transaction allow us focus therapeutic areas priority drive greatest longterm value us looking ahead continue implement biopharma strategy driving growth key brands executing new product launches investing diverse innovative pipeline including business development focusing prioritized markets increasing investments biologics manufacturing capabilities maintaining culture continuous improvement acquisition licensing arrangements acquisition licensing transactions allow us focus resources behind growth opportunities drive greatest longterm value focused following core therapeutic areas oncology immunooncology immunoscience cardiovascular diseases fibrosis genetically defined diseases significant transactions entered summarized kyorin pharmaceutical co ltd kyorin december bms kyorin entered exclusive worldwide license agreement granting bms right develop manufacture commercialize kyorin 's fpr agonist program kyorin option collaborate bms development commercialization japan cardioxyl december bms acquired outstanding shares cardioxyl privately held biotechnology company focused discovery development novel therapeutic agents cardiovascular disease acquisition provided bms full rights cxl nitroxyl prodrug phase ii development acute decompensated heart failure five prime therapeutics inc five prime november bms five prime entered exclusive worldwide licensing collaboration agreement development commercialization five primes colony stimulating factor receptor csfr antibody program including fpa currently phase development immunology oncology indications bms responsible development manufacturing commercialization fpa subject five primes option conduct certain studies cost develop fpa pigmented vilonodular synovitis pvns combination internal oncology pipeline assets five prime also retained option copromote us agreement replaces previous clinical collaboration agreement two parties promedior inc promedior september company purchased warrant gives bms exclusive right acquire promedior gain worldwide rights lead asset prm recombinant form human pentraxin protein phase ii development treatment idiopathic pulmonary fibrosis ipf myelofibrosis mf prm granted fast track designation us orphan designation us europe treatment mf addition prm granted orphan designation us europe treatment ipf uniqure nv uniqure may company entered collaboration license agreement uniqure granting bms exclusive license uniqures gene therapy technology platform specific collaboration targets potential gene therapy products collaboration targets developed uniqures platform may developed disease although parties intend focus initially cardiovascular diseases collaboration includes uniqures proprietary gene therapy program congestive heart failure intended restore hearts ability synthesize sa calcium sensor master regulator heart function thereby improve clinical outcomes patients reduced ejection fraction total companies may collaborate targets including sa bms solely responsible global commercialization products collaboration august company selected three additional collaboration targets company acquired million shares uniqure two separate tranches uniqure 's outstanding shares immediately following second two acquisitions company also granted two warrants company right purchase additional shares together shares currently owned bms would equal uniqure 's oustanding shares immediately issuance exercise warrant conditioned upon designation bms certain number additional collaboration targets payment bms uniqure related fees collaboration license agreement flexus april company acquired outstanding shares flexus privately held biotechnology company focused discovering developing novel anticancer therapeutics acquisition provided bms full rights f preclinical small molecule idoinhibitor targeted immunotherapy potential used combination bms 's immunooncology portfolio addition transaction included flexus 's idotdo discovery program includes idoselective idotdo dual tdoselective compounds novo nordisk novo nordisk march company acquired exclusive global license novo nordisk discovery biologics research program focused modulating innate immune system therapy autoimmune diseases bavarian nordic bavarian nordic march company acquired exclusive option globally license commercialize prostvac bavarian nordics investigational phase iii prostate specific antigentargeting cancer immunotherapy development treatment asymptomatic minimally symptomatic metastatic castrationresistant prostate cancer rigel pharmaceuticals inc rigel february company executed agreement rigel discovery development global commercialization cancer immunotherapies based rigels extensive portfolio small molecule tgf beta receptor kinase inhibitors collaboration focus developing new class therapeutics aimed increasing immune systems activity various cancers either monotherapy combination immune checkpoint inhibitors including opdivo yervoy california institute biomedical research calibr january company entered worldwide research collaboration calibr develop novel small molecule antifibrotic therapies exclusive global license agreement allows company develop manufacture commercialize calibr 's preclinical compounds resulting collaboration results operations total revenues composition changes revenues follows year ended december vs vs total revenues analysis change analysis change total foreign total foreign dollars millions change exchangeb change exchangeb united states europe rest world othera na na total revenues include royalties alliancerelated revenues products sold regional commercial organizations b foreign exchange impacts derived applying prior period average currency rates current period sales increase us revenues resulted launch opdivo daklinza higher demand eliquis sprycel partially offset expiration commercialization rights abilify transfer erbitux north america average us net selling prices increased approximately refer product sales discussion additional information decrease us revenues resulted diabetes business divestiture february partially offset higher demand eliquis yervoy sprycel higher average net selling prices approximately decrease europe revenues resulted unfavorable foreign exchange expiration commercialization rights abilify eu june partially offset launch daklinza certain eu countries third quarter higher demand eliquis revenues also impacted approximately million daklinza net product sales amounts previously deferred final pricing obtained france occurred revenues continue negatively impacted many european countries healthcare payers including government agencies continued reduce healthcare costs actions directly indirectly impose additional price reductions decrease europe revenues resulted expiration eu commercialization rights abilify june diabetes business divestiture loss exclusivity sustiva november partially offset higher demand eliquis yervoy orencia launch daklinza certain eu countries third quarter increase rest world revenues resulted launch daklinza sunvepra dual regimen japan third quarter higher demand eliquis partially offset unfavorable foreign exchange primarily japan increase rest world revenues resulted higher demand key products particularly eliquis yervoy sprycel launch daklinza sunvepra dual regimen japan third quarter partially offset diabetes business divestiture unfavorable foreign exchange primarily japan decrease revenues resulted expirationtransfer certain licensing royalty rights increase revenues resulted higher royalties mature brand overthecounter product alliances diabetes product supply sales refer item financial statementsnote alliances discussion alliances single country outside us contributed total revenues except japan contributed total revenues recognize revenue net grosstonet adjustments described critical accounting policies share certain abilify atripla revenues reflected net grosstonet adjustments alliance revenues although presented grosstonet adjustment tables share abilify atripla grosstonet adjustments approximately billion billion billion grosstonet adjustments decreased due expiration us commercialization rights abilify april activities ending reserve balances significant category grosstonet adjustments follows rebates chargebacks medicaid discounts dollars millions cash discounts medicare rebates sales returns adjustments total balance january provision related sale made current period prior period returns payments foreign currency translation balance december provision related sale made current period prior period returns payments foreign currency translation balance december reconciliation gross product sales net product sales excludes alliance revenues significant category grosstonet adjustments follows year ended december dollars millions gross product sales grosstonet adjustments chargebacks cash discounts medicaid medicare rebates sales returns rebates discounts adjustments total grosstonet adjustments net product sales grosstonet adjustment rates primarily function changes revenue mix contractual legislative discounts rebates grosstonet adjustments increased due chargebacks cash discounts increased primarily due higher product sales us particularly regarding eliquis opdivo medicaid medicare rebates increased primarily due higher product sales rebate rates us particularly medicare eliquis medicaid medicare rebates increased primarily due higher medicare sales rebate rates eliquis higher medicaid rebates virology products due price increase limitations partially offset diabetes business divestiture february us sales return reserve plavix reduced million million million considering several factors including actual return experience estimated inventory levels distribution channels accordance company policy products eligible returned six months prior twelve months product expiration us sales return reserve plavix material december rebates discounts adjustments increased primarily due additional rebates discounts daklinza including approximately million upon obtaining final pricing france amounts deferred march eliquis product revenues change attributable year ended december change foreign exchange dollars millions vs vs vs vs virology baraclude entecavir us nonus hepatitis c franchise daclatasvir asunaprevir na na na us na na nonus na na na reyataz atazanavir sulfate franchise us nonus sustiva efavirenz franchise us nonus oncology empliciti elotuzumab na na na na us na na erbitux cetuximab na us nonus na opdivo nivolumab na na na us na nonus na na na sprycel dasatinib us nonus yervoy ipilimumab us nonus neuroscience abilify aripiprazole us nonus immunoscience orencia abatacept us nonus cardiovascular eliquis apixaban na na us nonus na na mature products us nonus change excess baraclude oral antiviral agent treatment chronic hepatitis b us revenues decreased periods following loss exclusivity september international revenues decreased due unfavorable foreign exchange partially offset higher demand certain countries hepatitis c franchise includes daklinza nsa replication complex inhibitor revenues million million sunvepra asunaprevir ns protease inhibitor revenues million million daklinza launched us july additional competition expected us daklinza launched germany certain eu countries third quarter subsequently approved international markets daklinza sunvepra dual regimen launched japan third quarter international revenues also include million previously deferred revenue france recognized international revenues expected significantly decline due increased competition primarily japan reyataz franchise protease inhibitor treatment hiv includes reyataz also included combination therapy evotaz atazanavir mg cobicistat mg us revenues decreased periods due lower demand resulting increased competition international revenues decreased periods due unfavorable foreign exchange lower demand resulting increased competition sustiva franchise nonnucleoside reverse transcriptase inhibitor treatment hiv includes sustiva antiretroviral drug bulk efavirenz also included combination therapy atripla us revenues decreased due lower demand resulting increased competition partially offset higher average net selling prices us revenues increased due higher average net selling prices partially offset lower demand international revenues decreased periods due sustiva 's loss exclusivity europe november continues negatively impact demand average net selling prices atripla revenue sharing empliciti humanized monoclonal antibody treatment multiple myeloma empliciti launched us december erbitux monoclonal antibody designed exclusively target block epidermal growth factor receptor expressed surface certain cancer cells multiple tumor types well normal cells currently indicated use treatment patients certain types metastatic colorectal cancer squamous cell carcinoma head neck us revenues decreased due bms transferring rights erbitux north america eli lilly company lilly october refer item financial statementsnote alliances discussion opdivo fully human monoclonal antibody binds programmed death receptor pd natural killer nkt cells approved continues investigated anticancer treatment us revenues increased due launch opdivo december treatment unresectable melanoma subsequent approvals additional indications including nsq sq nsclc rcc well rapid commercial acceptance opdivo throughout year refer significant product pipeline highlights discussion additional opdivo approvals opdivo launched japan september subsequently approved eu june treatment unresectable melanoma july treatment advanced sq nsclc opdivo also approved international markets sprycel oral inhibitor multiple tyrosine kinases indicated firstline treatment adults philadelphia chromosomepositive chronic myeloid leukemia chronic phase treatment adults chronic accelerated myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy including gleevec imatinib meslylate us revenues increased periods primarily due higher demand international revenues decreased due unfavorable foreign exchange partially offset higher demand international revenues increased primarily due higher demand partially offset unfavorable foreign exchange yervoy monoclonal antibody treatment patients unresectable metastatic melanoma us revenues decreased due lower demand resulting introduction immunooncology products used treat patients melanoma including opdivo us revenues increased due higher demand international revenues decreased due unfavorable foreign exchange international revenues increased due higher demand abilify antipsychotic agent treatment schizophrenia bipolar mania disorder major depressive disorder us revenues decreased due expiration commercialization rights april us revenues increased primarily due higher average net selling prices partially offset reduction share abilify revenues bms 's share abilify revenue international revenues decreased periods following expiration eu commercialization rights june otsuka pharmaceutical co ltd becoming principal end customer sales certain markets orencia fusion protein indicated adult patients moderate severe active rheumatoid arthritis ra also indicated reducing signs symptoms certain pediatric patients moderately severely active polyarticular juvenile idiopathic arthritis us revenues increased periods due higher average net selling prices demand international revenues increased periods primarily due higher demand subcutaneous formulation partially offset unfavorable foreign exchange eliquis oral factor xa inhibitor targeted stroke prevention nonvalvular atrial fibrillation nvaf prevention treatment venous thromboembolic vte disorders us international revenues increased periods due higher demand following launches major markets reduction risk stroke systemic embolism patients nvaf treatment vte us eu international revenues also impacted unfavorable foreign exchange mature products includes products including lost exclusivity major markets diabetes alliance products overthe counter brands royalty revenue us revenues decreased periods primarily due diabetes business divestiture february international revenues decreased due expirationtransfer certain licensing royalty rights diabetes business divestiture february unfavorable foreign exchange continued generic erosion international revenues decreased due diabetes business divestiture continued generic erosion products partially offset higher alliance revenues estimated enduser demand pursuant us securities exchange commission sec consent order described sec consent order monitor level inventory hand us wholesaler distribution channel outside us direct customer distribution channel obligated disclose products levels inventory excess one month hand expected demand subject de minimis exception estimated levels inventory distribution channel excess one month hand following products material results operations dates indicated us products estimated levels inventory distribution channel excess one month hand december international products estimated levels inventory distribution channel excess one month hand september dafalgan analgesic product sold principally europe months inventory hand internationally direct customers compared months inventory hand june level inventory hand primarily due ordering patterns pharmacists france efferalgan analgesic product sold principally europe months inventory hand internationally direct customers september june level inventory hand primarily due ordering patterns pharmacists france changes distribution model thecounter products greece fervex cold flu product months inventory hand direct customers compared months inventory hand june level inventory hand primarily russia france support product seasonality donormyl prescription sleeping aid months inventory hand direct customers compared months inventory hand june level inventory hand primarily russia due lower expected demand competitor pricing us generally determine months hand estimates using inventory levels product hand amount outmovement provided three largest wholesalers account approximately total gross sales us products factors may influence estimates include generic competition seasonality products wholesaler purchases light increases wholesaler list prices new product launches new warehouse openings wholesalers new customer stockings wholesalers addition estimates calculated using thirdparty data may impacted recordkeeping processes businesses outside us significantly direct customers limited information direct customer product level inventory corresponding outmovement information reliability thirdparty demand information available varies widely direct customer product level inventory ultimate patientconsumer demand outmovement data exist otherwise available developed variety methodologies estimate data including using factors historical sales made direct customers thirdparty market research data related prescription trends enduser demand accordingly rely variety methods estimate direct customer product level inventory calculate months hand factors may affect estimates include generic competition seasonality products direct customer purchases light price increases new product launches new warehouse openings direct customers new customer stockings direct customers expected direct customer purchases governmental bidding situations information required estimate months hand direct customer distribution channel nonus business year ended december available prior filing annual report disclose product levels inventory excess one month hand expected demand subject de minimis exception next quarterly report form q expenses change dollar millions vs vs cost products sold marketing selling administrative research development incomeexpense total expenses change excess cost products sold cost products sold include material costs internal labor overhead owned manufacturing sites thirdparty processing costs supply chain costs settlement foreign currency forward contracts used hedge forecasted intercompany inventory purchase transactions essentially costs managed global manufacturing supply organization cost products sold also includes royalties profit sharing attributed licensed products alliances amortization acquired developed technology costs business combinations milestone payments occur regulatory approval cost products sold vary periods result product mix volume particularly resulting royalties profit sharing expenses connection alliances changes foreign currency price inflation costs attributed rationalization manufacturing sites resulting accelerated depreciation impairment charges stranded costs cost products sold remained relatively flat higher profit sharing royalties alliances primarily eliquis offset favorable foreign exchange cost products sold decreased primarily due diabetes business divestiture billion partially offset higher eliquis profit sharing million accelerated depreciation certain manufacturing facilities marketing selling administrative marketing selling administrative expenses include salary benefit costs thirdparty professional marketing fees outsourcing fees shipping handling costs advertising product promotion expenses attributed product manufacturing costs research development expenses expenses managed regional commercialization organizations global corporate organizations finance legal information technology human resources certain expenses shared alliance partners based upon contractual agreements marketing selling administrative expenses remained relatively flat increased salesrelated activities supporting eliquis opdivo hepatitis c franchise offset favorable foreign exchange million additional expenses related branded prescription drug fee resulting changes irs guidelines marketing selling administrative expenses remained relatively flat increased salesrelated activities supporting eliquis yervoy opdivo hepatitis c franchise higher variable employee compensation additional branded prescription drug fee offset lower expenses following diabetes business divestiture million july irs issued final rules regulations branded prescription drug fee annual nontaxdeductible fee payable federal government affordable care act based allocation companys market share branded prescription drugs sold certain government programs prior year final rules accelerated bms 's industry participants ' expense recognition criteria fee obligation year fee paid year market share used allocate fee determined result additional year expense recognized third quarter including million marketing selling administrative expenses million expense final rules regulations change amount timing annual fees paid research development research development activities include discovery research preclinical clinical development drug formulation well clinical trials medical support marketed products expenses include salary benefit costs thirdparty grants fees paid clinical research organizations supplies upfront contingent milestone payments licensing asset acquisitions investigational compounds iprd impairment charges proportionate allocations enterprisewide costs allocations include facilities information technology employee stock compensation costs appropriate costs certain expenses shared alliance partners based upon contractual agreements expenses vary periods number reasons including timing upfront contingent milestone payments licensing asset acquisitions iprd impairment charges research development expenses increased due higher charges resulting investigational compound acquisitions including million flexus million cardioxyl upfront payments new alliance licensing agreements including million five prime increased investments accelerate expand opdivo development programs partially offset lower iprd impairment charges including million lpa antagonist favorable foreign exchange research development expenses increased due million iprd impairment charges including million peginterferon lambda higher variable employee compensation clinical development costs million charge acquisition ipierian inc ipierian upfront contingent milestone payments alliance licensing agreements million refer item financial statementsnote alliances note acquisitions divestitures note goodwill intangible assets information incomeexpense year ended december dollars millions interest expense investment income provision restructuring litigation settlements equity net income affiliates outlicensed intangible asset impairment gain sale businesses product lines assets alliance licensing income pension charges loss debt redemption incomeexpense litigation settlements includes additional charge million contractual dispute related license subsequent company 's earnings release fourth quarter gain sale businesses product lines assets primarily resulted sale ixempra business mount vernon indiana manufacturing facility certain mature overthecounter product businesses transfer erbitux north america diabetes business divestiture refer item financial statementsnote alliances note acquisitions divestitures details alliance licensing income includes royalties transitional services fees resulting diabetes business divestitures income million resulting change fair value written option liability attributed reckitt benckiser group plc reckitt alliance refer item financial statementsnote alliances discussion pension settlement charges recognized determining annual lump sum payments would exceed annual interest service costs certain pension plans including primary us pension plan charges include acceleration portion unrecognized actuarial losses likely occur future additional pension settlement charge million recognized following purchase group annuity contract prudential insurance company america december refer item financial statementsnote pension postretirement postemployment liabilities details loss debt redemption resulted early redemption euro notes tender offer certain debt securities refer item financial statementsnote financial instruments fair value measurements details income taxes dollars millions earnings income taxes provision income taxes effective tax rate historically effective income tax rate lower us statutory rate due decision indefinitely reinvest earnings certain manufacturing operations switzerland ireland puerto rico bms operates favorable tax grant puerto rico scheduled expire prior tax impact attributed research development charges divestiture transactions specified items including additional transfer pricing reserves increased effective tax rate reduced effective tax rate tax benefits attributed research development charges resulting acquisitions flexus cardioxyl ipierian minimal income taxes attributed diabetes business divestiture gain capital loss deduction sale amylin shares tax basis differences resulting primarily allocated goodwill amylin deferred taxes earnings mix high low tax jurisdictions periods retroactive reinstatement research development credit legislation also impacted effective tax rates refer item financial statementsnote income taxes information nongaap financial measures nongaap financial measures including nongaap earnings related eps information adjusted exclude certain costs expenses gains losses specified items due significant andor unusual nature evaluated individual basis similar charges gains items recognized prior periods reasonably possible could reoccur future periods nongaap information intended portray results baseline performance include discovery development licensing manufacturing marketing distribution sale pharmaceutical products global basis enhance investors overall understanding past financial performance prospects future example nongaap earnings eps information indication baseline performance items considered us reflective ongoing results addition information among primary indicators use basis evaluating performance allocating resources setting incentive compensation targets planning forecasting future periods information intended considered isolation substitute net earnings diluted eps prepared accordance gaap specified items follows year ended december dollars millions accelerated depreciation asset impairment shutdown costs amortization acquired amylin intangible assets amortization amylin alliance proceeds amortization amylin inventory adjustment cost products sold additional year branded prescription drug fee process standardization implementation costs marketing selling administrative license asset acquisition charges iprd impairments research development provision restructuring gain sale businesses product lines assets pension charges acquisition alliance related itemsa litigation settlements outlicensed intangible asset impairment loss debt redemption upfront milestone licensing receipts incomeexpense increase pretax income income tax items specified tax chargeb income taxes increase net earnings includes million additional year branded prescription drug fee third quarter b specified tax charge relates transfer pricing matters reconciliations gaap nongaap follows year ended december dollars millions except per share data net earnings attributable bms used diluted eps calculation gaap specified items net earnings attributable bms used diluted eps calculation nongaap average common shares outstanding diluted diluted eps attributable bms gaap diluted eps attributable specified items diluted eps attributable bms nongaap financial position liquidity capital resources net cash position follows dollars millions cash cash equivalents marketable securities current marketable securities noncurrent total cash cash equivalents marketable securities shortterm borrowings longterm debt net cash position cash cash equivalents marketable securities held us approximately billion december remaining billion held primarily lowtax jurisdictions attributable earnings expected indefinitely reinvested offshore cash repatriations subject restrictions certain jurisdictions may subject withholding additional us income taxes believe existing cash cash equivalents marketable securities together cash generated operations issuance commercial paper us sufficient satisfy normal cash requirements least next years including dividends capital expenditures milestone payments working capital management continuously evaluates companys capital structure ensure company financed efficiently includes potential opportunities repurchase certain debt securities terminate certain interest rate swap contracts prior maturity access capital markets subject market conditions example issued senior unsecured notes registered public offering generating proceeds billion redeemedrepurchased certain notes nearly billion refer item financial statementsnote financial instruments fair value measurements details issued commercial paper meet nearterm domestic liquidity requirements average amount commercial paper outstanding million weightedaverage interest rate maximum month end amount commercial paper outstanding million outstanding borrowings december dividend payments billion billion billion dividend decisions made quarterly basis board directors capital expenditures approximately million approximately million expected approximately billion billion higher spending expected result expanding biologics manufacturing capabilities facilityrelated activities example constructing new largescale biologics manufacturing facility ireland produce multiple therapies growing biologics portfolio completed marketable securities portfolio subject changes fair value result interest rate fluctuations market factors may impact results operations investment policy places limits investments amount time maturity investments institution policy also requires investments entered corporate financial institutions meet high credit quality standards refer item financial statements note financial instruments fair value measurements details two separate billion fiveyear revolving credit facilities maintained syndicate lenders facilities provide customary terms conditions financial covenants extendable anniversary date consent lenders borrowings outstanding either revolving credit facility december additional regulations us could passed future could negatively impact results operations operating cash flow liquidity financial flexibility also continue monitor potential impact economic conditions certain european countries related impact prescription trends pricing discounts creditworthiness customers ability collect outstanding receivables direct customers currently believe economic conditions eu material impact liquidity cash flow financial flexibility exposure certain european governmentbacked entities higher risk default governmentbacked entities monitored economic factors including credit ratings creditdefault swap rates debttogross domestic product ratios addition entity specific factors manage exposure factoring certain receivables including receivables italy portugal spain circumstances permit factoring receivables countries million million million factoring receivables japan million million factoring agreements allow recourse event uncollectibility retain interest underlying assets sold credit ratings bms 's longterm shortterm credit ratings assigned moody 's investors service prime respectively longterm credit outlook revised negative stable april bms 's longterm shortterm credit ratings assigned standard poor 's respectively stable long term credit outlook bms 's longterm shortterm credit ratings assigned fitch f respectively stable longterm credit outlook longterm ratings reflect agencies ' opinion low default risk somewhat susceptible adverse effects changes circumstances economic conditions shortterm ratings reflect agencies ' opinion good extremely strong capacity timely repayment credit rating downgrade may affect interest rate debt may incur fair market value existing debt ability access capital markets generally cash flows following discussion cash flow activities dollars millions cash flow provided byused operating activities investing activities financing activities operating activities cash flow operating activities represents cash receipts cash disbursements activities investing activities financing activities operating cash flow derived adjusting net earnings noncontrolling interest noncash operating items gains losses attributed investing financing activities changes operating assets liabilities resulting timing differences receipts payments cash transactions recognized results operations result changes cash operating activities reflect timing cash collections customers alliance partners payments suppliers alliance partners employees pension contributions tax payments ordinary course business billion decrease cash provided operating activities primarily attributable timing payments alliance partners approximately million particularly active product ingredient supply medicaid rebates abilify higher upfront payments new alliance licensing agreements approximately million timing customer collections resulting primarily higher net product sales including extended payment terms certain new products less factoring approximately million partially offset timing cash collections payments ordinary course business including among items changes inventory levels particularly related abilify million decrease cash provided operating activities primarily attributable lower upfront contingent alliance proceeds approximately million reckitt alliance proceeds million additional net working capital requirements approximately million partially offset timing cash collections payments ordinary course business including among items lower pension contributions restructuring annual bonus payments investing activities cash requirements investing activities include cash used business asset acquisitions manufacturing facilityrelated capital expenditures purchase marketable securities maturities greater days reduced proceeds business divestitures sale maturity marketable securities billion decrease cash provided investing activities primarily attributable lower proceeds resulting diabetes business divestitures billion million billion cash used acquire flexus million cardioxyl million higher capital expenditures approximately million partially offset lower net purchases marketable securities billion cash used acquire ipierian million billion decrease cash used investing activities primarily attributable proceeds billion allocated diabetes business divestiture partially offset higher net purchases marketable securities approximately billion cash used acquire ipierian million financing activities cash requirements financing activities include cash used pay dividends repurchase common stock repay longterm debt borrowings reduced proceeds exercise stock options issuance longterm debt borrowings million increase cash used financing activities primarily attributable lower shortterm borrowings approximately million consisting primarily changes bank overdrafts billion increase cash used financing activities primarily attributable lower net borrowings longterm debt transactions billion million repayments million net borrowings lower proceeds stock option exercises million million including excess tax benefits partially offset lower cash used repurchase common stock none million contractual obligations payments due period contractual obligations december follows obligations expiring period dollars millions total later years shortterm borrowings longterm debt interest longterm debta operating leases purchase obligations uncertain tax positionsb longterm liabilities total includes estimated future interest payments periodic cash settlements derivatives b includes shortterm uncertain tax benefits uncertainties regarding timing resolution addition committed aggregated billion potential future research development milestone payments third parties licensing asset acquisitions development programs including earlystage milestones billion milestones achieved phase iii clinical trials late stage milestones billion milestones achieved post phase iii clinical trials payments generally due payable upon achievement certain developmental regulatory milestones specific timing predicted agreements also provide salesbased milestones aggregating billion would obligated pay alliance partners upon achievement certain sales levels addition royalties also certain manufacturing development commercialization obligations connection alliance arrangements practicable estimate amount obligations refer item financial statementsnote alliances information regarding alliances discussion contractual obligations refer item financial statementsnote income taxes note financial instruments fair value measurements note pension postretirement postemployment liabilities note leases sec consent order fcpa settlement previously disclosed august entered final settlement sec concluding investigation concerning certain wholesaler inventory accounting matters settlement reached consent copy attached exhibit quarterly report form q period ended september terms consent agreed subject certain defined exceptions limit sales products sold direct customers including wholesalers distributors hospitals retail outlets pharmacies government purchasers based expected demand amounts exceed approximately one month inventory hand without making timely public disclosure change practice also agreed consent certain measures implemented including establishing formal review certification process annual quarterly reports filed sec b establishing business risk disclosure group c retaining outside consultant comprehensively study help reengineer accounting financial reporting processes publicly disclosing sales incentives offered direct customers purpose inducing purchase products excess expected demand e ensuring budget process gives appropriate weight inputs come bottom top top bottom adequately documenting process established companywide policy limit sales direct customers purpose complying consent policy includes adoption various procedures monitor limit sales direct customers accordance terms consent procedures include governance process escalate appropriate management levels potential questions concerns regarding compliance policy timely resolution questions concerns addition compliance policy monitored regular basis maintain inventory management agreements imas us pharmaceutical wholesalers account nearly gross us revenues current terms imas wholesaler customers provide us weekly information respect months hand productlevel inventories amount outmovement products three largest wholesalers currently account approximately gross us revenues inventory information received wholesalers together internal information used estimate months hand product level inventories wholesalers estimate months hand product inventory levels us businesss wholesaler customers three largest wholesalers extrapolating months hand calculated three largest wholesalers contrast nonus business significantly direct customers limited information direct customer product level inventory corresponding outmovement information reliability thirdparty demand information available varies widely accordingly rely variety methods estimate months hand product level inventories business units believe abovedescribed procedures provide reasonable basis ensure compliance consent addition previously disclosed october company reached civil settlement sec alleged foreign corrupt practices act fcpa violations company agreed approximately million disgorgement penalties interest part settlement company also agreed two year selfmonitoring period reporting government maintaining procedures ensure compliance recently issued accounting standards recently issued accounting standards refer item financial statementsnote accounting policiesrecently issued accounting standards critical accounting policies preparation financial statements requires use estimates assumptions affect reported amounts assets liabilities reported amounts revenue expenses critical accounting policies significantly impact financial condition results operations require difficult subjective complex judgments often result need make estimates effect matters inherently uncertain uncertainty actual results may vary estimates accounting policies discussed audit committee board directors revenue recognition accounting policy revenue recognition substantial impact reported results relies certain estimates revenue recognized persuasive evidence arrangement exists sales price fixed determinable collectability reasonably assured title substantially risks rewards ownership transferred generally upon shipment except certain eu markets occur delivery products customer deferred approximately million invoiced daklinza early access program france portion amount recognized revenue final pricing obtained france revenue also reduced grosstonet sales adjustments discussed involve significant estimates judgment considering legal interpretations applicable laws regulations historical experience payer channel mix eg medicare medicaid current contract prices applicable programs unbilled claims processing time lags inventory levels distribution channel estimates assessed period adjusted required revised information actual experience alliance arrangements involving delivery one element undelivered element evaluated whether qualifies separate unit accounting consideration fixed determinable allocated undelivered element recognized related goods services delivered limited consideration contingent upon future deliverables consideration associated contingent milestones royalties allocated among underlying elements amounts determined payable bms grosstonet adjustments following categories grosstonet adjustments involve significant estimates judgments information obtained external sources refer total revenues discussion analysis significant category grosstonet sales adjustments chargebacks cash discounts us business participates programs government entities significant us department defense us department veterans affairs parties including covered entities b drug pricing program whereby pricing products extended wholesaler list price participating entities entities purchase products wholesalers lower program price wholesalers charge us difference acquisition cost lower program price accounts receivable reduced estimated amount unprocessed chargeback claims attributable sale typically within two four week time lag us certain countries cash discounts offered incentive prompt payment generally approximating sales price accounts receivable reduced estimated amount unprocessed cash discounts typically within one month time lag medicaid medicare rebates us business participates state government medicaid programs qualifying federal state government programs requiring discounts rebates participating state local government entities discounts rebates provided programs included medicaid rebate accrual medicaid rebates also extended drugs used managed medicaid plans estimated amount unpaid unbilled rebates presented liability rebates discounts offered managed healthcare organizations us managing prescription drug programs medicare advantage prescription drug plans covering medicare part drug benefit also pay point service discount centers medicare medicaid services medicare part beneficiaries coverage gap donut hole estimated amount unpaid unbilled rebates discounts presented liability sales returns products typically eligible returned six months prior twelve months product expiration accordance policy estimated returns established products determined considering historical experience factors including levels inventory distribution channel estimated shelf life product recalls product discontinuances price changes competitive products introductions generic products introductions competitive new products lower demand following loss exclusivity estimated amount product returns presented liability estimated returns new products determined considering historical sales return experience similar products within product line similar therapeutic category defer recognition revenue right return expires sufficient historical experience estimate sales returns developed limited circumstances typically occurs new product extension existing line product historical experience products similar therapeutic category lacking estimated levels inventory distribution channel projected demand also considered estimating sales returns new products rebates discounts adjustments grosstonet sales adjustments include programs based applicable laws regulations individual nonus countries well rebates offered managed healthcare organizations us lesser extent nonus programs include several different pricing schemes cost caps volume discounts outcomebased pricing schemes pricing clawbacks based sales individual companies aggregation companies participating specific market estimated amount unpaid unbilled rebates discounts presented liability use information external sources information external sources used estimate grosstonet adjustments estimate inventory wholesalers based projected prescription demandbased sales products historical inventory experience well analysis thirdparty information including written oral information obtained certain wholesalers respect inventory levels sellthrough customers thirdparty market research data internal information inventory information received wholesalers product recordkeeping process excludes inventory held intermediaries sell retailers hospitals also continued practice combining retail mail prescription volume retailequivalent basis use methodology internal demand forecasts also use information external sources identify prescription trends patient demand average selling prices estimates subject inherent limitations estimates rely thirdparty information certain thirdparty information form estimates reflect limitations including lags date thirdparty information generated date receive thirdparty information retirement benefits accounting pension postretirement benefit plans requires actuarial valuations based significant assumptions discount rates expected longterm rates return plan assets consultation actuaries significant assumptions others salary growth retirement turnover healthcare trends mortality rates evaluated selected based expectations actual experience remeasurement date pension expense could vary within range outcomes material effect reported earnings projected benefit obligations future cash funding actual results given year may differ estimated economic factors yield high quality corporate bonds coincides cash flows plans estimated payouts used determining discount rate citigroup pension discount curve used us plans us plans pension expense determined using weightedaverage discount rate present value benefit obligations december us pension plans determined using discount rate discount rate used determining us plans pension expense reduced additional expense would increase approximately million assumed discount rate used determining us pension plans projected benefit obligation december reduced additional projected benefit obligation would increase approximately billion new mortality tables rp mortality improvement scales mp issued society actuaries reflecting longer life expectancies previous tables new tables used measure us pension postretirement obligations beginning september resulting increase obligations approximately million revised mortality rates expected materially impact pension expense future periods expected longterm rate return plan assets estimated considering expected returns individual asset classes input external advisors also consider longterm historical returns including actual performance compared benchmarks similar investments us plans pension expense determined using expected longterm rate return plan assets expected longterm rate return plan assets used determining us plans pension expense reduced expense would increase million detailed discussion retirement benefits refer item financial statementsnote pension postretirement postemployment liabilities business combinations divestitures goodwill intangible assets acquired business combinations licensing transactions billion representing total assets december accounting transactions business combinations divestitures significantly different asset acquisitions divestitures example acquired iprd capitalized business combinations expensed asset acquisitions fair value contingent consideration goodwill recognized business combination transactions likewise portion reporting unit constitutes business divested goodwill associated business included carrying value business determining gain loss derecognition goodwill occur asset dispositions result important determine whether business asset group assets acquired divested business defined asc business combinations integrated set inputs processes capable generating outputs ability provide return investors owners typical inputs include longlived assets including intangible assets rights use longlived assets intellectual property ability obtain access required resources typical processes include strategic operational resource management processes typically documented evident organized workforce consider factors determining whether business acquired divested well compound 's development phase commercial products involved example evaluating acquisitions cardioxyl flexus ipierian concluded significant processes transferred us thus transactions accounted asset acquisitions result amounts allocated lead investigational compounds expensed capitalized addition contingent consideration potential development regulatory approval salesbased milestones salesbased royalties included purchase price refer item financial statementsnote acquisitions divestitures discussion acquisitions similarly evaluating divestitures erbitux ixempra businesses comprising alliances medicines company valeant pharmaceuticals international inc diabetes business astrazeneca plc astrazeneca concluded necessary inputs processes transferred consequently transactions accounted sales businesses resulted allocation goodwill million million carrying value businesses determining gain sale contingent proceeds related divestitures recognized realized valuation processes also required certain multiple element arrangements include determination judgmental complex matters discussed example bms purchased warrant gives bms exclusive right acquire promedior required determination best estimated selling price two separate elements identified transaction warrant clinical development services similarly divestiture diabetes business astrazeneca required determination best estimated selling price several elements including business supply development agreements including appropriate markups estimated fair value manufacturing facility refer item financial statementsnote alliances discussion transactions impairment intangible assets including iprd intangible assets billion december including licenses million developed technology rights million capitalized software million iprd million intangible assets assessed impairment whenever current facts circumstances warrant review although iprd assessed least annually intangible assets highly vulnerable impairment charges particularly newly acquired assets recently launched products iprd assets initially measured fair value therefore reduction expectations used valuations could potentially lead impairment common potential risks leading impairment include competition earlier expected loss exclusivity pricing pressures adverse regulatory changes clinical trial results delay failure obtain regulatory approval additional development costs inability achieve expected synergies higher operating costs changes tax laws macroeconomic changes complexity estimating fair value intangible assets connection impairment test similar initial valuation considering high risk nature research development industrys success rate bringing developmental compounds market iprd impairment charges likely occur future periods recognized million charge bms phase ii development treatment idiopathic pulmonary fibrosis million including million charge peginterferon lambda phase iii development treatment hcv discussion iprd impairments refer item financial statementsnote goodwill intangible assets property plant equipment property plant equipment tested impairment whenever current facts circumstances warrant review additionally longlived assets periodically reviewed determine change facts circumstances would result change estimated useful life asset possibly resulting acceleration depreciation circumstances exist estimate undiscounted future cash flows generated asset appropriate grouping assets compared carrying value determine whether impairment exists lowest level identifiable cash flows asset determined impaired loss measured based difference assets fair value carrying value expectations future cash flows subject change based upon near longterm production volumes margins generated asset well potential alternative future use accelerated depreciation related charges certain manufacturing rd facilities million million million contingencies normal course business subject contingencies legal proceedings claims arising business cover wide range matters including among others government investigations shareholder lawsuits product environmental liability contractual claims tax matters recognize accruals contingencies probable liability incurred amount loss reasonably estimated estimates subject uncertainties difficult predict actual results could vary estimates discussions contingencies refer item financial statementsnote accounting policiescontingencies note income taxes note legal proceedings contingencies income taxes valuation allowances recognized reduce deferred tax assets likely tax benefit realized assessment whether valuation allowance required often requires significant judgment including longrange forecasts future taxable income evaluation tax planning initiatives adjustments deferred tax valuation allowances made earnings period assessments made deferred tax assets billion december net valuation allowances billion billion december net valuation allowances billion deferred tax assets related us federal net operating loss carryforward million us federal tax credit carryforward million recognized december net operating loss carryforward expires varying amounts beginning us federal tax credit carryforward expires varying amounts beginning realization carryforwards dependent generating sufficient domesticsourced taxable income prior expiration million valuation allowance established item december although assured believe likely deferred tax assets valued realized taxes provided undistributed earnings foreign subsidiaries expected reinvested indefinitely offshore prior mead johnson nutrition company mead johnson splitoff following transactions occurred internal spinoff mead johnson shares still owned us ii conversion mead johnson class b shares class shares iii conversion mead johnson company limited liability company transactions well splitoff mead johnson exchange offer qualify taxexempt transactions internal revenue code based upon private letter ruling received internal revenue service related conversion mead johnson class b shares class shares outside legal opinions certain assumptions representations covenants mead johnson relied upon regarding future conduct business matters could affect tax treatment exchange example current tax law generally creates presumption exchange would taxable us mead johnson shareholders engage transactions result greater change stock ownership four year period beginning two years exchange offer unless established exchange offer part plan series related transactions effect change ownership internal spinoff exchange offer determined qualify tax exempt transaction transaction could subject tax exchange taxable sale us market value addition negative basis excess loss account ela existed investment stock mead johnson prior transactions received opinion outside legal counsel effect likely eliminated ela part transactions taxable income respect ela tax law area complex possible even internal spinoff exchange offer tax exempt internal revenue code irs could assert additional taxable income period respect ela could exposed additional taxes occur based upon understanding internal revenue code opinion outside legal counsel tax reserve million established reducing gain disposal mead johnson included discontinued operations agreed certain tax related indemnities mead johnson set forth tax sharing agreement including certain taxes related business prior completion ipo created part restructuring facilitate ipo mead johnson also agreed indemnify us potential tax effects resulting breach certain representations discussed well certain transactions related acquisition mead johnsons stock assets liabilities established possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credits deductibility certain expenses liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known example additional reserves million established certain transfer pricing matters related periods discussions income taxes refer item financial statementsnote accounting policiesincome taxes note income taxes product pipeline developments rd programs managed portfolio basis early discovery latestage development continually evaluate portfolio ensure appropriate balance earlystage latestage programs support future growth rd programs phase iii development considered significant programs constitute latestage development pipeline development programs include investigational compounds phase iii development initial indications marketed products phase iii development additional indications formulations spending programs represents approximately annual rd expenses individual investigational compound marketed product represented rd expenses last three years except opdivo latestage development programs could potentially impact revenue earnings within next years although expect latestage development programs make market following developments marketed products late stage pipeline opdivo fully human monoclonal antibody binds pd nkt cells approved continues investigated anticancer treatment opdivo part alliance ono unresectable inoperable metastatic advanced melanoma january company announced randomized phase iii study evaluating opdivo versus investigator 's choice patients recurrent metastatic platinumrefractory squamous cell carcinoma head neck stopped early assessment conducted independent data monitoring committee dmc concluded study met primary endpoint demonstrating superior overall survival patients receiving opdivo compared control arm january company announced fda approved opdivo combination yervoy treatment patients braf v wildtype braf v mutation positive unresectable metastatic melanoma approval expands original indication opdivoyervoy regimen treatment patients braf v wildtype unresectable metastatic melanoma include patients regardless braf mutational status based data phase iii checkmate trial evaluated progressionfree survival overall survival coprimary endpoints indication approved accelerated approval based progressionfree survival january company announced fda expanded use opdivo single agent include previously untreated braf mutation positive advanced melanoma patients use opdivo single agent patients braf v mutation positive unresectable metastatic melanoma approved accelerated approval based progressionfree survival november company announced fda approved opdivo single agent treatment previously untreated patients braf v wildtype unresectable metastatic melanoma november company announced results multiple clinical trials checkmate study evaluating opdivo single agent versus dacarbazine patients previously untreated braf wildtype unresectable metastatic melanoma opdivo continued demonstrate superior overall survival versus dacarbazine patients alive two years compared patients treated dacarbazine safety profile opdivo consistent prior studies study study evaluating opdivo combination yervoy patients unresectable metastatic melanoma proof concept opdivoyervoy regimen approval based data longest follow regimen various phase cohorts showed threeyear overall survival rate across phase dosing cohorts frequency treatmentrelated adverse events study similar cohorts consistent phase ii iii trials combination therapy september fda approved opdivo combination yervoy treatment patients braf v wildtype unresectable metastatic melanoma announcement marked first fda approval regimen two immunooncology agents cancer indication approved accelerated approval based tumor response rate durability response july european medicines agency ema validated companys type ii variation application seeks extend use opdivo combination yervoy treatment advanced unresectable metastatic melanoma adults application based data phase iii checkmate study phase ii checkmate study phase ib ca study validation application confirms submission complete starts ema 's centralized review process june company announced european commission ec approved opdivo treatment firstline previously treated unresectable metastatic melanoma patients regardless braf status approval allows marketing opdivo member states eu opdivo pd immune checkpoint inhibitor receive accelerated assessment europe first approval given ec pd inhibitor cancer may company announced positive results phase iii trial checkmate evaluating opdivoyervoy regimen opdivo monotherapy vs yervoy monotherapy patients previously untreated advanced melanoma opdivoyervoy regimen n opdivo monotherapy n demonstrated superiority yervoy n current standard care coprimary endpoint progressionfree survival pfs median pfs months opdivoyervoy regimen months opdivo monotherapy vs months yervoy monotherapy opdivoyervoy regimen demonstrated reduction risk disease progression vs yervoy hazard ratio ci p opdivo monotherapy demonstrated risk reduction versus yervoy monotherapy hazard ratio ci p hazard ratio exploratory endpoint comparing opdivoyervoy pfs opdivo pfs ci safety profile consistent previouslyreported studies evaluating opdivoyervoy regimen treatmentrelated adverse event rate opdivoyervoy regimen compared opdivo monotherapy yervoy monotherapy select treatmentrelated adverse events resolved using established management guidelines trial ongoing patients continue followed overall survival coprimary endpoint april company announced positive results phase ii trial checkmate evaluating opdivoyervoy regimen versus yervoy alone patients previously untreated advanced melanoma patients braf wildtype mutation status treated opdivoyervoy regimen experienced higher objective response rate orr n primary study endpoint compared n patients administered yervoy monotherapy p complete responses also reported n patients braf wildtype mutation status administered opdivoyervoy regimen patients received yervoy monotherapy similar results also observed braf mutationpositive patients nsclc december company ono announced ono received manufacturing marketing approval opdivo japan treatment patients unresectable advanced recurrent nsclc november company announced ec approved reconciliation indications nivolumab opdivo european marketing authorization application maa compliance ec regulations bms previously submitted two separate maas ema one name opdivo treatment unresectable metastatic melanoma adults one name nivolumab bms treatment locally advanced metastatic sq nsclc prior chemotherapy application reconcile two indications submitted opdivo brand name following approval indications ec earlier year company voluntarily withdrew marketing authorization nivolumab bms brand name withdrawal impact sq nsclc patients taking nivolumab since opdivo approved treatment sq nsclc well melanoma october company announced fda approved opdivo treatment previously treated patients nsq nsclc regardless pdl expression expands upon current indication opdivo patients previously treated sq nsclc september company announced longer term month survival data checkmate openlabel randomized phase iii study evaluating opdivo n versus docetaxel n previously treated patients advanced nsq nsclc opdivo continued demonstrate superior overall survival studys primary endpoint estimated patients alive months ci versus docetaxel based minimum followup months opdivo also continued demonstrate reduction risk death hazard ratio ci study grade treatmentrelated adverse events reported patients treated opdivo versus docetaxel arm september company announced updated results opdivoyervoy arms checkmate multiarm phase ib trial evaluating opdivo patients chemotherapynave advanced nsclc study opdivo administered monotherapy part combination agents including yervoy different doses schedules results cohorts checkmate previouslyunreported updated results include findings administration four new dosing schedules opdivoyervoy n resulted confirmed objective response rates ranging depending administered regimen median duration response reached arms median followup months months median progressionfree survival pfs ranged months months types treatmentrelated serious adverse events reported cohorts checkmate consistent previouslyreported opdivoyervoy cohorts trial new dosing schedules study resulted less toxicity previouslyreported dosing schedules characterized low frequency treatmentrelated adverse events leading discontinuation treatmentrelated deaths september company announced longer term survival safety data checkmate two pivotal trials evaluating opdivo previously treated sq nsclc showing sustained survival benefit across studies trials opdivo showed estimated month overall survival rate checkmate checkmate survival benefit independent pdl expression safety profile opdivo consistent previouslyreported trials checkmate also favorable compared docetaxel july ema validated companys type ii variation application seeks extend use opdivo monotherapy nsq nsclc based data phase iii checkmate study july company announced ec approved nivolumab bms treatment locally advanced metastatic sq nsclc prior chemotherapy approval marks first major treatment advance sq nsclc decade eu nivolumab first pd immune checkpoint inhibitor demonstrate overall survival previouslytreated metastatic sq nsclc may company announced results checkmate phase iii openlabel randomized study evaluating opdivo n versus docetaxel n previously treated patients advanced sq nsclc one year opdivo demonstrated overall survival rate versus docetaxel median overall survival months versus months respectively opdivo reduced risk death based upon hazard ratio ci p safety profile opdivo checkmate consistent prior studies favorable versus docetaxel may company announced opdivo first pd inhibitor demonstrate superior overall survival versus standard care docetaxel openlabel randomized phase iii study checkmate evaluating previouslytreated patients advanced nsq nsclc reduction risk progression death primary study endpoint reported opdivo n versus docetaxel n based upon hazard ratio ci p opdivo associated doubling overall median survival across continuum pdl expression starting level expression trial safety profile opdivo checkmate favorable versus docetaxel grade treatmentrelated adverse events reported patients treated opdivo versus docetaxel arm april company announced checkmate stopped early assessment conducted independent dmc concluded study met primary endpoint march company announced fda approved opdivo treatment patients advanced sq nsclc progression platinumbased chemotherapy opdivo first pd therapy demonstrate overall survival previously treated advanced sq nsclc opdivo demonstrated significantly superior overall survival vs docetaxel reduction risk death hazard ratio ci p prespecified interim analysis phase iii clinical trial median overall survival months opdivo arm ci months docetaxel arm ci indications november company announced fda approved opdivo treatment patients advanced rcc received prior anti angiogenic therapy november company announced ema validated type ii variation application seeks extend current indication opdivo include treatment adult patients advanced rcc prior therapy validation application confirms submission complete begins emas centralized review process september company announced results checkmate phase iii study comparing opdivo everolimus advanced rcc prior anti angiogenic treatment showing significant overall survival benefit opdivo trial opdivo demonstrated median overall survival benefit months compared months everolimus clinical benefit opdivo observed regardless level pdl expression safety profile shown checkmate consistent previously reported opdivo trials july company announced checkmate stopped early assessment independent dmc concluded study met primary endpoint may company announced results interim analysis ca phase iii doseranging trial evaluating safety antitumor activity opdivo previouslytreated patients hepatocellular carcinoma hcc advanced liver cancer initial findings demonstrated estimated survival rate evaluable patients n months results also show safety profile opdivo generally consistent previously reported opdivo tumor types empliciti humanized monoclonal antibody treatment multiple myeloma empliciti part alliance abbvie inc abbvie january company abbvie announced committee medicinal products human use chmp ema adopted positive opinion recommending empliciti granted approval treatment multiple myeloma combination therapy revlimid dexamethasone patients received least one prior therapy application reviewed ec authority approve medicines eu december company abbvie announced extended followup data prespecified interim overall survival analysis empliciti combination revlimid dexamethasone erd patients relapsed refractory multiple myeloma eloquent followup data demonstrated empliciti combination rd improvement progressionfree survival hazard ratio hr ci p versus rd alone result consistent improvement pfs observed time primary analysis hr ci p november company abbvie announced fda approved empliciti treatment multiple myeloma combination therapy revlimid dexamethasone patients received one three prior therapies june company abbvie announced results interim analysis phase iii randomized openlabel eloquent trial trial n evaluated empliciti combination lenalidomide dexamethasone eld versus lenalidomide dexamethasone alone ld treatment relapsed refractory multiple myeloma study met coprimary endpoints demonstrating superior pfs orr eld arm demonstrated reduction risk disease progression death compared ld arm hr ci p pfs rates eld arm versus ld arm versus year versus years respectively significant orr also observed eld arm compared ld arm odds ratio p safety profile consistent previouslyreported studies minimal incremental adverse events addition empliciti lenalidomide dexamethasone sprycel oral inhibitor multiple tyrosine kinases indicated firstline treatment adults philadelphia chromosomepositive chronic myeloid leukemia cml chronic phase cp treatment adults chronic accelerated myeloid lymphoid blast phase cml resistance intolerance prior therapy including gleevec imatinib mesylate sprycel part alliance otsuka pharmaceutical co ltd otsuka august company otsuka announced fda approved update sprycel product labeling labeling includes fiveyear efficacy safety data adult patients newly diagnosed philadelphia chromosomepositive ph cml cp sevenyear data cp ph cml patients resistant intolerant prior therapy including gleevec imatinib mesylate yervoy monoclonal antibody treatment patients unresectable metastatic melanoma october company announced fda approved yervoy adjuvant treatment patients cutaneous melanoma pathologic involvement regional lymph nodes mm undergone complete resection including total lymphadenectomy october company announced yervoy phase iii trial study subjects stage ivrecurrent nsclc compared efficacy yervoy combination paclitaxel carboplatin versus placebo versus paclitaxel carboplatin alone meet primary endpoint overall survival yervoy treatment arms discontinued new safety concerns yervoy identified either study company complete full evaluation data work investigators future publication results july company announced two yervoy phase iii trials study metastatic castration resistant prostate cancer study newly diagnosed extensivestage disease small cell lung cancer meet primary endpoints overall survival versus standard care discontinued new safety concerns yervoy identified either study company complete full evaluation data work investigators future publication results july japanese ministry health labour welfare approved yervoy first second line treatment unresectable malignant melanoma hepatitis c portfolio daklinza dcv nsa replication complex inhibitor sunvepra asv ns protease inhibitor beclabuvir bcv nsb non nucleoside polymerase inhibitor development january company announced fda approved daklinza combination sofosbuvir without ribavirin genotypes expanded label includes data three additional challengingtotreat patient populations chronic hcv patients hiv coinfection advanced cirrhosis postliver transplant recurrence hcv daklinza plus sofosbuvir regimen already available treatment chronic hcv genotype currently week oncedaily alloral treatment option patients sustained virologic response svr rates reduced genotype patients cirrhosis receiving daklinza sofosbuvir weeks without ribavirin sofosbuvir product gilead sciences inc gilead january company announced ec approved daklinza treatment chronic hcv three new patient populations expanded label allows use daklinza combination sofosbuvir without ribavirin depending indication hcv genotype hcv patients decompensated cirrhosis hiv coinfection postliver transplant recurrence hcv member states eu november company announced data phase iii ally trial investigating regimen daklinza combination sofosbuvir ribavirin genotype hcv patients advanced fibrosis cirrhosis treatment durations weeks patient population one difficult treat among svr rates cure proved harder achieve results show patients advanced fibrosis cohort achieved svr week arms study svr rates patients cirrhosis week arms respectively october company announced national institute health care excellence nice recommended daklinza england wales treatment adult patients chronic hcv specifically nice recommended daklinza treat certain patients hcv genotypes approximately people uk thought chronic hcv roughly patients estimated genotype difficulttotreat often aggressive form chronic hcv september company announced ec approved updated label daklinza treatment genotype chronic hcv update allows use daklinza combination sofosbuvir weeks patients without cirrhosis member states eu marks first time patients genotype hcv oncedaily alloral treatment regimen shorter duration july company announced fda approved daklinza use sofosbuvir treatment patients chronic hcv genotype approval marks first time patients chronic hcv genotype week oncedaily alloral treatment option svr rates reduced hcv genotype infected patients cirrhosis receiving regimen july company announced plan seek regulatory approval new drug application hcv tripleregimen trio dcv asv bcv united states europe may company announced fda amended previously granted breakthrough therapy designation investigational daclatasvir sofosbuvir combination use hcv patients updated designation reflects recently presented data hcv genotype patients advanced cirrhosis childpugh class b c develop genotype hcv recurrence postliver transplant april company announced primary endpoints successfully met ally phase iii clinical trial evaluating week combination daclatasvir sofosbuvir oncedaily ribavirin treatment patients chronic hcv either advanced cirrhosis postliver transplant recurrence hcv february company announced results ally phase iii clinical trial evaluating investigational oncedaily combination daclatasvir sofosbuvir treatment patients chronic hcv coinfected hiv patient population historically challenging treat large part due potential drugdrug interactions therapy regimens used treat infection among ally patients treated weeks treatmentnave experienced n achieved cure svr weeks treatment study met primary endpoint n treatmentnave genotype patients achieving svr treatment daclatasvir combination sofosbuvir study showed high svr rates discontinuations due adverse events serious adverse events related study medications throughout treatment phase february fda notified company intention rescind breakthrough therapy designation certain genotype hcv regimens related daclatasvir investigational bms therapies impact current submissionresubmission timetable nda daclatasvir combination antiviral agents treatment hcv reyataz franchise protease inhibitor treatment hiv includes reyataz also included combination therapy evotaz atazanavir mg cobicistat mg evotaz part license agreement gilead july company announced ec approved evotaz treatment hiv infected adults without known mutations associated resistance atazanavir evotaz oncedaily single tablet two drug regimen combining reyataz tybost tybost product gilead june fda granted pediatric exclusivity reyataz provides additional six month period exclusivity us january company announced fda approved evotaz treatment hiv infection adults oncedaily single tablet two drug regimen combining reyataz tybost orencia fusion protein indicated adult patients moderate severe active ra also indicated reducing signs symptoms certain pediatric patients moderately severely active polyarticular juvenile idiopathic arthritis june company announced data orencia phase iiib avert ample trials trials included early moderate severe ra patients active disease avert trial data suggests potentially faster onset clinical response greater drugfree clinical remission earlier use patients taking orencia plus methotrexate patients taking methotrexate alone exploratory data patients high anticitrullinated protein antibody levels baseline ample trial suggest better response orencia adalimumab adalimumab product abbvie april ema approved clickject prefilled pen new autoinjector delivery device orencia use adult patients eu moderate severe active ra combination methotrexate inadequate diseasemodifying antirheumatic drug response eliquis oral factor xa inhibitor targeted stroke prevention nvaf prevention treatment vte disorders eliquis part alliance pfizer inc pfizer december company pfizer announced results posthoc early time course subanalysis phase iii amplify trial subanalysis demonstrated eliquis comparable conventional therapy subcutaneous enoxaparin overlapped followed oral warfarin doseadjusted international normalized ratio recurrent vte vterelated death significantly less major bleeding first days starting treatment results subanalyses consistent overall results eliquis phase iii amplify trial september company pfizer announced first patient enrolled phase iv clinical trial augustus evaluate safety eliquis versus warfarin vitamin k antagonists patients nvaf recent acute coronary syndrome undergoing percutaneous coronary intervention also known stent special note regarding forwardlooking statements annual report including documents incorporated reference written oral statements make time time contain certain forwardlooking statements within meaning section securities act section e securities exchange act identify forwardlooking statements fact use words expect anticipate estimate target may project guidance intend plan believe words terms similar meaning expression connection discussion future operating financial performance one also identify forwardlooking statements fact relate strictly historical current facts forwardlooking statements based current expectations involve inherent risks uncertainties including factors could delay divert change could cause actual outcomes differ materially current expectations statements likely relate among things goals plans projections regarding financial position results operations cash flows market position product development product approvals sales efforts expenses performance results current anticipated products outcome contingencies legal proceedings financial results based current expectations involve inherent risks uncertainties including internal external factors could delay divert change next several years included important factors cautionary statements included annual report particularly item risk factors believe could cause actual results differ materially forwardlooking statement although believe prudent plans assumptions assurance given goal plan set forth forwardlooking statements achieved readers cautioned place undue reliance statements speak date made undertake obligation release publicly revisions forwardlooking statements result new information future events otherwise item quantitative qualitative disclosures market risk exposed market risk resulting changes currency exchange rates interest rates certain derivative financial instruments used available costeffective basis hedge underlying economic exposure financial instruments including derivatives subject counterparty credit risk considered part overall fair value measurement derivative financial instruments used trading purposes foreign exchange risk significant amounts revenues earnings cash flow exposed changes foreign currency rates primary net foreign currency translation exposures euro japanese yen chinese renminbi canadian dollar south korean foreign currency forward contracts used manage risk primarily arises certain intercompany purchase transactions designated foreign currency cash flow hedges appropriate addition exposed foreign exchange transaction risk arising nonfunctional currency denominated assets liabilities earnings denominated nonus dollar currencies foreign currency forward contracts used offset exposures designated hedges estimate appreciation underlying currencies hedged levels us dollar variables held constant would decrease fair value foreign exchange forward contracts million december reducing earnings remaining life contracts also exposed translation risk nonus dollardenominated net assets nonus dollar borrowings used hedge foreign currency exposures net investment certain foreign affiliates designated hedges net investments effective portion foreign exchange gains losses hedges included foreign currency translation component accumulated comprehensive incomeloss net investment decreases equivalent value nonus debt borrowings change remeasurement basis debt would subject recognition income changes occur additional information refer item financial statementsnote financial instruments fair value measurements interest rate risk use fixedtofloating interest rate swap contracts designated fair value hedges forward starting interest rate swap contracts designated cash flow hedges part interest rate risk management strategy contracts intended provide us appropriate balance fixed floating rate debt forward starting swap contracts used manage interest rate future debt issuances estimate increase basis points shortterm longterm interest rates would decrease fair value interest rate swap contracts million decrease basis points shortterm longterm interest rates would decrease fair value forward starting interest rate swap contracts million thereby reducing earnings remaining life contracts estimate increase basis points longterm interest rates would decrease fair value longterm debt million marketable securities subject changes fair value result interest rate fluctuations market factors policy invest institutions meet high credit quality standards estimate increase basis points interest rates general would decrease fair value debt security portfolio approximately million credit risk although material certain european governmentbacked entities higher risk default greece portugal italy spain monitored economic factors including credit ratings creditdefault swap rates debttogross domestic product ratios entity specific factors historically exposure limited factoring receivables credit exposures europe may increase future due reductions factoring arrangements ongoing sovereign debt crisis monitor investments counterparties objective minimizing concentrations credit risk investment policy establishes limits amount time maturity investments individual counterparty policy also requires investments entered corporate financial institutions meet high credit quality standards use derivative instruments exposes us credit risk fair value derivative instrument contract positive exposed credit risk counterparty fails perform fair value derivative instrument contract negative counterparty exposed credit risk fail perform obligation collateral required party whether derivatives asset liability position policy diversifying derivatives counterparties mitigate overall risk counterparty defaults additional information refer item financial statementsnote financial instruments fair value measurements item financial statements supplementary data bristolmyers squibb company consolidated statements earnings dollars millions except per share data year ended december earnings net product sales alliance revenues total revenues cost products sold marketing selling administrative research development incomeexpense total expenses earnings income taxes provision income taxes net earnings net earnings attributable noncontrolling interest net earnings attributable bms earnings per common share basic diluted cash dividends declared per common share consolidated statements comprehensive income dollars millions year ended december comprehensive income net earnings comprehensive incomeloss net taxes reclassifications earnings derivatives qualifying cash flow hedges pension postretirement benefits availableforsale securities foreign currency translation total comprehensive incomeloss comprehensive income comprehensive income attributable noncontrolling interest comprehensive income attributable bms accompanying notes integral part consolidated financial statements bristolmyers squibb company consolidated balance sheets dollars millions except share per share data december assets current assets cash cash equivalents marketable securities receivables inventories deferred income taxes prepaid expenses assets heldforsale total current assets property plant equipment goodwill intangible assets deferred income taxes marketable securities assets total assets liabilities current liabilities shortterm borrowings accounts payable accrued expenses deferred income accrued rebates returns income taxes payable dividends payable total current liabilities pension postretirement postemployment liabilities deferred income income taxes payable liabilities longterm debt total liabilities commitments contingencies note equity bristolmyers squibb company shareholders equity preferred stock convertible series par value per share authorized million shares issued outstanding liquidation value per share common stock par value per share authorized billion shares billion issued capital excess par value stock accumulated comprehensive loss retained earnings less cost treasury stock million common shares million total bristolmyers squibb company shareholders ' equity noncontrolling interest total equity total liabilities equity accompanying notes integral part consolidated financial statements bristolmyers squibb company consolidated statements cash flows dollars millions year ended december cash flows operating activities net earnings adjustments reconcile net earnings net cash provided operating activities net earnings attributable noncontrolling interest depreciation amortization net deferred income taxes stockbased compensation impairment charges pension settlements amortization adjustments changes operating assets liabilities receivables inventories accounts payable deferred income income taxes payable net cash provided operating activities cash flows investing activities sale maturities marketable securities purchase marketable securities capital expenditures divestiture proceeds acquisition payments net cash provided byused investing activities cash flows financing activities shortterm borrowings net issuance longterm debt repayment longterm debt interest rate swap contract terminations issuance common stock repurchase common stock dividends net cash used financing activities effect exchange rates cash cash equivalents increasedecrease cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year accompanying notes integral part consolidated financial statements note accounting policies recently issued accounting standards basis consolidation consolidated financial statements prepared conformity united states us generally accepted accounting principles gaap including accounts bristolmyers squibb company controlled majorityowned subsidiaries certain variable interest entities may referred bristol myers squibb bms company intercompany balances transactions eliminated material subsequent events evaluated disclosed report issuance date alliance license arrangements assessed determine whether terms provide economic control entity requiring consolidation entity entities controlled means majority voting interest referred variable interest entities consolidated bms power direct activities variable interest entity significantly impacts economic performance obligation absorb losses right receive benefits could potentially significant entity use estimates preparation financial statements requires use management estimates assumptions significant assumptions estimates determining fair value potential impairment intangible assets sales rebate return accruals legal contingencies income taxes estimated selling prices used multiple element arrangements pension postretirement benefits actual results may differ estimated results reclassifications certain prior period amounts reclassified conform current period presentation advertising product promotion costs previously presented separately consolidated statements earnings included marketing selling administrative expenses revenue recognition revenue recognized persuasive evidence arrangement exists sales price fixed determinable collectability reasonably assured title substantially risks rewards ownership transferred generally time shipment including supply commercial products alliance partners principal end customer sale however certain revenue nonus businesses recognized date receipt customer alliance revenue related abilify atripla recognized products sold end customer alliance partner royalties recognized thirdparty sales reliably measurable collectability reasonably assured refer note alliances detail regarding alliances revenue reduced time recognition expected sales returns discounts rebates sales allowances based historical experience updated changes facts circumstances including impact applicable healthcare legislation revenue deferred historical experience products similar therapeutic category right return longer exists sufficient historical experience estimate sales returns developed income taxes provision income taxes includes income taxes paid payable current year plus change deferred taxes year deferred taxes result differences financial tax basis assets liabilities adjusted changes tax rates tax laws changes enacted valuation allowances recognized reduce deferred tax assets likely tax benefit realized assessment whether valuation allowance required often requires significant judgment including longrange forecast future taxable income evaluation tax planning initiatives adjustments deferred tax valuation allowances made earnings period assessments made tax benefits recognized uncertain tax position likely tax position sustained examination taxing authorities based technical merits position tax benefit recognized financial statements particular tax position based largest benefit likely realized upon settlement cash cash equivalents cash cash equivalents include bank deposits time deposits commercial paper money market funds cash equivalents consist highly liquid investments original maturities three months less time purchase recognized cost approximates fair value marketable securities investments companies marketable securities classified availableforsale date purchase reported fair value fair value determined based observable market quotes valuation models using assessments counterparty credit worthiness credit default risk underlying security overall capital market liquidity investments less owned companies accounted using equity method accounting ability exercise significant influence maintained share net income losses equity investments included incomeexpense equity investments reviewed impairment assessing decline market value investment carrying value temporary considers intent ability retain investment duration extent market value less cost investee 's financial condition inventory valuation inventories stated lower average cost market property plant equipment depreciation expenditures additions renewals improvements capitalized cost depreciation computed straightline method based estimated useful lives related assets ranging years buildings years machinery equipment fixtures impairment longlived assets current facts circumstances periodically evaluated determine carrying value depreciable assets held used may recoverable circumstances exist estimate undiscounted future cash flows generated longlived asset appropriate grouping assets compared carrying value determine whether impairment exists lowest level identifiable cash flows asset determined impaired loss measured based difference assets fair value carrying value estimate assets fair value based quoted market prices active markets available quoted market prices available estimate fair value based various valuation techniques using level fair value inputs including discounted value estimated future cash flows capitalized software eligible costs obtain internal use software capitalized amortized estimated useful life software business combinations businesses acquired consolidated upon obtaining control fair value assets acquired liabilities assumed recognized date acquisition excess purchase price estimated fair values net assets acquired recognized goodwill business acquisition costs expensed incurred goodwill acquired inprocess research development intangible assets fair value intangible assets typically determined using income method utilizing level fair value inputs market participant valuations assume global view considering potential jurisdictions indications based discounted aftertax cash flow projections risk adjusted estimated probability technical regulatory success iprd finitelived intangible assets including licenses developed technology rights iprd projects reach commercialization amortized straightline basis estimated useful life estimated useful lives determined considering period assets expected contribute future cash flows goodwill tested least annually impairment assessing qualitative factors performing quantitative analysis determining whether likely fair value net assets carrying amounts examples qualitative factors assessed include share price financial performance compared budgets longterm financial plans macroeconomic industry market conditions well substantial excess fair value carrying value net assets annual impairment test performed prior year relevant factor assessed individually aggregate iprd tested impairment annual basis frequently events occur circumstances change would indicate potential reduction fair values assets carrying value carrying value iprd determined exceed fair value impairment loss recognized difference finitelived intangible assets tested impairment facts circumstances suggest carrying value asset may recoverable carrying value exceeds projected undiscounted pretax cash flows intangible asset impairment loss equal excess carrying value estimated fair value discounted aftertax cash flows recognized restructuring restructuring charges recognized result actions streamline operations rationalize manufacturing facilities estimating impact restructuring plans including future termination benefits exit costs requires judgment actual results could vary estimates contingencies loss contingencies legal proceedings claims may occur wide range matters including government investigations shareholder lawsuits product environmental liability contractual claims tax matters accruals recognized probable liability incurred amount loss reasonably estimated gain contingencies including contingent proceeds related divestitures recognized realized legal fees expensed incurred shipping handling costs shipping handling costs included marketing selling administrative expenses million million million advertising product promotion costs advertising product promotion costs included marketing selling administrative expenses million million million advertising product promotion costs expensed incurred foreign currency translation foreign subsidiary earnings translated us dollars using average exchange rates net assets foreign subsidiaries translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recognized oci research development research development costs expensed incurred clinical study costs accrued service periods specified contracts adjusted necessary based upon ongoing review level effort costs actually incurred strategic alliances third parties provide licensing rights develop manufacture market andor sell pharmaceutical products rights owned party research development recognized net reimbursements connection alliance agreements upfront contingent milestone payments asset acquisitions investigational compounds also included research development expenses cash flow upfront contingent milestone payments licensing investigational compounds included operating activities asset business acquisitions included investing activities divestiture proceeds included investing activities well royalties consideration received subsequent related sale asset business adjustments reflected operating activities include divestiture gains losses related royalties research development asset acquisition charges gains losses debt redemption changes fair value written option liabilities recently issued accounting standards january financial accounting standards board fasb issued amended guidance recognition measurement presentation disclosures financial instruments effective january early adoption permitted new guidance requires fair value adjustments equity securities readily determinable fair values currently classified availableforsale reported earnings new guidance also requires qualitative impairment assessment equity investments without readily determinable fair value would require impairment charge earnings assessment indicates impairment exists company assessing potential impact new standard consolidated financial statements november fasb issued amended guidance presentation deferred tax assets liabilities new guidance requires deferred tax assets liabilities classified noncurrent bms elected early adopt standard december prospectively refer note income taxes information april fasb issued amended guidance presentation debt issuance costs new guidance requires debt issuance costs presented reduction carrying value debt balance sheet consistent debt discounts bms elected early adopt standard december adoption standard material impact consolidated financial statements refer note financial instruments fair value measurements information may fasb issued new standard related revenue recognition requires entity recognize amount revenue expects entitled transfer promised goods services customers new standard replace existing revenue recognition standards us gaap becomes effective july fasb decided delay effective date one year january early adoption permitted earlier new standard applied retrospectively prior reporting period presented retrospectively cumulative effect change recognized date initial application retained earnings company assessing potential impact new standard financial reporting yet selected transition method april fasb issued amended guidance use presentation discontinued operations entity 's consolidated financial statements new guidance restricts presentation discontinued operations business circumstances disposal business operations represents strategic shift major effect entity 's operations financial results guidance became effective january note business segment information bms operates single segment engaged discovery development licensing manufacturing marketing distribution sale innovative medicines help patients prevail serious diseases global research development organization supply chain organization responsible discovery development manufacturing supply products regional commercial organizations market distribute sell products business also supported global corporate staff functions segment information consistent financial information regularly reviewed chief executive officer purposes evaluating performance allocating resources setting incentive compensation targets planning forecasting future periods products sold principally wholesalers lesser extent directly distributors retailers hospitals clinics government agencies pharmacies gross revenues three largest pharmaceutical wholesalers us percentage global gross revenues follows mckesson corporation amerisourcebergen corporation cardinal health inc selected geographic area information follows revenues property plant equipment dollars millions united states europe rest world othera total revenues include royalties alliancerelated revenues products sold regional commercial organizations product revenues follows year ended december dollars millions virology baraclude entecavir hepatitis c franchise reyataz atazanavir sulfate franchise sustiva efavirenz franchise oncology empliciti elotuzumab erbitux cetuximab opdivo nivolumab sprycel dasatinib yervoy ipilimumab neuroscience abilify aripiprazole immunoscience orencia abatacept cardiovascular eliquis apixaban mature products total revenues composition total revenues follows year ended december dollars millions net product sales alliance revenues revenues total revenues note alliances bms enters collaboration arrangements third parties development commercialization certain products although arrangements unique nature parties active participants operating activities collaboration exposed significant risks rewards depending commercial success activities bms may either inlicense intellectual property owned party outlicense intellectual property party arrangements also typically include research development manufacturing andor commercial activities cover single investigational compound commercial product multiple compounds andor products various life cycle stages rights obligations parties global limited geographic regions refer collaborations alliances partners alliance partners several key products sustiva atripla empliciti erbitux opdivo sprycel yervoy abilify orencia eliquis well products comprising diabetes alliance discussed certain mature brands included alliance arrangements payments alliance partners accounted presented results operations considering specific nature payment underlying activities payments relate multiple alliance activities including transfer rights separated individual units accounting standalone value activities occur life arrangements situations arrangement consideration allocated activities rights relative selling price basis multiple alliance activities rights standalone value combined single unit accounting common activities bms alliance partners presented results operations follows bms principal end customer sale product sales included net product sales bms 's alliance partner principal end customer sale bms 's contractual share thirdparty sales andor royalty income included alliance revenue sale commercial products considered part bms 's ongoing major central operations refer revenue recognition included note accounting policies information regarding recognition criteria amounts payable bms alliance partners principal end customer sale supply commercial products included alliance revenue sale commercial products considered part bms 's ongoing major central operations profit sharing royalties salesbased fees payable bms alliance partners included cost products sold incurred cost reimbursements parties recognized incurred included cost products sold marketing selling administrative expenses research development expenses based underlying nature related activities subject reimbursement upfront contingent development approval milestones payable bms alliance partners investigational compounds commercial products deferred amortized shorter contractual term periods related compounds products expected contribute future cash flows amortization presented consistent nature payment arrangement example amounts received investigational compounds presented incomeexpense activities performed time related sale commercial products part bmss ongoing major central operations amounts received commercial products presented alliance revenue sale commercial products considered part bmss ongoing major central operations except astrazeneca plc astrazeneca alliance pertaining amylin products see discussion specific astrazeneca alliance disclosure herein upfront contingent approval milestones payable bms alliance partners commercial products capitalized amortized shorter contractual term periods related products expected contribute future cash flows amortization included cost products sold upfront contingent milestones payable bms alliance partners prior regulatory approval expensed incurred included research development expenses royalties contingent consideration payable bms alliance partners related divestiture businesses included income earned equity net income affiliates included incomeexpense payments bms alliance partners presented cash flows operating activities except otherwise described selected financial information pertaining alliances follows including net product sales bms principal thirdparty customer sale products subject alliance expenses summarized include amounts attributed activities products alliance payments alliance partners related amortization payments deferred capitalized year ended december dollars millions revenues alliances net product sales alliance revenues total revenues payments tofrom alliance partners cost products sold marketing selling administrative research development incomeexpense noncontrolling interest pretax selected alliance balance sheet information december dollars millions receivables alliance partners accounts payable alliance partners deferred income alliances bms entered certain licensing alliance agreements including options license acquire related assets upfront payments new agreements charged research development expenses million prior period amounts disclosed research development expenses upfront payments alliance partners revised include similar type payments specific information pertaining significant alliances discussed including nature purpose significant rights obligations parties specific accounting policy elections income statement classification amounts attributable payments parties pfizer bms pfizer inc pfizer parties worldwide codevelopment cocommercialization agreement eliquis anticoagulant discovered bms pfizer funds development costs depending study profits losses shared equally global basis except certain countries pfizer commercializes eliquis pays bms compensation based percentage net sales upon entering agreement coexclusive license rights product granted pfizer exchange upfront payment potential milestone payments parties assumed certain obligations actively participate alliance actively participate joint executive committee various operating committees joint responsibilities research development distribution sales marketing activities alliance using resources infrastructures bms manufactures product alliance principal end customer product sales us significant countries europe well canada australia china japan south korea bms transferred full commercialization rights pfizer certain smaller countries order simplify operations transferred countries bms supplies product pfizer cost plus percentage net sales endcustomers company determined rights transferred pfizer standalone value rights sold separately bms party could pfizer receive benefit delivered rights without fulfillment ongoing obligations bms alliance agreement including exclusive supply arrangement global alliance treated single unit accounting upfront proceeds subsequent contingent milestone proceeds amortized life related product bms received million nonrefundable upfront milestone licensing payments related eliquis december amortization eliquis deferred income included income eliquis commercial product commencement alliance summarized financial information related alliance follows year ended december dollars millions revenues pfizer alliance net product sales alliance revenues total revenues payments tofrom pfizer cost products sold profit sharing cost reimbursements pfizer incomeexpense amortization deferred income selected alliance cash flow information deferred income selected alliance balance sheet information december dollars millions deferred income gilead bms gilead sciences inc gilead joint ventures us us canada europe develop commercialize atripla efavirenz mg emtricitabine mg tenofovir disoproxil fumarate mg combining sustiva product bms truvada emtricitabine tenofovir disoproxil fumarate product gilead joint ventures consolidated gilead parties actively participate joint executive committee various operating committees direct oversight activities joint ventures joint ventures purchase sustiva truvada active pharmaceutical ingredient api bulk form parties complete finishing atripla joint ventures gilead sell distribute atripla principal end customer product sales parties longer coordinate joint promotional activities alliance revenue recognized atripla include bulk efavirenz component atripla based relative ratio average respective net selling prices truvada sustiva alliance revenue deferred related alliance receivable recognized combined product sold thirdparty customers europe following loss exclusivity sustiva effective january percentage atripla net sales europe recognized bms equal difference average net selling prices atripla truvada alliance continue europe either party terminates arrangement last patent expiration occurs atripla truvada sustiva us agreement may terminated gilead upon launch generic version sustiva bms upon launch generic version truvada event gilead terminates agreement upon loss exclusivity sustiva bms receive quarterly royalty payment months following termination payment first months following termination equal atripla net sales multiplied ratio difference average net selling prices atripla truvada atripla average net selling price second third years following termination payment bms reduced respectively atripla net sales multiplied price ratio described bms continue supply sustiva cost plus markup joint ventures threeyear period unless either party elects terminate supply arrangement entered licensing agreement gilead develop commercialize fixeddose combination containing reyataz gileads cobicistat pharmacoenhancing boosting agent increases blood levels certain human immunodeficiency virus hiv medicines potentially allow one pill daily dosing evotaz atazanavir mg cobicistat mg approved us food drug administration fda january european commission ec july summarized financial information related alliance follows year ended december dollars millions revenues gilead alliances alliance revenues equity net loss affiliates selected alliance balance sheet information december dollars millions deferred income otsuka bms worldwide commercialization agreement otsuka pharmaceutical co ltd otsuka codevelop copromote abilify excluding certain asian countries us portion agreement expired april agreement expired european union eu countries june non us country exclusive right sell abilify agreement expires later april loss exclusivity country parties actively participated joint executive governance operating committees otsuka responsible providing sales force efforts us effective january however bms responsible certain operating expenses various annual limits bms purchased api otsuka completed manufacturing product subsequent sale thirdparty customers us certain countries otsuka assumed responsibility providing funding sales force efforts eu effective april bms also provided certain services including distribution customer management pharmacovigilence bms principal end customer product sales exclusive distributor exclusive right sell abilify otsuka principal end customer product sales us eu alliance revenue includes bmss share total net sales thirdparty customers territories bmss contractual share us net sales set forth table assessment bms 's expected annual contractual share completed quarterly reporting period adjusted based upon reported us abilify net sales year end bms 's annual contractual share alliance revenue recognized interim period quarter exceed amounts due contract annual us net sales bms share us net sales billion billion billion billion billion billion billion billion billion excess billion bmss contractual share thirdparty net sales eu countries us alliance revenue recognized abilify shipped risks rewards ownership transferred thirdparty customers bms otsuka also alliance sprycel us japan eu oncology territory parties copromote product us eu february copromotion agreement otsuka terminated japan parties actively participate various governance committees however bms control decision making bms responsible development manufacture product also principal end customer product sales ixempra ixabepilone included alliance prior bms 's divestiture business fee paid otsuka based following percentages combined annual net sales sprycel ixempra oncology territory including post divestiture ixempra sales net sales million million million million million million billion excess billion annual periods otsuka contributes first million certain commercial operational expenses relating oncology products oncology territory costs excess million summarized financial information related alliance follows year ended december dollars millions revenues otsuka alliances net product sales alliance revenuesa total revenues payments tofrom otsuka cost products sold oncology fee royalties cost product supply includes amortization extension payment reduction alliance revenue million million lilly bms commercialization agreement eli lilly company lilly lillys subsidiary imclone codevelopment promotion erbitux us canada japan parties actively participated joint executive committee various operating committees shared responsibilities research development using resources infrastructures lilly manufactured bulk requirements erbitux facilities filling finishing performed third party bms oversight responsibility bms exclusive distribution rights north america responsible promotional efforts north america although lilly right copromote us expense bms principal end customer product sales north america paid lilly distribution fee erbitux net sales north america plus share certain royalties paid lilly bmss rights obligations respect commercialization erbitux north america would expired september october bms transferred rights erbitux north america lilly exchange salesbased royalties described transferred rights include limited full commercialization manufacturing responsibilities transaction accounted business divestiture resulted noncash charge million intangible assets directly related business allocation goodwill bms receive royalties september included income earned royalty rates applicable north america erbitux net sales million million million million plus net sales excess amounts respective years bms shared rights erbitux japan agreement lilly merck kgaa received pretax profit merck kgaas net sales erbitux japan shared equally lilly bms transferred cocommercialization rights japan merck kgaa exchange sales based royalties included income earned march bms lilly terminated arrangement necitumumab imcf rights returning lilly discovered imclone necitumumab fully human monoclonal antibody part alliance bms lilly summarized financial information related alliance follows year ended december dollars millions revenues lilly alliance net product sales alliance revenues total revenues payments tofrom lilly cost products sold distribution fees royalties amortization intangible asset cost product supply incomeexpense royalties loss sale business selected alliance balance sheet information december dollars millions intangible assets nonrefundable upfront milestone licensing payments astrazeneca prior diabetes business divestiture discussed bms alliance astrazeneca consisting three worldwide codevelopment commercialization agreements covering onglyza related combination products sold various names farxiga related combination products beginning august bms 's acquisition amylin pharmaceuticals inc amylin amylin 's portfolio products including bydureon byetta symlin myalept well certain assets owned amylin including manufacturing facility located west chester ohio coexclusive license rights product products underlying agreement granted astrazeneca exchange upfront payment potential milestone payments parties assumed certain obligations actively participate alliance parties actively participated joint executive committee various operating committees joint responsibilities research development distribution sales marketing activities alliance using resources infrastructures bms manufactured products three alliances principal end customer product sales substantially countries alliance agreement rights transferred astrazeneca standalone value rights sold separately bms party could astrazeneca received benefit delivered rights without fulfillment ongoing obligations bms alliance agreements including exclusive supply arrangement global alliance treated single unit accounting result upfront proceeds subsequent contingent milestone proceeds amortized life related products bms received billion nonrefundable upfront payment astrazeneca consideration entering amylin alliance astrazeneca exercised option equal governance rights certain key strategic financial decisions regarding amylin alliance paid bms million consideration payments accounted deferred income amortized based relative fair value predominant elements included alliance estimated useful lives intangible assets related bydureon estimated useful life years byetta estimated useful life years symlin estimated life years myalept estimated useful life years amylin manufacturing plant estimated useful life years amortization presented reduction cost products sold alliance assets acquired shortly commencement alliance astrazeneca entitled share proceeds sale assets amortization acquired amylin intangible assets manufacturing plant also presented cost products sold bms entitled reimbursements capital expenditures related acquired amylin manufacturing facility bms astrazeneca also shared certain tax attributes related amylin alliance prior termination alliance bms received nonrefundable upfront milestone licensing payments million related onglyza million related farxiga amortization onglyza farxiga deferred income included income onglyza farxiga commercial products commencement alliance parties also shared commercialization development expenses equally well profits losses february bms astrazeneca terminated alliance agreements bms sold astrazeneca substantially diabetes business comprising alliance divestiture included shares amylin resulting transfer ohio manufacturing facility intellectual property related onglyza farxiga including bms 's interest outlicensing agreement onglyza japan purchase bmss manufacturing facility located mount vernon indiana substantially employees dedicated diabetes business transferred astrazeneca bms astrazeneca entered several agreements connection sale including supply agreement development agreement transitional services agreement agreements bms obligated supply certain products including active product ingredients onglyza farxiga perform ongoing development activities certain clinical trial programs provide transitional services accounting financial services customer service distribution regulatory development information technology certain administrative services various periods order facilitate orderly transfer business operations annual costs attributed development agreement expected exceed approximately million consideration transaction includes billion payment closing contingent regulatory salesbased milestone payments billion including million related approval milestones million related salesbased milestones payable royalty payments based net sales payments million certain assets transferred astrazeneca astrazeneca also pay bms required product supply price approximating product cost well negotiated transitional service fees royalty rates net sales follows onglyza farxiga worldwide net sales million onglyza farxiga worldwide net sales million amylin products us net sales stock asset purchase agreement contains multiple elements delivered subsequent closing transaction including china diabetes business transferred mount vernon indiana manufacturing facility transferred activities development supply agreements elements determined standalone value result portion consideration received closing allocated undelivered elements using relative selling price method determining best estimated selling price element remaining amount consideration included calculation gain sale diabetes business contingent milestone royalty payments similarly allocated among underlying elements amounts determined payable bms amounts allocated sale business immediately recognized results operations amounts allocated elements recognized results operations extent element delivered consideration billion accounted including royalties million contingent regulatory milestone payments related approval farxiga us japan approximately billion consideration allocated sale business remaining million allocated undelivered elements described consideration includes million earned royalties including million allocated elements delivered gain sale diabetes business million including million third quarter resulting primarily transfer china diabetes business astrazeneca gain based difference consideration allocated sale business excluding royalties net transaction fees carrying value diabetes business net assets including million allocation goodwill reversal million net deferred tax liabilities attributed amylin consideration million received transfer mount vernon indiana manufacturing facility related inventories resulting gain million amounts allocated delivered elements consideration allocated development supply agreements continue amortized applicable service periods amortization deferred income attributed development agreement included income sale services considered part bmss ongoing major central operations revenues attributed supply agreement included alliance revenues consideration transaction presented cash flow purposes based allocation process described either investing activity attributed sale business related assets operating activity attributed transitional services supply arrangement development agreement september bms transferred percentage future royalty rights amylin net product sales us cppib credit europe sarl luxembourg private limited liability company cppib transferred rights represent approximately potential future royalties bms entitled exchange transfer bms receive additional tieredbased royalty amylin net product sales us cppib included income earned summarized financial information related astrazeneca alliances follows year ended december dollars millions revenues astrazeneca alliances net product sales alliance revenues total revenues payments tofrom astrazeneca cost products sold profit sharing amortization deferred income cost reimbursements tofrom astrazeneca recognized cost products sold marketing selling administrative research development incomeexpense amortization deferred income provision restructuring royalties transitional services gain sale business selected alliance cash flow information deferred income divestiture proceeds selected alliance balance sheet information december dollars millions deferred income attributed assets yet transferred astrazeneca services yet performed astrazeneca sanofi bms sanofi codevelopment cocommercialization agreements plavix avaproavalide effective january sanofi assumed essentially worldwide operations alliance exception plavix us puerto rico bms operating partner controlling interest exchange rights transferred sanofi bms receives quarterly royalties january december terminal payment sanofi million end royalties received sanofi territory covering americas australia optout markets former development royalties presented alliance revenues million million million royalties attributed territory covering europe asia continue earned territory partnership included equity net income affiliates alliance revenues attributed supply irbesartan api sanofi million million million supply arrangement irbesartan expired summarized financial information related alliance follows year ended december dollars millions revenues sanofi alliances net product sales alliance revenues total revenues payments tofrom sanofi equity net income affiliates noncontrolling interest pretax selected alliance cash flow information distributions tofrom sanofi noncontrolling interest distributions sanofi investment affiliates selected alliance balance sheet information december dollars millions investment affiliates territory covering europe asiaa noncontrolling interest included alliance receivables following summarized financial information interests partnerships sanofi territory covering europe asia consolidated accounted using equity method year ended december dollars millions net sales gross profit net income cost products sold territory covering europe asia includes discovery royalties million million million paid directly sanofi expenses shared based applicable ownership percentages current assets current liabilities include approximately million million million related receivablespayables attributed cash distributions bms sanofi well intercompany balances partnerships within territory ono bms principal end customer product sales exclusive right develop manufacture commercialize opdivo antipd human monoclonal antibody investigated anticancer treatment territories worldwide except japan south korea taiwan ono pharmaceutical co ltd ono responsible development commercialization prior arrangement described ono entitled receive royalties following regulatory approvals territories excluding three countries listed royalty rates net sales north america applicable territories subject customary adjustments alliance arrangement expanded july establish collaboration activities japan south korea taiwan pertaining opdivo several bms compounds including yervoy lirilumab urelumab bms antilag parties right obligation jointly develop commercialize compounds bms responsible supply products profits losses development costs shared equally combination therapies involving compounds parties otherwise sharing activities involving one partys compounds bms ono also alliance codevelop cocommercialize orencia japan bms responsible order fulfillment distribution intravenous formulation ono responsible subcutaneous formulation formulations jointly promoted parties assigned customer accounts bms responsible product supply copromotion fee paid party sale made partys assigned customer summarized financial information related alliance follows year ended december dollars millions revenues ono alliances net product sales alliance revenues total revenues payments tofrom ono cost products sold copromotion fee profit sharing cost reimbursements ono abbvie bms abbvie inc abbvie alliance empliciti humanized monoclonal antibody treatment multiple myeloma terms alliance bms granted exclusive global rights codevelop commercialize empliciti pdl biopharma inc part abbvie abbvie currently participates joint development us commercialization committees bms final decision making authority parties codeveloping product abbvie funds global development costs bms solely responsible supply distribution sales marketing activities within alliance principal end customer product sales abbvie shares profits losses us paid tiered royalties net sales empliciti outside us addition abbvie also entitled receive milestone payments bms certain regulatory events sales thresholds achieved agreement may terminated bms subsequent notice period either party material breach party financial information related alliance material years ended december fstar october bms entered agreement fstar alpha ltd fstar agreement provides bms exclusive option purchase fstar phase ready lead asset fs targeted therapy development treatment breast gastric cancer among welldefined population herpositive patients bms paid million fstar shareholders consideration option grant certain licensing rights included research development expenses responsible conducting funding development fs option exercisable bms 's discretion expires upon earlier days following obtaining proof concept june additional million payable upon exercise option plus additional aggregate consideration million contingent development regulatory approval milestone payments us europe bms obligated provide additional financial support fstar fstar determined business defined asc business combinations result contingent consideration included purchase price goodwill recognized however fstar variable interest entity equity holders lack characteristics controlling financial interest bms determined primary beneficiary power direct activities significantly directly impacting economic performance entity option rights described upon consolidation noncontrolling interest credited million reflect fair value fs iprd asset million deferred tax liabilities promedior september bms purchased warrant gives bms exclusive right acquire promedior inc promedior biotechnology company whose lead asset prm developed treatment idiopathic pulmonary fibrosis ipf myelofibrosis mf warrant exercisable upon completion either ipf mf phase ii clinical studies conducted promedior expected occur earlier upfront payment allocated warrant million included research development expenses third quarter remaining million million upfront payment allocated promediors obligation complete phase ii studies amortized expected period phase ii studies allocation determined using level inputs following bms 's review phase ii clinical study results bms elects exercise warrant obligated pay additional million based ipf study results million based mf study results plus additional aggregate consideration million contingent development regulatory approval milestone payments us europe five prime november bms five prime therapeutics inc five prime entered exclusive worldwide licensing collaboration agreement development commercialization five primes colony stimulating factor receptor csfr antibody program including fpa currently phase development immunology oncology indications bms responsible development manufacturing commercialization fpa subject five primes option conduct certain studies cost develop fpa pigmented vilonodular synovitis pvns combination internal oncology pipeline assets five prime also retained option copromote us agreement replaces previous clinical collaboration agreement two parties consideration licensing rights bms made upfront payment million fourth quarter included research development expense bms also committed pay billion upon achievement contingent development regulatory milestones well future royalties product approved commercialized reckitt benckiser group may bms reckitt benckiser group plc reckitt started threeyear alliance several overthecounterproducts sold primarily mexico brazil reckitt received right sell distribute market products may bms receives royalties net sales products exclusively supplies certain products reckitt pursuant supply agreement cost plus markup certain limited assets including market authorizations certain employees directly attributed business transferred reckitt start alliance period bms retained ownership assets related business including trademarks covering products framework alliance bms also granted reckitt option acquire trademarks inventory certain assets exclusively related products end alliance period price determined primarily based upon multiple sales may may april alliance modified provide option reckitt purchase bms manufacturing facility located mexico primarily dedicated products included alliance july reckitt notified bms exercising option substantially employees facility expected transferred reckitt closing expected occur may refer note assets heldforsale information nonrefundable upfront proceeds million received bms allocated two units accounting including rights transferred reckitt fair value option purchase remaining assets using best estimate selling price elements considering various market factors market factors included analysis estimated excess fair value business potential purchase price option exercised fair value option determined using level inputs included liabilities bms recognized income million decrease fair value option zero due strengthening us dollar local currencies anticipated proceeds expected approximate fair value assets transferred amount allocated rights transferred reckitt amortized alliance revenue contractual term summarized financial information related alliance follows year ended december dollars millions revenues reckitt alliance alliance revenues selected alliance cash flow information deferred income changes operating assets liabilities selected alliance balance sheet information december dollars millions deferred income medicines company february bms medicines company entered twoyear alliance recothrom recombinant thrombin use topical hemostat control nonarterial bleeding surgical procedures previously acquired bms connection acquisition zymogenetics inc medicines company received right sell distribute market recothrom global basis two years bms exclusively supplied recothrom medicines company cost plus markup received royalties net sales recothrom certain employees directly attributed business certain assets transferred medicines company start alliance period including biologics license application related regulatory assets bms retained assets related recothrom including patents trademarks inventory bms also granted medicines company option acquire patents trademarks inventory certain assets exclusively related recothrom price determined based multiple sales plus cost remaining inventory held bms time medicines company exercised option acquired business million february refer note assets heldforsale information nonrefundable upfront proceeds million received bms allocated two units accounting including rights transferred medicines company fair value option purchase remaining assets using best estimate selling price elements considering various market factors market factors included analysis estimated excess fair value business potential purchase price option exercised fair value option million december determined using level inputs included accrued expenses amount allocated rights transferred medicines company amortized alliance revenue contractual term summarized financial information related alliance follows year ended december dollars millions revenues medicines company alliance alliance revenues incomeexpense gain sale business selected alliance cash flow information deferred income changes operating assets liabilities divestiture proceeds selected alliance balance sheet information december dollars millions deferred income valeant october bms pharmaswiss sa whollyowned subsidiary valeant pharmaceuticals international inc valeant entered alliance certain mature brand products europe valeant received right sell distribute market products europe december bms exclusively supplied products valeant cost plus markup bms also granted valeant option acquire trademarks intellectual property exclusively related products price determined based multiple sales valeant exercised option acquired business million january refer note assets heldforsale information nonrefundable upfront proceeds million received bms allocated two units accounting including rights transferred valeant fair value option purchase remaining assets using best estimate selling price elements considering various market factors market factors included analysis estimated excess fair value business potential purchase price option exercised fair value option determined using level inputs included accrued expenses million charge included expenses increase fair value option million amount allocated rights transferred valeant amortized alliance revenue contractual term summarized financial information related alliance follows year ended december dollars millions revenues valeant alliance net product sales alliance revenues total revenues incomeexpense gain sale business selected alliance cash flow information changes operating assets liabilities divestiture proceeds note acquisitions divestitures cardioxyl acquisition december bms acquired outstanding shares cardioxyl pharmaceuticals inc cardioxyl privately held biotechnology company focused discovery development novel therapeutic agents cardiovascular disease acquisition provided bms full rights cxl nitroxyl prodrug phase ii development acute decompensated heart failure consideration includes upfront payment million contingent development regulatory salesbased milestone payments billion significant cardioxyl processes acquired therefore transaction accounted asset acquisition cardioxyl determined business term defined asc business combinations consideration allocated cxl resulting million research development expenses net operating losses tax credit carryforwards resulting million deferred tax assets flexus acquisition april bms acquired outstanding shares flexus biosciences inc flexus privately held biotechnology company focused discovery development novel anticancer therapeutics acquisition provided bms full rights f preclinical small molecule idoinhibitor targeted immunotherapy addition bms acquired flexus 's idotdo discovery program includes idoselective idotdo dual tdoselective compounds consideration includes upfront payment million plus acquisition costs contingent development regulatory milestone payments million significant flexus processes acquired therefore transaction accounted asset acquisition flexus determined business consideration allocated f idotdo discovery program resulting million research development expenses net operating losses tax credit carryforwards resulting million deferred tax assets ipierian acquisition april bms acquired outstanding shares ipierian inc ipierian biotechnology company focused new treatments tauopathies class neurodegenerative diseases acquisition provided bms full rights ipn preclinical monoclonal antibody treat progressive supranuclear palsy tauopathies consideration includes upfront payment million contingent development regulatory milestone payments million future royalties net sales acquired preclinical assets approved commercialized significant ipierian processes acquired therefore transaction accounted asset acquisition ipierian determined business consideration allocated ipn resulting million research development expenses net operating losses tax credit carryforwards resulting million deferred tax assets divestitures addition divestiture transactions astrazeneca lilly medicines company valeant discussed note alliances bms divested ixempra business several businesses product lines transactions generated net proceeds million resulting pretax gains million including million deferred gain additional contingent proceeds recognized earnings received revenues pretax earnings related businesses material note assets heldforsale december bms agreed sell pipeline investigational hiv medicines viiv healthcare includes number programs different stages discovery preclinical clinical development transaction excludes bmss hiv marketed medicines certain bms employees offered opportunity transfer viiv healthcare bms provide certain rd services transitional period transaction expected close first half upon obtaining customary regulatory approvals accounted sale business consideration includes upfront payment million contingent development regulatory milestone payments billion salesbased milestone payments billion future royalties products approved commercialized bms also reimbursed rd services assets heldforsale million december comprising primarily goodwill related investigational hiv business business comprising alliance reckitt assets heldforsale million december comprising inventory goodwill intangible assets related businesses comprising alliances medicines company valeant allocation goodwill based relative fair value businesses divested company 's reporting unit note incomeexpense incomeexpense includes year ended december dollars millions interest expense investment income provision restructuring litigation settlements equity net income affiliates outlicensed intangible asset impairment gain sale businesses product lines assets alliance licensing income pension charges loss debt redemption incomeexpense litigation settlements includes million contractual dispute related license includes unrealized foreign exchange loss million resulting remeasurement bolivardenominated cash monetary balances bmss whollyowned subsidiary venezuela december exchange rate changed simadi rate official cencoex rate considering limited amount foreign currency exchanged second half published exchange rates continuing deterioration economic conditions venezuela note restructuring following provision restructuring year ended december dollars millions employee termination benefits exit costs provision restructuring restructuring charges included employee termination benefits manufacturing selling administrative research development workforce reductions across geographic regions approximately restructuring actions primarily related specialty care transformation initiatives designed create simplified organization across functions geographic markets sales force reductions several european countries following restructuring sanofi otsuka alliance agreements subject local regulations costs recognized completion discussions works councils following table represents activity employee termination exit cost liabilities year ended december dollars millions liability january charges change estimates provision restructuring foreign currency translation liabilities related assets heldforsale spending liability december note income taxes provisionbenefit income taxes consisted year ended december dollars millions current us nonus total current deferred us nonus total deferred total provision effective tax rate reconciliation effective taxbenefit rate us statutory federal income tax rate earnings income taxes dollars millions earningsloss income taxes us nonus total us statutory rate foreign tax effect certain operations ireland puerto rico switzerland us tax effect capital losses valuation allowance release us federal state foreign contingent tax matters us federal research based credits goodwill allocated divestitures us branded prescription drug fee rd charges state local taxes net valuation allowance foreign effective tax rate lower us statutory rate primarily attributable undistributed earnings certain foreign subsidiaries considered expected indefinitely reinvested offshore us taxes provided approximately billion undistributed earnings foreign subsidiaries december undistributed earnings primarily relate operations switzerland ireland puerto rico undistributed earnings repatriated us future determined earnings remitted foreseeable future additional tax provisions would required due complexities tax laws assumptions would made practicable estimate amounts income taxes provided reforms us tax laws related foreign earnings proposed adopted may increase taxes could reduce results operations cash flows bms operates favorable tax grant puerto rico scheduled expire prior divestiture certain businesses resulted capital loss tax benefits including million sale amylin shares valuation allowances attributed capital loss carryforwards released following divestiture recothrom ixempra mature brands additional reserves million established certain transfer pricing matters related tax periods retroactive reinstatement us federal research development credit resulted additional tax credits million orphan drug credits included us federal research based credits periods presented goodwill allocated business divestitures including diabetes business deductible tax purposes well us branded prescription drug fee periods research development charges resulting primarily acquisition flexus cardioxyl ipierian also deductible tax purposes deferred taxes valuation allowance components current noncurrent deferred income tax assetsliabilities follows december dollars millions deferred tax assets foreign net operating loss carryforwards us capital loss carryforwards state net operating loss credit carryforwards us federal net operating loss credit carryforwards deferred income milestone payments license fees pension postretirement benefits intercompany profit inventory items foreign deferred tax assets sharebased compensation legal settlements repatriation foreign earnings internal transfer intellectual property total deferred tax assets valuation allowance deferred tax assets net valuation allowance deferred tax liabilities depreciation acquired intangible assets goodwill total deferred tax liabilities deferred tax assets net recognized deferred income taxes current deferred income taxes noncurrent income taxes payable current income taxes payable noncurrent total company elected early adopt accounting standard update december prospective basis results deferred taxes reported noncurrent balance sheet internal transfers intellectual property resulted deferred tax assets million prepaid taxes million included assets december assets amortized expected lives us federal net operating loss carryforwards million december carryforwards acquired result certain acquisitions subject limitations section internal revenue code net operating loss carryforwards expire varying amounts beginning us federal tax credit carryforwards expire varying amounts beginning realization us federal tax credit carryforwards dependent generating sufficient domesticsourced taxable income prior expiration capital loss carryforward available million dependent generating sufficient domesticsourced capital gain income scheduled expire foreign state net operating loss carryforwards expire varying amounts beginning certain amounts unlimited lives december valuation allowance million established following items million primarily foreign net operating loss tax credit carryforwards million state deferred tax assets including net operating loss tax credit carryforwards million us federal net operating loss carryforwards million us federal capital losses million us federal deferred tax assets changes valuation allowance follows year ended december dollars millions balance beginning year provision utilization foreign currency translation acquisitions balance end year income tax payments million million million current tax benefit realized result stock related compensation credited capital excess par value stock million million million business conducted various countries throughout world subject tax numerous jurisdictions significant number tax returns filed subject examination various federal state local tax authorities tax examinations often complex tax authorities may disagree treatment items reported requiring several years resolve liabilities established possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credits deductibility certain expenses liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known effect changes estimates related contingent tax liabilities included effective tax rate reconciliation reconciliation beginning ending amount gross unrecognized tax benefits follows year ended december dollars millions balance beginning year gross additions tax positions related current year gross additions tax positions related prior years gross additions tax positions assumed acquisitions gross reductions tax positions related prior years settlements reductions tax positions related lapse statute cumulative translation adjustment balance end year additional information regarding unrecognized tax benefits follows year ended december dollars millions unrecognized tax benefits recognized would impact effective tax rate accrued interest accrued penalties interest expense penalty expensebenefit accrued interest penalties payable unrecognized tax benefits included either current noncurrent income taxes payable interest penalties related unrecognized tax benefits included income tax expense bms currently examination number tax authorities including limited major tax jurisdictions listed table proposed considering proposing material adjustments tax issues transfer pricing certain tax credits deductibility certain expenses bms estimates reasonably possible total amount unrecognized tax benefits december decrease range approximately million million next twelve months result settlement certain tax audits events expected change unrecognized tax benefits primarily settlement related involve payment additional taxes adjustment certain deferred taxes andor recognition tax benefits reasonably possible new issues raised tax authorities may increase unrecognized tax benefits however estimate increases reasonably made time bms believes adequately provided open tax years tax jurisdiction following summary major tax jurisdictions tax authorities may assert additional taxes based upon tax years currently audit subsequent years likely audited us canada france germany italy mexico note earnings per share year ended december amounts millions except per share data net earnings attributable bms used basic diluted eps calculation weightedaverage common shares outstanding basic contingently convertible debt common stock equivalents incremental shares attributable sharebased compensation plans weightedaverage common shares outstanding diluted earnings per share basic earnings per share diluted note financial instruments fair value measurements financial instruments include cash cash equivalents marketable securities accounts receivable payable debt instruments derivatives changes exchange rates interest rates create exposure market risk certain derivative financial instruments used available costeffective basis hedge underlying economic exposure instruments qualify cash flow net investment fair value hedges upon meeting certain criteria including effectiveness offsetting hedged exposures changes fair value derivatives qualify hedge accounting recognized earnings occur derivative financial instruments used trading purposes financial instruments subject counterparty credit risk considered part overall fair value measurement counterparty credit risk monitored ongoing basis mitigated limiting amounts outstanding individual counterparty utilizing conventional derivative financial instruments entering agreements counterparties meet high credit quality standards consolidated financial statements would materially impacted counterparty failed perform according terms agreement collateral required party whether derivatives asset liability position terms agreements fair value measurements fair value financial instruments classified one following categories level inputs utilize unadjusted quoted prices active markets accessible measurement date identical assets liabilities fair value hierarchy provides highest priority level inputs level inputs utilize observable prices similar instruments quoted prices identical similar instruments nonactive markets additionally certain corporate debt securities utilize thirdparty matrix pricing model using significant inputs corroborated market data substantially full term assets equity fixed income funds primarily invested publicly traded securities valued respective net asset value underlying investments significant unfunded commitments restrictions redemptions related equity fixed income funds december level derivative instruments valued using london interbank offered rate libor yield curves less credit valuation adjustments observable forward foreign exchange rates reporting date valuations derivative contracts may fluctuate considerably volatility underlying foreign currencies underlying interest rates driven market conditions duration contract level unobservable inputs used little market data available fair value written options acquire outstanding shares sell assets certain businesses refer note alliances discussion based option pricing methodology considers revenue profitability projections volatility discount rates potential exercise price assumptions financial assets liabilities measured fair value recurring basis summarized december december dollars millions level level level total level level level total cash cash equivalents money market securities marketable securities certificates deposit corporate debt securities equity funds fixed income funds auction rate securities ars derivative assets interest rate swap contracts forward starting interest rate swap contracts foreign currency forward contracts equity investments derivative liabilities interest rate swap contracts forward starting interest rate swap contracts foreign currency forward contracts written option liabilities contingent consideration liability following table summarizes activity financial assets utilizing level fair value measurements written contingent written contingent option consideration option consideration dollars millions ars liabilities liability ars liabilities liability fair value january realized losses sales settlements changes fair value fair value december availableforsale securities following table summarizes availableforsale securities gross gross unrealized unrealized gain loss amortized accumulated accumulated dollars millions cost oci oci fair value december certificates deposit corporate debt securities equity investments total december certificates deposit corporate debt securities ars equity investments total availableforsale securities included current marketable securities million december million december non current availableforsale corporate debt securities mature within five years december equity investments million million included assets december respectively fair value option financial assets investments equity fixed income funds offsetting changes fair value certain employee retirement benefits included current marketable securities changes fair value significant qualifying hedges following summarizes fair value outstanding derivatives december december dollars millions balance sheet location notional fair value notional fair value derivatives designated hedging instruments interest rate swap contracts assets interest rate swap contracts liabilities forward starting interest rate swap contracts assets forward starting interest rate swap contracts liabilities foreign currency forward contracts prepaid expenses foreign currency forward contracts assets foreign currency forward contracts accrued expenses cash flow hedges foreign currency forward contracts used hedge certain forecasted intercompany inventory purchase transactions certain foreign currency transactions effective portion changes fair value contracts designated cash flow hedges temporarily reported accumulated comprehensive loss included earnings hedged item affects earnings net gains foreign currency forward contracts expected reclassified net earnings primarily included cost products sold within next two years notional amount outstanding foreign currency forward contracts primarily attributed euro million japanese yen million december fair value foreign currency forward contract attributed japanese yen notional amount million designated cash flow hedge million included accrued expenses december bms entered million forward starting interest rate swap contracts maturing march hedge variability probable forecasted interest expense associated potential future issuances debt contracts designated cash flow hedges effective portion fair value changes included comprehensive income earnings impact related discontinued cash flow hedges hedge ineffectiveness significant periods presented cash flow hedge accounting discontinued forecasted transaction longer probable occurring within days originally forecasted date hedge longer effective assessments determine whether derivatives designated qualifying hedges highly effective offsetting changes cash flows hedged items performed inception quarterly basis net investment hedges nonus dollar borrowings million million designated hedge foreign currency exposures net investment certain foreign affiliates borrowings designated net investment hedges recognized long term debt effective portion foreign exchange gains losses remeasurement debt recognized foreign currency translation component accumulated comprehensive loss related offset longterm debt fair value hedges fixedtofloating interest rate swap contracts designated fair value hedges used interest rate risk management strategy create appropriate balance fixed floating rate debt contracts underlying debt hedged benchmark risk recorded fair value effective interest rate contracts onemonth libor december plus interest rate spread ranging underlying swap terminated prior maturity fair value basis adjustment underlying debt instrument amortized reduction interest expense remaining life debt notional amount fixedtofloating interest rate swap contracts executed million billion notional amount fixedto floating interest rate swap contracts terminated million million generating proceeds million million including accrued interest million million additional contracts terminated connection debt redemptions debt obligations shortterm borrowings million million december respectively consisting primarily bank overdrafts average amount commercial paper outstanding million weightedaverage interest rate maximum month end amount commercial paper outstanding million outstanding borrowings december borrowings longterm debt includes december dollars millions principal value euro notes due notes due notes due euro notes due notes due debentures due notes due euro notes due debentures due euro notes due notes due notes due notes due notes due debentures due maturing subtotal adjustments principal value fair value interest rate swap contracts unamortized basis adjustment swap terminations unamortized bond discounts issuance costsa total excludes unamortized bond issuance costs million reclassified december fair value longterm debt million million december respectively estimated based upon quoted market prices similar debt instruments fair value shortterm borrowings approximates carrying value due short maturities debt instruments senior unsecured notes issued registered public offerings notes rank equally right payment bms 's existing future senior unsecured indebtedness redeemable whole part time predetermined redemption price bms also terminated forward starting interest rate swap contracts entered resulting unrealized loss comprehensive income following table summarizes note issuances amounts millions euro us dollars us dollars principal value notes due notes due euro notes due euro notes due notes due total proceeds net discount deferred loan issuance costs forward starting interest rate swap contracts terminated notional amount unrealized gainloss company repurchased million longterm debt cash tender offer redeemed billion billion longterm debt following issuance new senior unsecured notes connection debt redemption activities certain interest rate swap contracts entered terminated second quarter debt redemptions debt redemption activity follows dollars millions principal amount carrying value debt redemption price notional amount interest rate swap contracts terminated interest rate swap termination payments loss debt redemptiona including acceleration debt issuance costs loss interest rate lock contract related fees notes principal amount million matured repaid interest payments million million million net amounts received interest rate swap contracts two separate billion fiveyear revolving credit facilities maintained syndicate lenders facilities provide customary terms conditions financial covenants extendable anniversary date consent lenders borrowings outstanding either revolving credit facility december financial guarantees provided form standby letters credit performance bonds million december standby letters credit issued financial institutions support guarantees various obligations performance bonds issued support range ongoing operating activities including sale products hospitals foreign ministries health bonds customs duties value added tax guarantees related miscellaneous legal actions significant majority outstanding financial guarantees expire within year expected funded note receivables december dollars millions trade receivables less allowances net trade receivables alliance partners receivables prepaid refundable income taxes miscellaneous receivables receivables nonus receivables sold nonrecourse basis million million million aggregate receivables three pharmaceutical wholesalers us represented total trade receivables december respectively changes allowances bad debt chargebacks cash discounts follows year ended december dollars millions balance beginning year provision utilization assets heldforsale balance end year note inventories december dollars millions finished goods work process raw packaging materials inventories inventories expected remain onhand beyond one year including million inventory pending regulatory approval included assets million december million december note property plant equipment december dollars millions land buildings machinery equipment fixtures construction progress gross property plant equipment less accumulated depreciation property plant equipment mount vernon indiana manufacturing facility transferred astrazeneca third quarter connection sale diabetes business facility 's gross property plant equipment million date transfer million net accumulated depreciation refer note alliances discussion sale diabetes business fully depreciated bulk manufacturing facility ceased use resulting million reduction gross property plant equipment accumulated depreciation depreciation expense million million million note goodwill intangible assets december estimated dollars millions useful lives goodwill intangible assets licenses years developed technology rights years capitalized software years inprocess research development iprd gross intangible assets less accumulated amortization total intangible assets reduction goodwill resulted allocation amounts business divestitures refer note alliances note acquisitions divestitures note assets heldforsale discussion divestitures amortization expense million million million future annual amortization expense intangible assets expected approximately million million million million million intangible asset impairment charges million million none licenses million million net accumulated amortization derecognized result transfer erbitux north american business lilly october refer note alliances discussion million iprd impairment charge recognized bms lysophosphatidic acid receptor antagonist phase ii development treatment ipf full writeoff required considering occurrence certain adverse events voluntary suspension study internal assessment indicating significantly lower likelihood regulatory commercial success bms acquired bms acquisition amira pharmaceuticals inc addition contingent consideration liability million related acquisition also reversed lower likelihood success million iprd impairment charge recognized peginterferon lambda phase iii development treatment hepatitis c virus hcv full writeoff required assessing potential commercial viability asset estimating fair value assessment considered lower likelihood filing registration certain markets completing revised projections revenues expenses significant decline prior projected revenues resulted global introduction oral noninterferon products used treat patients hcv alternative uses product note accrued expenses december dollars millions employee compensation benefits royalties accrued research development restructuring current pension postretirement benefits litigation settlements total accrued expenses note sales rebates return accruals reductions trade receivables accrued rebates returns liabilities follows december dollars millions chargebacks related government programs cash discounts reductions trade receivables medicaid medicare rebates sales returns rebates discounts adjustments accrued rebates returns note deferred income december dollars millions alliances note total deferred income current portion noncurrent portion alliances include unamortized amounts upfront milestone licensing receipts revenue deferrals attributed gilead alliance deferred income undelivered elements diabetes business divestiture upfront milestone licensing receipts amortized shorter contractual rights period expected life product deferrals included approximately million invoiced daklinza early access program france december deferred final pricing obtained french government amortization deferred income million million million note equity common stock capital treasury stock excess par value retained noncontrolling dollars shares millions shares par value stock earnings shares cost interest balance january net earnings cash dividends declared stock repurchase program employee stock compensation plans distributions balance december net earnings cash dividends declared employee stock compensation plans debt conversion variable interest entity distributions balance december net earnings cash dividends declared employee stock compensation plans debt conversion distributions balance december treasury stock recognized cost reacquire shares shares issued treasury recognized utilizing firstin firstout method components comprehensive incomeloss follows dollars millions pretax tax tax derivatives qualifying cash flow hedgesa unrealized gains reclassified net earnings derivatives qualifying cash flow hedges pension postretirement benefits actuarial gains amortizationb settlementsc pension postretirement benefits availableforsale securities unrealized losses realized gainsc availableforsale securities foreign currency translation derivatives qualifying cash flow hedgesa unrealized gains reclassified net earnings derivatives qualifying cash flow hedges pension postretirement benefits actuarial losses amortizationb settlements curtailmentsc pension postretirement benefits availableforsale securities unrealized gains realized gainsc availableforsale securities foreign currency translation derivatives qualifying cash flow hedgesa unrealized gains reclassified net earnings derivatives qualifying cash flow hedges pension postretirement benefits actuarial losses amortizationb settlements curtailmentsc pension postretirement benefits availableforsale securities unrealized losses realized losses availableforsale securities foreign currency translation included cost products sold b included cost products sold research development marketing selling administrative expenses c included incomeexpense accumulated balances related component comprehensive loss net taxes follows december dollars millions derivatives qualifying cash flow hedges pension postretirement benefits availableforsale securities foreign currency translation accumulated comprehensive loss note pension postretirement postemployment liabilities bms sponsors defined benefit pension plans defined contribution plans termination indemnity plans regular fulltime employees principal defined benefit pension plan bristolmyers squibb retirement income plan covering us employees representing approximately consolidated pension plan assets obligations future benefits related service plan eliminated bms contributes least minimum amount required employee retirement income security act erisa plan benefits based primarily participants years credited service final average compensation plan assets consist principally equity fixedincome securities comprehensive medical group life benefits provided substantially us retirees electing participate comprehensive medical group life plans medical plan contributory contributions adjusted periodically vary date retirement life insurance plan noncontributory plan assets consist principally equity fixedincome securities net periodic benefit costcredit defined benefit pension postretirement benefit plans includes pension benefits benefits dollars millions service cost benefits earned year interest cost projected benefit obligation expected return plan assets amortization prior service credits amortization net actuarial gainloss curtailments settlements special termination benefits net periodic benefit costcredit september bms fiduciary counselors inc independent fiduciary bristolmyers squibb company retirement income plan entered definitive agreement transfer certain us pension assets prudential insurance company america prudential settle approximately billion pension obligations bms purchased group annuity contract prudential december irrevocably assumed obligation make future annuity payments certain bms retirees transaction change amount monthly pension benefit received affected retirees surviving beneficiaries resulted pretax settlement charge million pension settlement charges also recognized determining annual lump sum payments exceed annual interest service costs certain pension plans including primary us pension plan changes defined benefit postretirement benefit plan obligations assets funded status amounts recognized consolidated balance sheets follows pension benefits benefits dollars millions benefit obligations beginning year service costbenefits earned year interest cost plan participants contributions curtailments settlements plan amendments actuarial gainslosses retiree drug subsidy benefits paid exchange rate gains benefit obligations end year fair value plan assets beginning year actual return plan assets employer contributions plan participants contributions settlements retiree drug subsidy benefits paid exchange rate losses fair value plan assets end year funded status assetsliabilities recognized assets accrued expenses pension postretirement liabilities funded status recognized accumulated comprehensive loss net actuarial gainslosses prior service credit total accumulated benefit obligation defined benefit pension plans million million december respectively additional information related pension plans follows dollars millions pension plans projected benefit obligations excess plan assets projected benefit obligation fair value plan assets pension plans accumulated benefit obligations excess plan assets accumulated benefit obligation fair value plan assets actuarial assumptions weightedaverage assumptions used determine benefit obligations december follows pension benefits benefits discount rate rate compensation increase weightedaverage actuarial assumptions used determine net periodic benefit creditcost years ended december follows pension benefits benefits discount rate expected longterm return plan assets rate compensation increase yield high quality corporate bonds matching duration benefit obligations used determining discount rate citigroup pension discount curve used developing discount rate us plans expected return plan assets determined using expected rate return calculated value assets referred marketrelated value marketrelated value plan assets exceeded fair value approximately million december differences assumed actual returns amortized marketrelated value straightline basis threeyear period several factors considered developing expected return plan assets including longterm historical returns input external advisors individual asset class return forecasts developed based upon market conditions example priceearnings levels yields longterm growth expectations expected longterm rate return weightedaverage target asset allocation individual asset class historical longterm actual annualized returns us pension plans follows years years years actuarial gains losses resulted changes actuarial assumptions changes discount rate revised mortality rates differences assumed actual experience differences actual expected return plan assets gains losses amortized life expectancy plan participants us plans years expected remaining service periods plans extent exceed higher marketrelated value projected benefit obligation respective plan amortization net actuarial loss prior service credit expected approximately million periodic benefit cost credit included cost products sold research development marketing selling administrative expenses except curtailments settlements special termination benefits included expenses assumed healthcare cost trend rates december follows healthcare cost trend rate assumed next year rate cost trend rate assumed decline ultimate trend rate year rate reaches ultimate trend rate onepercentagepoint change assumed healthcare cost trend rates would material impact cost benefit obligation plan assets fair value pension postretirement plan assets asset category december follows december december dollars millions level level level total level level level total equity securities equity funds fixed income funds corporate debt securities venture capital limited partnerships us treasury agency securities shortterm investment funds insurance contracts event driven hedge funds cash cash equivalents total plan assets fair value investment valuation policies per investment class follows level inputs utilize unadjusted quoted prices active markets accessible measurement date identical assets liabilities fair value hierarchy provides highest priority level inputs instruments include equity securities equity funds fixed income funds publicly traded national securities exchange cash cash equivalents cash cash equivalents highly liquid investments original maturities three months less time purchase recognized cost approximates fair value pending trade sales purchases included cash cash equivalents final settlement level inputs utilize observable prices similar instruments quoted prices identical similar instruments nonactive markets observable inputs corroborated market data substantially full term assets liabilities equity funds fixed income funds event driven hedge funds shortterm investment funds classified level within fair value hierarchy valued net asset value shares held year end significant unfunded commitments restrictions redemptions related investments valued nav december corporate debt securities us treasury agency securities classified level within fair value hierarchy valued utilizing observable prices similar instruments quoted prices identical similar instruments markets active level unobservable inputs used little market data available venture capital limited partnerships classified level within fair value hierarchy invest underlying securities whose market values determined using pricing models discounted cash flow methodologies similar techniques significant unobservable inputs used valuation methodologies include discount rates earnings interest taxes depreciation amortization ebitda multiples revenue multiples significant changes inputs could result significantly lower higher fair value measurements insurance contracts held certain foreign pension plans carried contract value approximates estimated fair value based fair value underlying investment insurance company following summarizes activity financial assets utilizing level fair value measurements venture capital limited insurance dollars millions partnerships contracts total fair value january purchases sales settlements net realized gainslosses unrealized gainslosses fair value december purchases sales settlements net realized gainslosses unrealized losses fair value december investment strategy emphasizes equities order achieve higher expected returns lower expenses required cash contributions longterm target asset allocation public equity international global us private equity longduration fixed income maintained us pension plans investments diversified within three major asset categories approximately us pension plans equity investments actively managed venture capital limited partnerships typically valued three month lag using latest available information bms common stock represents less plan assets december contributions estimated future benefit payments contributions pension plans million million million expected approximately million estimated annual future benefit payments including lump sum payments range million million next five years aggregate billion subsequent five year period savings plans principal defined contribution plan bristolmyers squibb savings investment program contribution based employee contributions level company match expense attributed defined contribution plans us approximately million note employee stock benefit plans may shareholders approved stock award incentive plan plan replaced stock incentive plan plan provides million shares authorized grants plus shares outstanding awards plan february expire forfeited canceled withheld satisfy tax withholding obligations december million shares available award shares issued treasury stock satisfy obligations plan executive officers key employees may granted options purchase common stock less market price date option granted options generally become exercisable ratably four years maximum term ten years plan provides granting stock appreciation rights whereby grantee may surrender exercisable rights receive common stock andor cash measured excess market price common stock option exercise price company granted stock options stock appreciation rights since restricted stock units may granted key employees subject restrictions continuous employment generally vesting occurs ratably four year period grant date compensation expense recognized vesting period stock unit right receive stock end specified vesting period voting rights market share units granted executives vesting conditioned upon continuous employment vesting date payout factor least share price award date payout factor share price vesting date divided share price award date maximum share price used payout factor calculated using average closing prices grant vest date nine trading days immediately preceding grant vest date vesting occurs ratably four years performance share units granted executives three year cycle granted target number units subject adjustment based company performance number shares issued performance share units vest determined based achievement annual performance goals number shares issued performance share unit awards also adjusted based company 's threeyear total shareholder return relative peer group companies vesting occurs third anniversary grant date stockbased compensation expense awards ultimately expected vest recognized vesting period forfeitures estimated based historical experience time grant revised subsequent periods actual forfeitures differ estimates information related stockbased compensation benefits follows years ended december dollars millions stock options restricted stock units market share units performance share units total stockbased compensation expense income tax benefit stock options restricted stock units market share units performance share units weighted number weighted number weighted number weighted number average average average average options exercise price nonvested grantdate nonvested grantdate nonvested grantdate shares thousands outstanding shares awards fair value awards fair value awards fair value balance january granted releasedexercised adjustments actual payout forfeitedcanceled balance december vested expected vest restricted market performance dollars millions stock units share units share units unrecognized compensation cost expected weightedaverage period years compensation cost recognized amounts millions except per share data weightedaverage grant date fair value per share restricted stock units market share units performance share units fair value options awards vested year stock options restricted stock units market share units performance share units total intrinsic value stock options exercised year fair value awards approximates closing trading price bms 's common stock grant date fair value market share units also considers payout formula probability satisfying market conditions following table summarizes significant ranges outstanding exercisable options december options outstanding exercisable number weightedaverage weightedaverage aggregate outstanding exercisable remaining contractual exercise price intrinsic value range exercise prices thousands life years per share millions aggregate intrinsic value preceding table represents total pretax intrinsic value based closing stock price december note leases annual minimum rental commitments noncancelable operating leases primarily real estate motor vehicles approximately million next five years aggregate million thereafter operating lease expenses approximately million sublease income material periods presented note legal proceedings contingencies company certain subsidiaries involved various lawsuits claims government investigations legal proceedings arise ordinary course business claims proceedings involve various types parties including governments competitors customers suppliers service providers licensees employees shareholders among others resolution matters often develop long period time expectations change result new findings rulings appeals settlement arrangements company recognizes accruals contingencies probable liability incurred amount loss reasonably estimated matters involve patent infringement antitrust securities pricing sales marketing practices environmental commercial contractual rights licensing obligations health safety matters consumer fraud employment matters product liability insurance coverage legal proceedings material company believes could become material described although company believes substantial defenses matters assurance increase scope pending matters future lawsuits claims government investigations legal proceedings material unless otherwise noted company unable assess outcome respective litigation able provide estimated range potential loss furthermore failure enforce patent rights would likely result substantial decreases respective product revenues generic competition intellectual property baraclude south korea daewoong pharmaceutical co ltd hanmi pharmaceuticals co ltd donga pharmaceutical co ltd generic companies initiated separate invalidity actions korean intellectual property office korean patent patent covering entecavir molecule january korean intellectual property tribunal ruled ' patent valid decision affirmed appeal september patent court patent expired october following expiration patent generic companies entered south korean market expect continuing declines net product sales baraclude plavix australia previously disclosed sanofi notified august genrx proprietary limited genrx obtained regulatory approval application clopidogrel bisulfate mg tablets australia genrx formerly subsidiary apotex inc apotex since changed name apotex august apotex filed application federal court australia federal court seeking revocation sanofis australian patent case nsd sanofi filed counterclaims infringement sought injunction september federal court granted sanofis injunction subsidiary company subsequently added party proceedings february second company spirit pharmaceuticals pty ltd also filed revocation suit patent case consolidated apotex case trial occurred april august federal court australia held claims patent covering clopidogrel bisulfate hydrochloride hydrobromide taurocholate salts valid federal court also held process claims pharmaceutical composition claims claim directed clopidogrel pharmaceutically acceptable salts invalid company sanofi filed notices appeal full court federal court australia full court appealing holding invalidity claim covering clopidogrel pharmaceutically acceptable salts process claims pharmaceutical composition claims stayed federal courts ruling apotex filed notice appeal appealing holding validity clopidogrel bisulfate hydrochloride hydrobromide taurocholate claims hearing appeals occurred february september full court held claims patent invalid november company sanofi applied high court australia high court special leave appeal judgment full court march high court denied company sanofis request hear appeal full court decision case remanded federal court proceedings related damages sought apotex australian government intervened matter also seeking damages alleged losses experienced period injunction place company apotex settled apotex case case dismissed australian government 's claim still pending possible time predict outcome australian governments claim impact company eliquis interpartes review ipr august bristolmyers squibb received petition inter partes review us patent patent filed united states patent trademark office coalition affordable drugs affiliated entities individuals associated hedge fund patent composition matter patent contains claims directed apixaban active ingredient eliquis petition requests patent trial appeal board ptab initiate proceeding review validity patent including claims cover apixaban company responded opposed petition november ptab expected render decision whether initiate proceeding midfebruary ptab decides initiate proceeding decision merits would expected first half company intends vigorously defend patent challenge patent expires february company filed request patent term restoration us patent trademark office requesting patent expiration date restored december sprycel european union may apotex actavis group ptc ehf generics uk limited mylan unnamed company filed oppositions european patent office epo seeking revocation european patent patent covering dasatinib active ingredient sprycel patent scheduled expire april excluding potential term extensions january opposition division epo revoked patent company appeal epos decision epo board appeal patent remain force pending outcome appeal epos decision intend pursue legal options defend intellectual property rights future infringement orphan drug exclusivity data exclusivity sprycel eu expire november decision affect validity sprycel patents within outside europe including different patent covers monohydrate form dasatinib us company entered settlement agreement apotex regarding patent infringement suit whereby apotex launch generic dasatinib monohydrate abbreviated new drug application product september earlier certain circumstances antipd antibody patent oppositions litigation brought claims infringement number ongoing patent litigations merck co inc merck around world respect patents directed methods treating cancer using pd antibody alliance ono bms exclusive rights patents including european patent ep patent merck filed opposition european patent office epo seeking revocation patent june opposition division epo maintained validity claims patent merck appealed decision may merck filed lawsuit united kingdom uk seeking revocation uk national version patent july bms ono sued merck patent infringement trial held uk july october court issued judgment finding patent valid infringed merck appealed judgment february merck filed lawsuit netherlands seeking revocation dutch national version patent bms ono subsequently sued merck patent infringement trial regarding validity infringement patent held january decision dutch court pending december bms ono filed lawsuits respect national versions patent several european countries including france germany ireland spain switzerland bms ono file patent infringement actions merck national courts europe around time merck launches keytruda abovementioned national courts determine merck infringes valid claim patent bms ono may entitled monetary damages including royalties future sales keytruda bms ono seeking injunction prevent merck marketing keytruda litigations unless appropriate financial remedy agreed upon awarded court september bms ono filed lawsuit united states alleging mercks marketing keytruda infringes us patent patent trial matter currently scheduled begin april june july bms ono filed lawsuits united states alleging mercks marketing keytruda infringes us patent nos patent patent respectively patents related patent lawsuits bms ono seeking prevent stop marketing keytruda united states unless appropriate financial remedy agreed upon awarded court april merck three companies opposed european patent ep patent directed class antipd antibodies february bms ono submitted request amend claims patent oral proceedings opposition division epo scheduled july september merck filed lawsuit australia seeking revocation australian patent directed class antipd antibodies based application patent march bms ono countersued merck patent infringement ono bms similar patents applications pending united states countries september danafarber cancer institute danafarber filed complaint massachusetts federal court seeking correct inventorship five related us patents specifically danafarber seeking add two scientists inventors patents three patents patents currently subject patent infringement proceedings filed bms ono merck delaware federal court specified pricing sales promotional practices litigation awp litigation previously disclosed company together number pharmaceutical manufacturers defendant number private class actions well suits brought attorneys general various states actions plaintiffs allege defendants caused average wholesale prices awps products inflated thereby injuring government programs entities persons reimbursed prescription drugs based awps company remains defendant two state attorneys general suits pending state courts pennsylvania wisconsin company designated one four defendants separate trials wisconsin settlement reached company defendants one hand state wisconsin beginning august company defendant trial commonwealth court pennsylvania commonwealth court brought commonwealth pennsylvania september jury issued verdict company finding company liable fraudulent negligent misrepresentation however commonwealth court judge issued decision pennsylvania consumer protection claim go jury finding company liable million enjoining company contributing provision inflated awps company appealed decision pennsylvania supreme court june pennsylvania supreme court vacated commonwealth judge 's decision remanded matter back commonwealth court january commonwealth court entered judgment favor company commonwealth pennsylvania appealed decision pennsylvania supreme court affirmed lower court 's decision favor company december qui tam litigation march company served unsealed qui tam complaint filed three former sales representatives california superior court county los angeles california department insurance elected intervene lawsuit complaint alleges company paid kickbacks california providers pharmacies violation california insurance frauds prevention act cal ins code december company california department insurance reached agreement financial terms settlement principle parties continuing negotiations terms final settlement plavix state attorneys general lawsuits company certain affiliates sanofi defendants consumer protection andor false advertising actions brought several states relating sales promotion plavix possible time reasonably assess outcome lawsuits potential impact company product liability litigation company party various product liability lawsuits plaintiffs cases seek damages relief various grounds alleged personal injury economic loss previously disclosed addition lawsuits company also faces unfiled claims involving products plavix previously disclosed company certain affiliates sanofi defendants number individual lawsuits various state federal courts claiming personal injury damage allegedly sustained using plavix currently claims involving injury plaintiffs well claims spouses andor beneficiaries filed state federal courts various states including california new jersey delaware new york february judicial panel multidistrict litigation granted company sanofis motion establish multidistrict litigation coordinate federal pretrial proceedings plavix product liability related cases new jersey federal court possible time reasonably assess outcome lawsuits potential impact company reglan company one number defendants numerous lawsuits behalf approximately plaintiffs including injury plaintiffs claiming personal injury allegedly sustained using reglan another brand generic drug metoclopramide product indicated gastroesophageal reflux certain gastrointestinal disorders well claims spouses andor beneficiaries company generic subsidiary apothecon inc distributed metoclopramide tablets manufactured another party possible time reasonably assess outcome lawsuits resolution pending lawsuits however expected material impact company byetta amylin former subsidiary company lilly codefendants product liability litigation related byetta date separate lawsuits pending behalf active plaintiffs including pending settlements include injury plaintiffs well claims spouses andor beneficiaries various courts us company agreed principle resolve claims majority cases brought individuals allege personal injury sustained using byetta primarily pancreatic cancer pancreatitis cases claiming alleged wrongful death majority cases pending federal court san diego multidistrict litigation mdl coordinated proceeding california superior court los angeles jccp november defendants ' motion summary judgment based federal preemption granted mdl jccp plaintiffs appealed us court appeals ninth circuit cases jccp yet formally dismissed amylin product liability insurance covering substantial number claims involving byetta additional liability amylin respect byetta expected shared company astrazeneca possible reasonably predict outcome lawsuit claim proceeding potential impact company shareholder derivative litigation december two shareholder derivative lawsuits filed new york state court certain officers directors company plaintiffs allege among things breaches fiduciary duty surrounding companys previously disclosed october civil settlement securities exchange commission alleged foreign corrupt practices act violations company agreed payment approximately million disgorgement penalties interest government investigations like pharmaceutical companies company certain subsidiaries subject extensive regulation national state local government agencies us countries bms operates result company time time subject various governmental inquiries investigations possible criminal charges substantial fines andor civil penalties could result government investigations significant investigations conducted government agencies listed abilify state attorneys general investigation march company received letter delaware attorney generals office advising multistate coalition investigating whether certain abilify marketing practices violated respective states consumer protection statutes possible time reasonably assess outcome investigation environmental proceedings previously reported company party several environmental proceedings matters responsible various state federal foreign laws including comprehensive environmental response compensation liability act cercla certain costs investigating andor remediating contamination resulting past industrial activity companys current former sites waste disposal reprocessing facilities operated third parties cercla matters respect cercla matters company responsible various state federal foreign laws company typically estimates potential costs based information obtained us environmental protection agency counterpart state foreign agency andor studies prepared independent consultants including total estimated costs site expected costsharing potentially responsible parties company accrues liabilities probable reasonably estimable company estimated share future costs sites million december represents sum best estimates best estimate reasonably made estimates minimal probable amount among range costs without taking account potential recoveries parties north brunswick township board education previously disclosed october company contacted counsel representing north brunswick nj board education boe regarding site waste materials er squibb sons may disposed fill material containing industrial waste heavy metals excess residential standards discovered expansion project north brunswick township high school well number neighboring residential properties adjacent public park areas january new jersey department environmental protection njdep sent company others information request letter possible waste disposal site company responded march boe township current owners school property park conducting jointly financing soil remediation work ground water investigation work work plan approved njdep asked company contribute cost company actively monitoring cleanup project including costs date neither school board township asserted claim company instead company local entities negotiated agreement attempt resolve matter informal means avoid litigation central component agreement provision company interim funding help defray cleanup costs assure work interrupted company transmitted interim funding payments december november parties commenced mediation late however efforts successful parties moved binding allocation process parties expected conduct fact expert discovery followed formal evidentiary hearings written argument addition september township boe filed suits several parties alleged contributed waste materials site litigation settled parties company currently believe responsible additional amounts beyond two interim payments totaling million already transmitted additional possible loss expected material note selected quarterly financial data unaudited dollars millions except per share data first quarter second quarter third quarter fourth quarter year total revenues gross margin net earningsloss net earningsloss attributable noncontrolling interest bms earningsloss per share basica earningsloss per share diluteda cash dividends declared per common share cash cash equivalents marketable securitiesb total assets longterm debt equity dollars millions except per share data first quarter second quarter third quarter fourth quarter year total revenues gross margin net earnings net earningsloss attributable noncontrolling interest bms earnings per share basica earnings per share diluteda cash dividends declared per common share cash cash equivalents marketable securitiesb total assets longterm debt equity earnings per share quarters may add amounts year period computed discrete basis b marketable securities includes current noncurrent assets following specified items affected comparability results first second third fourth dollars millions quarter quarter quarter quarter year cost products solda marketing selling administrativeb license asset acquisition charges iprd impairments research development provision restructuring gainloss sale businesses product lines assets pension charges acquisition alliance related items litigation settlements outlicensed intangible asset impairment loss debt redemption incomeexpense increasedecrease pretax income income tax items increasedecrease net earnings specified items cost products sold accelerated depreciation asset impairment shutdown costs b specified items marketing selling administrative process standardization implementation costs first second third fourth dollars millions quarter quarter quarter quarter year cost products solda additional year branded prescription drug fee process standardization implementation costs marketing selling administrative license asset acquisition charges iprd impairments research development provision restructuring gainloss sale businesses product lines assets pension charges acquisition alliance related itemsb litigation settlements outlicensed intangible asset impairment loss debt redemption upfront milestone licensing receipts incomeexpense increasedecrease pretax income income tax items specified tax chargec income taxes increasedecrease net earnings specified items cost products sold accelerated depreciation asset impairment shutdown costs b includes million additional year branded prescription drug fee third quarter c specified tax charge relates transfer pricing matters report independent registered public accounting firm board directors shareholders bristolmyers squibb company audited accompanying consolidated balance sheets bristolmyers squibb company subsidiaries company december related consolidated statements earnings comprehensive income cash flows three years period ended december financial statements responsibility companys management responsibility express opinion financial statements based audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits provide reasonable basis opinion opinion consolidated financial statements present fairly material respects financial position bristolmyers squibb company subsidiaries december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america also audited accordance standards public company accounting oversight board united states companys internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission report dated february expressed unqualified opinion companys internal control financial reporting deloitte touche llp parsippany new jersey february item changes disagreements accountants accounting financial disclosure none item controls procedures evaluation disclosure controls procedures december management carried evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure controls procedures term defined exchange act rule ae based evaluation management concluded december disclosure controls procedures effective managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting supervision participation management including chief executive officer chief financial officer management assessed effectiveness internal control financial reporting december based framework internal controlintegrated framework issued committee sponsoring organizations treadway commission based assessment management concluded companys internal control financial reporting effective december provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance united states generally accepted accounting principles due inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate deloitte touche llp independent registered public accounting firm audited companys financial statements included report issued report effectiveness companys internal control financial reporting december included herein changes internal control financial reporting changes company 's internal control financial reporting quarter ended december materially affected reasonable likely materially affect company 's internal control financial reporting item b information none report independent registered public accounting firm board directors shareholders bristolmyers squibb company audited internal control financial reporting bristolmyers squibb company subsidiaries company december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission companys management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying managements report internal control financial reporting responsibility express opinion companys internal control financial reporting based audit conducted audit accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion companys internal control financial reporting process designed supervision companys principal executive principal financial officers persons performing similar functions effected companys board directors management personnel provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting including possibility collusion improper management override controls material misstatements due error fraud may prevented detected timely basis also projections evaluation effectiveness internal control financial reporting future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate opinion company maintained material respects effective internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission also audited accordance standards public company accounting oversight board united states consolidated financial statements year ended december company report dated february expressed unqualified opinion consolidated financial statements deloitte touche llp parsippany new jersey february part iii item directors executive officers registrant reference made proxy statement filed march respect directors registrant incorporated herein reference made part hereof response information required item b information required item respect executive officers registrant included part ia reliance general instruction g instruction item b regulation sk item executive compensation reference made proxy statement filed march respect executive compensation incorporated herein reference made part hereof response information required item item security ownership certain beneficial owners management related stockholder matters reference made proxy statement filed march respect security ownership certain beneficial owners management incorporated herein reference made part hereof response information required item item certain relationships related transactions reference made proxy statement filed march respect certain relationships related transactions incorporated herein reference made part hereof response information required item item auditor fees reference made proxy statement filed march respect auditor fees incorporated herein reference made part hereof response information required item part iv item